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SUMMARY
The hepatic monooxygenase system catalyses the 
oxidative metabolism of both endogenous steroids and 
xenobiotics, and consists of three main components : 
cytochrome P-450, NADPH cytochrome P-450 reductase and lipid 
(reviewed by Skett 1987). Multiple pathways exist for 
cytochrome P-450-catalysed biotransformation in the liver, 
and these pathways are modulated by a large number of 
environmental and hormonal factors (reviewed by Mathis et al 
1988). In particular, growth hormone plays a central role in 
the regulation of hepatic drug and steroid metabolism 
(Waxman 1988).
Sex differences in hepatic biotransformations have been 
widely documented in the rat. Neonatal androgenic imprinting 
of cytochrome P-450 is mediated via the hypothalamo- 
pituitary-liver axis (Skett and Gustafsson 1979) by 
modulations of the GH secretory pattern (Eden 1979). Thus 
pulsatile GH secretion in male rats results in the 
predominance of oxidative drug and steroid metabolism, 
whilst continuous GH secretion in the female results in 
higher reductase activity (Mode et al 1982). Alterations of 
GH secretion towards a more continuous pattern have been 
correlated with the feminisation of hepatic steroid 
metabolism (Mode et al 1981). In addition, insulin has been 
documented to exert a MmasculinisigM influence on this 
system (Skett 1986).
(xi)
The majority of studies carried out in this field have 
used in vivo animal models (Kramer et al 1979), isolated 
perfused livers (Schalch et al 1979), and liver microsomes 
prepared from pretreated rats (Gustafsson and Stenberg 
1974). However each of these models suffer from a number of 
disadvantages, and their use is now becoming limited and is 
being largely replaced by cultured hepatocytes. This is an 
important technique in that it is a relatively physiological 
preparation, and allows the study of the effect of
individual hormones in this system without the interactions 
caused by administration of exogenous hormones to the intact 
animal.
The primary aim of this project was to determine 
whether or not GH produced its characteristic feminising 
effect on steroid metabolism in isolated hepatocytes, and to 
correlate the results obtained with the situation in vivo.
Incubation of hepatocytes with GH caused no significant 
changes in either hepatic steroid metabolism or
intracellular cyclic AMP levels. Previous reports have 
suggested that the lack of effects of GH in vitro may be due 
to the absence of additional hormonal factors that are 
involved in the intact animal (Colby 1980). We therefore 
initiated studies to determine the interactions of GH with 
insulin, dexamethasone and thyroxine, each of which is known 
to influence hepatic drug and steroid metabolism (Skett
1987). These effects are substantiated by studies in
adrenalectomised, thyroidectomised or diabetic animals,
(xii)
where removal of a particular hormone markedly altered 
drug metabolism (Kato and Gillette 1965).
Insulin stimulated steroid metabolism in a non-specific 
manner, as has been reported previously (Hussin and Skett 
1987), an effect that was potently antagonised by GH. Pyerin 
and coworkers, in a series of articles, have documented the 
phosphorylation of cytochrome P-450 by both cyclic 
AMP-dependent and independent protein kinases concomitant 
with the denaturation / inactivation of cytochrome P-450 
(Pyerin et al 1987). A phosphorylation mechanism appears to 
be involved in the action of insulin to stimulate steroid 
metabolism, and so altered phosphorylation of the cytochrome 
P-450 protein may constitute this effect. The interaction
observed with GH may also involve a phosphorylation
\
mechanism, as has been reported elsewhere (Yamada et al 
1987).
Dexamethasone stimulated steroid metabolism in a 
non-specific manner, and this effect was again antagonised 
by GH. The effect of dexamethasone over short-term 
incubations may represent a glucocorticoid effect, while the 
effects of long term incubation probably represents 
induction of cytochrome P-450pcn (gene IIIA1) (Schuetz et al 
1984). The interaction with GH may involve its action to 
suppress cytochrome P-450 expression (Yamazoe et al 1987, 
Waxman et al 1988a).
Incubation with thyroxine exhibited dose-related and 
sex-dependent effects in the short incubation studies, while
(xiii)
no significant effects were observed over the longer 
incubations, except at 72h of incubation. Further incubation 
with GH decreased steroid metabolism markedly in the former, 
but enzyme activity was maintained at control levels in 
cultured hepatocytes over 72hr of incubation.
GH modified the effects of insulin, dexamethasone and 
thyroxine in a non-sex-specific manner. Incubation of 
hepatocytes with GH in the presence of both dexamethasone 
and thyroxine, however, resulted in an increase in 
female-specific activities together with a decrease in 
male-specific activities, which is characteristic of the 
feminisation of steroid metabolism. The role of the 
permissive hormones, dexamethasone and thyroxine (Malbon et 
al 1988), is unclear at this stage. It is possible that 
inclusion of these hormones simply serves to mimic the 
hormonal environment in vivo, and that GH interacts with 
both dexamethasone and thyroxine in producing the feminising 
effect. A synergistic effect of cortisol and thyroxine on 
the stimulation of cytochrome P-450!5P (gene IIC12) by GH 
has recently been documented (Mode et al 1989). It has also 
been suggested that both glucocorticoids and thyroxine are 
required for the maintenance of GH receptors, and therefore 
GH responsiveness, in cultured hepatocytes (Christoffersen 
et al 1984, Duran-Garcia et al 1987).
Studies with the putative insulin mediator extract 
isolated from hepatocytes showed that the effects of insulin 
to stimulate steroid metabolism may be mediated by this
(xiv)
inositol phosphate glycan (IPG) (Saltiel 1987). Thus the 
insulin mediator stimulated steroid metabolism in a dose-and 
concentration-dependent manner. In addition, this effect was 
maximal at physiologically relevant concentrations, as was 
seen with insulin. GH antagonised the stimulatory effect of 
the insulin mediator, indicating that the level of 
interaction between the two hormones was distal to the point 
of insulin mediator generation.
Chromatography of the AGlx8-purified acid-hydrolysed 
insulin mediator indicated the presence of carbohydrates, as 
has been documented before (Larner et al 1988, Saltiel et al 
1987), although a more sensitive technique is required to 
fully distinguish between the components on chromatography.
(xv)
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INTRODUCTION
1.1 HISTORICAL BACKGROUND : CYTOCHROME P-450
The cytochromes P-45 0 comprise a superfamily of 
enzymes that play a central role in the oxidative 
biotransformation of both endogenous compounds, such as 
steroids and eicosanoids, and exogenous substances (e.g. 
xenobiotics).
A vast amount of information has accumulated over the 
past four decades regarding the cytochrome P-450 system : 
Mueller and Miller first reported in 1949 that certain 
carcinogens were metabolised by liver microsomes 
supplemented with NADPH. Brodie et al (1955) subsequently 
reported that these enzymes, mediating biotransformation of 
compounds, were located in the endoplasmic reticulum of the 
liver parenchymal cells. Mason (1957) characterised the 
process of mixed-function oxidation, although the relevance 
of this finding was not fully realised at that time. The 
cytochrome P-450 pigment was discovered by Garfinkel (1958) 
and Klingenberg (1958), although once again the significance 
of this protein was not recognised. Omura and Sato (1964) 
first demonstrated this cytochrome P-450 protein as being 
the terminal oxidase in the adrenal mixed function oxidase 
system using the carbon monoxide spectrum. In addition, 
their observation of intense bands in the Soret region of 
the ethyl isocyanide difference spectrum of reduced 
microsomes revealed the haemoprotein nature of the pigment. 
They named it cytochrome P-450, and further showed that
-2-
detergent solubilised the pigment and converted it to a 
carbon monoxide form with maximum absorption at 420nm.
Cooper et al (1965) subsequently assigned a physiological 
role to the cytochrome P-450 system.
The role of the protease-solubilised microsomal NADPH 
cytochrome c reductase described by Horecker (1950) was then 
established as being part of the NADPH-cytochrome P-450 
reductase protein. Strittmatter and Velick (1956) documented 
the microsomal origin of this protein. Lu and Coon (1968) 
solubilised rabbit liver microsomes and separated fractions 
containing cytochrome P-450, NADPH-cytochrome P-450 
reductase and phospholipid, and showed catalytic activity 
upon combining these fractions in a reconstituted system.
The diversity of substrates metabolised by the 
cytochrome P-450 system led to the suggestion that 
isoenzymes of cytochrome P-450 may be present (Alvares et al 
1967). Cytochrome P-450 has subsequently been isolated, 
purified and characterised by a number of groups (Ryan et al 
1975, Guengerich 1977) and the idea of a distinct family of 
isoenzymes with unique yet overlapping substrate 
specificities was proposed by Lu and West (1980). Since then 
primary sequences of some cytochromes P-450 and their genes 
have been determined (Black and Coon, 1986) as well as the 
correlation of different isoenzymes with specific reactions 
(Waxman 1984, Morgan et al 1985a).
Many studies have established the importance of gonadal 
hormones in the regulation of hepatic drug and steroid 
metabolism in rats (Yates et al 1958, Conney 1967, Gillette 
et al 1972). Corticosteroid metabolism in rats was shown to
be enhanced by oestradiol and diminished by testosterone 
administration, resulting in a higher rate of corticosteroid 
metabolism in females than males (Forchielli and Dorfman, 
1956). The existence of sex differences in hepatic 
metabolism was first reported by Nicholas and Barron (1932) 
and Hoick et al (1937) who showed that the barbiturate dose 
required to anaesthetise male animals was twice that in 
females, indicating a sex difference in hexobarbitai 
metabolism. Sex differences in the metabolism of gonadal 
steroids have also been reported (Yates et al 1958, Conney 
1967) .
Several groups have isolated male-specific and 
female-specific cytochrome P-450 forms (Kamataki et al 
1981). Colby et al (1973, 1974) have indicated the 
requirement of the pituitary gland in mediating the effects 
of oestogens and androgens on hepatic metabolism, as well as 
for the maintenance of sex differences in hepatic metabolism 
(Wilson 1968, Gustafsson and Stenberg 1974a, Denef 1974). 
Gustafssons' group subsequently showed the existence of a 
pituitary "feminising factor" in the regulation of steroid 
metabolism (Gustafsson and Stenberg 1974) and this factor 
has been identified as growth hormone (Mode et al 1983).
Kato and co-workers have also indicated a role of the 
gonadal hormones (Kato et al 1969), thyroid hormones (Kato 
and Takahashi 1968), adrenal steroids (Kato and Gillette 
1965) and insulin (Kato and Gillette 1965) in the regulation 
of this system, a view that has been reinforced by 
subsequent reports (Colby et al 1974).
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1.2 COMPONENTS OF THE CYTOCHROME P-450 SYSTEM
The metabolism of drugs and steroids can be divided 
into two categories. Phase I metabolism primarily catalyses 
the oxidation, reduction, hydrolysis and hydration of 
xenobiotics. Oxidative metabolism can then be further 
categorised into the mixed-function oxidases and cytochrome 
P-450-independent reactions (such as alcohol dehydrogenase) 
Thus Phase I metabolism ("functionalisation") converts the 
xenobiotic to a chemically reactive form, thereby making it 
available for Phase II metabolism, whereas Phase II 
metabolism is a conjugation reaction which enhances the 
elimination of the xenobiotic from the body.
The enzymes responsible for drug metabolism are known 
to be present and functional in the lung, kidney, gut, 
adrenal cortex, skin, brain, aorta and placenta, although 
the liver is the major site for these enzymes. The phase I 
mixed-function oxidases are exclusively present embedded in 
the endoplasmic reticulum, while the phase II enzymes 
(except for UDP-glucuronyltransferase) are primarily 
resident in the cell cytoplasm. The components and 
mechanisms involved in the monooxygenase system are 
discussed below.
Lu and Coon (1968) first demonstrated catalytic 
activity of solubilised components of the cytochrome P-450 
system in a reconstituted system. Further, they showed that 
two other components, NADPH cytochrome P-450 reductase and 
lipid were important to achieve maximal activity in a 
reconstituted system, and assigned a role to each of the
components. Thus, cytochrome P-450 was responsible for 
binding to molecular oxygen and substrate, and upon 
reduction, released one atom of oxygen as water and 
transferred the second atom to the substrate; the NADPH 
cytochrome P-450 reductase transferred reducing electrons 
from NADPH to cytochrome P-45 0; and the lipid component 
appeared to function as a matrix to allow effective 
interaction between the reductase and cytochrome P-450.
Thus the cytochrome P-450-catalysed mixed function 
oxidase reaction is :
NADPH + H+ + 02 + RH ----- NADP+ + H20 + ROH
An additional cytochrome P-45 0-linked monooxygenase 
system, whose role is probably to synergise with 
NADPH-dependent metabolism involves NADH cytochrome b5 
reductase, cytochrome b5 and cytochrome P-450.
1.2.1.1 CYTOCHROME P-450
Cytochrome P-450 is a haemoprotein which contains iron 
protoporphyrin IX as the prosthetic group (Maines and Anders 
1973). Four of the six ligands of the iron of cytochrome 
P-450 are co-ordinated with pyrrole nitrogens. The fifth 
ligand is a sulphur atom (Waterman and Mason 1972), probably 
associated with a cysteine residue that has been identified 
close to the haem moiety (Dus et al 1976). The exact nature 
of the sixth ligand has not been determined, although both a 
nitrogen histidyl imidazole group (Dus et al 1970) and water 
(Griffin and Peterson 1973) have been suggested as suitable 
candidates.
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Omura and Sato (1964) first showed that the cytochrome 
P-450 haemoprotein, in its reduced state, readily combines 
with carbon monoxide to yield an absorption maximum at 
450nm. Cytochrome P-45 0 exists in high- and low-spin forms 
both in the absence and presence of substrates (Sliger et al 
1976). At any given time, the iron of a single molecule of 
cytochrome P-450 is either in the low-spin state {s=l/2 ie 
one unpaired d-electron) or high-spin state (s=5/2 ie five 
unpaired d-electrons). The time spent in each state 
determines the equilibrium and this is established by the 
conformation of the protein associated with the haem (Hall 
1987) .
Perturbations of the protein may alter the spin state 
equilibrium. Thus the hydrophobic Type I substrates (eg 
hexobarbitone, benzphetamine, endogenous steroids), which 
bind to low-spin cytochrome P-450, perturb the protein by 
combining with the substrate binding site located on a 
hydrophobic region of the protein near the sixth ligand of 
the iron. When the substrate combines with its binding site, 
the weak sixth ligand is displaced and the 6-coordinated 
iron (low-spin, 418nm Soret minimum) shifts to the 
5-coordinated iron (high-spin, 393nm Soret maximum) (Kumaki 
and Nebert 1978). This results in a shift of the 
equilibrium towards a high-spin state. This change in 
configuration from low-spin to high-spin is characterised as 
a Type I spectral change, and exhibits an absorption maxima 
at 390nm and a minima at 420nm.
Type II compounds, such as aniline, are mainly amines 
and bind to the haem iron of cytochrome P-450 (Kumaki and
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Nebert 1978) to form a strong ligand that maintains the iron 
in the low-spin 6-coordinated state. This causes a shift in 
the equilibrium towards the low-spin state.
1.2.1.2 NADPH CYTOCHROME P-450 REDUCTASE
Horecker (1950) first characterised this NADPH-linked 
reductase activity. The reductase contains one molecule each 
of FMN and FAD as the prosthetic group (Iyanagi and Mason 
1973). The role of NADPH cytochrome P-450 reductase appears 
to be the transfer of reducing electrons from NADPH to 
cytochrome P-450 (Lu and Coon 1968). The FAD acts as the 
acceptor flavin from NADPH while FMN appears to be the 
donating flavin to cytochrome P-450 during electron transfer 
(Vermilion and Coon 1978, Iyanagi et al 1977).
Five functional domains in NADPH cytochrome P-450 
reductase have been identified. These include a hydrophobic 
amino-terminal membrane-binding domain, which is also 
required for the reduction of cytochrome P-450 (Black et al 
1979, Gum and Strobel 1981) and hydrophilic regions involved 
in FMN, FAD, NADPH and cytochrome P-45 0 binding (Porter and 
Kasper 1986, Nisimoto 1986). Further, residues Tyr-140 and 
Tyr-178 are involved in binding FMN to NADPH cytochrome 
P-450 reductase (Shen et al 1989). Carboxyl groups on the 
NADPH cytochrome P-450 reductase also appear to be involved 
in the interaction with cytochrome P-450 during electron 
transfer and in the rate of hydroxylation of substrates, 
therefore suggesting that electrostatic interactions play an 
important role in the binding and electron transfer steps
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between cytochrome P-450 and the reductase (Nadler and 
Strobel 1988).
The stoichiometry of this reaction shows that 
approximately 20-30 molecules of cytochrome P-450 are 
present to one NADPH cytochrome P-450 reductase (Shiraki and 
Guengerich). This may therefore be the rate-determining step 
in this reaction (Miwa et al 1978, Dutton et al 1987).
1.2.1.3 LIPID
Lipid, in the form of phosphatidylcholine, is thought 
to provide a matrix for effective interaction between 
cytochrome P-450 and NADPH cytochrome P-450 reductase (Lu 
and Coon 1974). Further, sex differences in microsomal lipid 
composition are known to exist, and are reflected in the 
drug-metabolising activities in reconstituted systems (Barr 
and Skett 1984). In addition, Meftah and Skett (1987a & b) 
have more recently shown that the lipid component is an 
important requirement for the maintenance of the sex 
differences observed in hepatic drug metabolism.
1.2.1.4 CYTOCHROME b5 REDUCTASE
The addition of NADH to an oxidising system was 
reported to have a synergistic effect with NADPH (Conney et 
al 1957). Strittmatter and Velick (1957) isolated an 
NADH-specific reductase with cytochrome b5 as the 
intermediate transfer component. Cytochrome b5 reductase 
transfers electrons from NADH to cytochrome P-450 at the
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level of the second electron only (Imai and Sato 1977). 
Reduction of cytochrome P-45 0 by cytochrome b5 instead of 
NADPH-cytochrome P-450 reductase (first electron transfer) 
was reported to be inhibitory on hepatic drug metabolism 
(Golly et al 1988).
1.2.2 BIOCHEMICAL MECHANISMS
Figure 1 illustrates the sequence of events in a 
typical cytochrome P-450-catalysed drug-oxidation. The 
catalytic cycle of cytochrome P-45 0 (reviewed by White and 
Coon 1980, Hall 1987) consists of two parts, oxygen
activation and oxygen insertion, and proceeds from steps 1
to 7 :
Step 1 :
The oxidised or ferric form of cytochrome P-450 binds 
to the substrate. Three classes of substrate have been 
proposed (Schenkman et al 1967), Type I, Type II and reverse 
Type I (or modified Type II). Type I substrates are 
hydrophobic in nature and therefore bind to the hydrophobic 
moiety of cytochrome P-450 causing a type I spectral change 
(absorption maxima at 390nm and minima at 420nm). Type II
substrates are mainly amines and interact with the haem
prosthetic group, and are characterised by absorption maxima 
and minima at 325nm and 425-435nm respectively. The third 
class, reverse Type I substrates characteristically display 
absorption minima at 390nm and maxima at 420nm (Hall 1987).
Step 2:
The cytochrome P-450 complex in the ferric oxidation
FIGURE 1 : CATALYTIC CYCLE OF CYTOCHROME P-450.
ROH RH
RH
-10-
state undergoes a one-electron reduction to the ferrous 
state (Peters et al 1965). The electron originates from 
NADPH and is transferred to the cytochrome P-450 complex by 
cytochrome P-450 reductase.
Step 3:
The reduced cytochrome P-450-substrate complex (ferrous 
form) reacts with molecular oxygen to form a tertiary 
P-450-02-substrate complex (oxyferrous complex). 
Alternatively, the complex can bind carbon monoxide to 
produce an absorption maximum at about 450nm (Omura and Sato 
1964).
Step 4:
A second one-electron insertion takes place which 
re-oxidises the iron to its ferric form and the oxygen 
molecule is activated (White and Coon 1980). The source of 
this second electron can be NADPH cytochrome P-45 0 reductase 
or NADH cytochrome b5 reductase (Imai and Sato 1977). The 
extent of involvement of cytochrome b5 depends upon the form 
of cytochrome P-450 involved (Imai 1981).
Step 5:
The two oxygen atoms separate at this stage and water 
is released, resulting in the formation of an oxene 
intermediate which subsequently oxidises the substrate. This 
oxene intermediate is atomic oxygen bound to the ferric 
haemoprotein (Feii-02 complex) and is a potent oxidising 
agent since it is highly electron deficient. Very little 
else is known about this step.
Step 6:
The oxygen atom of the oxene intermediate is
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transferred to the substrate to form the hydroxylated form.
Step 7:
The hydroxylated product is subsequently released from 
the enzyme complex and the iron haemoprotein returns to the 
ferric state.
Monooxgenase reactions take place on or near the outer 
surface of the membrane. Membrane topology theories of 
cytochrome P-450 are an extension of the studies carried out 
using bacterial cytochrome P-450cam (gene CIA1). In 
addition, the location and sequence of a-helical regions in 
mammalian cytochrome P-450 have been predicted from their 
homology with cytochrome P-450cam (Haniu et al 1986, Edwards 
et al 1989). Cytochrome P-450 is thought to be bound to the 
endoplasmic reticulum by one or two transmembrane 
hydrophobic segments located at the amino-terminus of the 
polypeptide chain (Nelson and Strobel 1988, Brown and Black 
1989). The remainder of the protein, comprising the haem 
moiety, is thought to be exposed to the cytosolic side of 
the membrane. The catalytic domain of cytochrome P-450 must 
therefore be orientated in a manner that is complementary to 
the arrangement of reductase and substrate, so as to allow 
adequate electron transfer. The hydrophobic portion of NADPH 
cytochrome P-450 reductase, which accounts for about 10% of 
the molecule, is embedded in the membrane with its catalytic 
site in juxtaposition with the catalytic site of cytochrome 
P-450 (section 1.2.1.2). Similar hydrophobic regions of NA.DH 
cytochrome b5 reductase and cytochrome b5 also provide the 
opportunity for their interaction at the catalytic site of
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cytochrome P-450 (Kensil and Strittmatter 1986, Aring et al 
1987). These cytochrome P-450 molecules are believed to 
congregate around a single molecule of the reductase such 
that the reductase can react with one and then with another 
of the cytochrome P-450 molecules (French et al 1980).
1.2.3 SYNTHESIS AND DEGRADATION OF CYTOCHROME P-450
The cytochrome P-450 isoenzymes consist of both a haem 
prosthetic group and a protein component. The haem is 
synthesised by the haem biosynthetic pathway (Granick and 
Urata 1963), and the protein component by the normal method 
of protein synthesis, that is, transcription and 
translation. The protein component of cytochrome P-450 is 
responsible for the presence of isoenzymes, although marked 
amino acid sequence homologies have been reported within 
gene families (Black and Coon 1986). The cytochrome P-450 
holoenzyme is formed upon incorporation of the haem into the 
apoprotein of cytochrome P-450 (Bornheim et al 1987). 
Inhibitors of haem biosynthesis blocked the induction of 
cytochrome P-450 and its transcription by 
3-methylcholanthrene, thus implying that haem acts as a 
positive regulator of cytochrome P-450 gene transcription 
(Bhat and Padmanaban 1988).
Cytochrome P-450 is degraded by the haem oxygenase 
system (Maines et al 1986). This system consists of one of 
the two isoforms of haem oxygenase, and NADPH cytochrome 
P-450 reductase, and utilises NADPH (or NADH) and molecular 
oxygen to catalyse the cleavage of the haem molecule at the
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a-meso bridge to form the biliverdin IX a-isomer (Kutty et 
al 1988). In turn, biliverdin is converted into bilirubin in 
the course of catalytic activity of isomer-specific 
biliverdin reductase.
1.3 REGULATION OF CYTOCHROME P-45O-DEPENDENT STEROID
METABOLISM
1.3.1 ROLE OF GONADAL HORMONES
The rat hepatic drug- and steroid-metabolising system 
exhibits sex-related differences in metabolism around the 
onset of puberty (Stenberg 1976). Adult males have higher 
hydroxylating activity, whereas metabolism is primarily 
reductive in adult females. In general, androgens increase 
oxidative metabolism and decrease reductive metabolism, 
whilst oestrogens exert the opposite effects (Kato et al 
1969, Kramer et al 1978, Berg and Gustafsson 1973, Mode and 
Norstedt 1982).
Steroid hormones are thought to be the physiological 
correlates of xenobiotics in hepatic P-450 metabolism 
(Gustafsson and Stenberg 1974a) which is supported by the 
finding that steroid metabolism proceeds at lower Km values 
than for xenobiotic metabolism, indicating that steroids may 
be the preferred substrates in vivo (Skett 1978).
The significance of sex differences in hepatic steroid 
metabolism are, as yet, unclear. One possible explanation 
could be the maintenance of sex hormone concentrations. For 
example, the high 5a-reductase activity in females rapidly
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converts testosterone to 5a-dihydrotestosterone, whilst 
oestrogens are readily hydroxylated in males. This would 
result in the metabolism and excretion of unwanted steroids 
in the animal.
It is now widely accepted that gonadal hormones play a 
vital role in the regulation of hepatic drug and steroid 
metabolism. Firstly, sex-dependent effects in hepatic 
metabolism are not observed in male and female rats until 
the onset of puberty (DeMoor and Denef 1968, Stenberg 1976, 
Berg and Gustafsson 1973). Secondly, castration of male 
animals at different ages resulted in differences in hepatic 
steroid metabolism (Berg and Gustafsson 1973, Kato et al 
1969).
Yates et al (1958) showed that castration of adult male 
rats resulted in an increase in 5a-reductase activity, an 
effect that was reversed upon treatment with testosterone.
In a similar set of experiments, it was shown that 
castration of adult male rats resulted in an increase in the 
female-specific 5a-reductase activity together with a 
decrease in hydroxylating activity (Einarsson et al 1973, 
Kato et al 1969, Berg and Gustafsson 1973), and that this 
"feminisation" of male liver enzymes could be reversed by 
testosterone treatment. In contrast, ovariectomy had no 
effects on steroid metabolism (Gustafsson and Stenberg 
1974b), although oestrogen administration to male rats 
resulted in a feminisation of steroid metabolism (Skett 
1978). These preliminary results therefore suggested that, 
although androgens were necessary for maintaining a 
"male-type" of metabolism, oestrogens were relatively
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unimportant for "female-type" activities.
1.3.2 NEONATAL IMPRINTING
Gustafsson and Stenberg (1974b) showed that hepatic 
steroid metabolism in neonatally castrated males could not 
be "remasculinised" upon postpubertal treatment with 
testosterone. Conversely, steroid metabolism in adult female 
rats could not be masculinised upon postpubertal androgen 
treatment. The authors therefore proposed the phenomenon of 
"neonatal imprinting" (Gustafsson and Stenberg 1974c, 
Gustafsson et al 1975, Gustafsson and Stenberg 1976, 
Gustafsson et al 1977), that exposure to androgens in the 
neonatal period was essential for the expression of the 
adult male type of steroid metabolism (reviewed by Skett and 
Gustafsson 1979). The absence of neonatal androgens in the 
female therefore resulted in the expression of 
female-specific activities (5a-reductase, 15p-hydroxylase) 
and the relative absence of male-specific hydroxylating 
enzymes.
Einarsson et al (1973) suggested that the enzymes 
responsible for steroid metabolism could be divided into 
three categories according to their developmental regulation
I : This group is best represented by 6{3-hydroxylase 
activity, which is two to three times higher in male than 
female rats. This sexual difference was completely abolished 
both by neonatal and postpubertal testectomy, and stimulated
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by testosterone propionate treatment. 6p-hydroxylase 
activity could also be stimulated in castrated female rats 
upon testosterone administration, although not to levels in 
the male. These results therefore suggest that this group of 
enzymes has a basal activity regulated by nongonadal factors 
and is reversibly induced by androgen treatment.
II : The second group of enzymes, typified by 
16a-hydroxylase activity was generally more active in male 
than female rats. Only neonatal testectomy completely 
abolished this sexual difference whereas postpubertal 
testectomy reduced but did not abolish the sex difference in 
enzyme activity between male and female animals.
Testosterone propionate administration to postpubertally 
gonadectomised male rats restored 16a-hydroxylase activity. 
Testosterone treatment of castrated female rats also 
resulted in an increase in enzyme activity. This group of 
enzymes is therefore irreversibly imprinted neonatally and 
reversibly stimulated postpubertally by androgens. 
17-oxosteroid oxidoreductase activity is also regulated in 
this manner.
5a-reductase activity is about ten fold higher in 
female than male animals. This sex difference in enzyme 
activity, similar to that of a Group II enzyme, was 
neonatally imprinted and partially controlled by androgens 
postpubertally. 15p-hydroxylase activity has only been 
detected in females and can also be characterised as a Group 
II enzyme.
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Group II enzymes can be further subdivided into three 
groups according to their sensitivity to imprinting 
(Gustafsson and Stenberg 1974b) :
a) Enzymes imprinted by a low dose of androgen and 
imprinting is complete within 7 days e.g. 5a-reductase;
b) Enzymes imprinted by a higher dose of androgen and 
imprinting takes 7 days;
c) Imprinting is not complete by 3 0 days of age e.g. 
16a-hydroxylase.
Ill : The third category (Einarsson et al 1973), 
exemplified by 7a-hydroxylase activity, is generally more 
active in female than male rats. Neonatal or postpubertal 
testectomy had little effects on enzyme activity, indicating 
that this group of enzymes is primarily regulated by 
nongonadal factors.
Immunochemical evidence for neonatal printing of 
cytochrome P-450 has also been documented (Chao and Chung 
1981).
1.3.3 HYPOTHALAMO-PITUITARY-LIVER AXIS
Several groups have independently reported that 
hypophysectomy of adult male and female rats resulted in the 
abolition of the sex differences observed in hepatic drug 
and steroid metabolism between males and females and enzyme 
activities returned to prepubertal levels (Denef 1974, 
Gustafsson and Stenberg 1974a, Kramer et al 1975a, Kamataki 
et al 1985). This effect was more prominent in adult female
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rats, where hypophysectomy resulted in a marked decrease in 
the female-specific 5a-reductase activity and an increase in 
male-specific oxidations. Thus hypophysectomy of female rats 
resulted in a "masculinisation" of steroid metabolism, 
indicating that the female pattern of steroid metabolism was 
dependent on the presence of an intact pituitary (Gustafsson 
and Stenberg 1974a). Further, the effects of the gonadal 
hormones were not observed in hypophysectomised rats 
(Gustafsson and Stenberg 1974d, Kramer et al 1975b, Colby et 
al 1973, Lax et al 1974), but unaffected by either 
adrenalectomy or thyroidectomy (Kramer et al 1979), thus 
indicating that the presence of the pituitary gland was 
essential for mediating gonadal hormone action. In addition, 
the absence of androgen receptors in the liver also supports 
an indirect action of androgens (Gustafsson et al 1976).
Implantation of an ectopic pituitary (secretes PRL and 
GH) under the kidney capsule of hypophysectomised male and 
female rats resulted in a feminisation of hepatic steroid 
metabolism (Eneroth et al 1977, Gustafsson and Skett 1978), 
suggesting that the pituitary gland may be releasing a 
"feminising factor" that is normally secreted in females 
only, and results in the feminisation effect observed. The 
administration to cultured hepatoma cells of a pituitary 
extract containing the feminising factor also resulted in 
the feminisation of hepatic steroid metabolism (Skett et al 
1978, Gustafsson et al 1975).
Neither the liver nor the pituitary are sexually 
differentiated and so it was postulated that the control 
centre responsible for regulating the sex differences in
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hepatic drug and steroid metabolism resided in higher 
centres of the CNS. Gustafsson and coworkers, in a series of 
articles, revealed that the hypothalamus was intricately 
involved in the regulation of this system via the 
hypothalamo-pituitary-liver axis (reviewed by Gustafsson et 
al 1980).
1.3.4 ROLE OF PITUITARY HORMONES
The addition of purified pituitary hormones exhibited a 
variety of effects. Firstly, FSH administration resulted in 
a partial masculinisation of steroid metabolism (Gustafsson 
and Stenberg 1975a), whereas treatment with LH and PRL 
(Gustafsson and Stenberg 1975b) had little effect. In 
contrast, Lax et al (1976) reported a decrease in reductive 
metabolism (masculinisation) in response to PRL. Colby et al 
(1974) using a combination of pituitary hormones showed that 
although FSH, LH, PRL, ACTH or GH administered to 
hypophysectomised rats had no effects on corticosterone 
metabolism, a combination of ACTH and GH significantly 
reduced reductase activity. In sharp contrast to this, 
however, Kramer and Colby (197 6 ) have reported an increase 
in reductive metabolism upon treatment with GH alone.
GH administered to normal male rats decreased 
ethylmorphine and aniline metabolism, whilst no effects were 
observed in female rats (Kramer et al 1975a). In contrast,
GH treatment of hypophysectomised rats of either sex 
increased ethylmorphine metabolism without altering either 
the rate of aniline metabolism or hepatic cytochrome P-450
content.
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1.3.5 ROLE OF GROWTH HORMONE
Wilson (1968) reported a decrease in hepatic drug 
metabolism in response to growth hormone, probably due to a 
decrease in cytochrome P-450 content and NADPH cytochrome 
P-450 reductase activity (Wilson 1973). It was further 
demonstrated that the effect of growth hormone was not 
dependent on the gonadal status of the animal (Wilson 1971).
As was discussed in the previous section, a pituitary 
feminising factor is thought to be involved in maintaining 
the female pattern of steroid metabolism (Gustafsson et al 
1975, Skett et al 1978). The identity of this feminising 
factor is now thought to be growth hormone (GH) (Rumbaugh 
and Colby 1980, Mode et al 1981, Skett and Young 1982), 
rather than a novel pituitary hormone. In fact, purification 
of the pituitary feminising factor showed the presence of 
growth hormone in the extract (Mode et al 1983).
The difficulty in the recognition of GH as the elusive 
pituitary feminising factor arose due to the similarity of 
MEAN serum GH concentrations in male and female animals.
Eden (1979) showed that GH is secreted in a pulsatile manner 
in adult male rats, peaking every 3-4 hours with intervening 
low or undetectable levels. In contrast, GH is secreted in 
a more continuous manner in the female, and with a higher 
baseline. Prepubertal GH secretion is not sexually 
differentiated and the characteristic GH secretion profiles 
develop at the onset of puberty. This sex difference in the
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pattern of GH secretion in adult rats is thought to dictate 
the sex-specific pattern of hepatic steroid metabolism in 
adult rats. Although sex differences in drug metabolism in 
mice exist, these are "reversed" as compared to the 
situation in rats. Nevertheless, GH also appeared to be the 
regulatory agent maintaining these sex differences in mice 
(MacLeod and Shapiro 1989).
Rumbaugh and Colby (1980) have subsequently reported 
that GH mediated the effects of oestradiol on hepatic drug 
and steroid metabolism, and further observed a feminisation 
effect in response to twice daily injection of GH in 
hypophysectomised animals. This effect was, however, only 
observed in the presence of ACTH and T4 , suggesting that 
interactions with other hormones may also be important.
Mode et al (1981) demonstrated that continuous 
administration of human GH (hGH) by Alzet osmotic minipumps 
to hypophysectomised rats caused a complete feminisation of 
hepatic steroid metabolism. However, in contrast to the 
results of Rumbaugh and Colby (1980), these authors found 
that feminisation was still achieved in hypophysectomised, 
adrenalectomised, thyroidectomised and castrated male rats, 
thus excluding the dependency on the secretions of these 
glands. The discrepancy between the two reports can be 
partially accounted for since the method of GH 
administration was different (intermittent or continuous).
Several workers have reported similar results to the 
above, that is, continuous GH administration resulted in the 
feminisation of hepatic steroid metabolism whilst 
intermittent GH administration resulted in the expression of
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male-specific and abolition of female-specific enzyme 
activities (Kato et al 1986, Mode et al 1982).
Jansson et al (1985 ) have proposed that neonatal 
androgens imprint the high amplitude pulses characteristic 
of GH secretion in adult male rats. Further, the role of the 
GH secretory pattern on the regulation of male- and 
female-specific activities has been implicated. Thus the 
female-specific 5a-reductase activity was shown to be 
regulated by the GH secretory pattern (Miller and Colas 
1982), as was the expression of 150-hydroxylase (MacGeoch et 
al 1985) and 16a-hydroxylase (Morgan et al 1985b) 
activities. GH was also thought to act as a repressive 
factor for testosterone 60-hydroxylation (Yamazoe et al 
1986).
Since GH is thought to be the pituitary feminising 
factor, Norstedt et al (1983) have suggested that the factor 
released from the hypothalamus could be the growth hormone 
release inhibitory factor, somatostatin. The authors showed 
that both specific hypothalamic lesions and 
anti-somatostatin reduced somatostatin levels in the brain, 
together with decreases in microsomal steroid 60- and 
16a-hydroxylases. It was therefore suggested that 
somatostatin maintained the male pattern of steroid 
metabolism, and that the absence of this inhibitory 
influence in females led to the secretion of growth hormone 
and a feminisation of steroid metabolism.
Figure 2 summarises the proposed model for the 
imprinting and regulation of the rat hepatic drug- and 
steroid-metabolising system.
FIGURE 2 : NEONATAL IMPRINTING OF HEPATIC STEROID
METABOLISING ENZYMES.
(adapted from S ke t t  and Gustafsson 1979)
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1.3.6 ROLE OF GLUCOCORTICOIDS
Remmer (1958) first demonstrated that adrenalectomy 
decreased hepatic microsomal oxidative activities in rats, 
an effect that could be fully reversed upon administration 
of glucocorticoids. Kato and Gillette (1965) then reported a 
sex difference in the effects of adrenalectomy on hepatic 
drug metabolism. Androgen-dependent substrates were 
metabolised more slowly in males, whereas no changes on 
hepatic metabolism were observed upon adrenalectomy in 
females.
Kato and Gillette (1965) subsequently showed that the 
metabolism of aminopyrine and hexobarbital by male rat liver 
microsomes was markedly decreased upon adrenalectomy whereas 
aniline and zoxazolamine metabolism was relatively 
unaffected. In contrast, adrenalectomy exerted no changes in 
drug metabolism in adult female rats, and so the authors 
suggested a possible permissive role of these hormones in 
mediating the actions of androgens in the male. They further 
suggested that this decrease in metabolism in male-specific 
activities (aminopyrine and hexobarbital) was as a 
consequence of a reduced binding capacity of cytochrome 
P-450 for hexobarbital and aminopyrine (Kato et al 1971), 
probably due to an impairment of the action of androgens to 
increase the binding capacity of cytochrome P-450 for these 
substrates.
Adrenalectomy resulted in a decrease in male-specific 
enzyme activities (Gustafsson and Stenberg 1974d) and in 
17p-oxosteroid oxidoreductase activity, together with an
-24-
increase in 5a-reductase activity (Lax et al 1979), thus 
reinforcing the results of Kato and coworkers described 
above.
Colby et al (1973, 1974) reported that administration 
of adrenal steroids had little effects on the 5a-reduction 
of corticosterone and testosterone, since neither 
adrenalectomy nor corticosteroid treatment exerted any 
effects on enzyme activity. Treatment with the pituitary 
hormone adrenocorticotropin (ACTH), which stimulates the 
release of corticosteroids from the adrenal glands, did not 
affect the reduction of corticosterone (Colby et al 1974). 
However a combination of ACTH and GH was reported to 
markedly decrease the reduction of corticosterone, showing 
that hormonal interactions may be important in this system.
The actions of corticosteroids on hepatic drug 
metabolism were demonstrated in gonadectomised (Ichii and 
Yago 1969) and hypophysectomised rats (Bousquet et al 1965), 
indicating that their effects are not mediated by androgenic 
or pituitary factors. Similarily the gonadal hormones 
exhibited an effect in adrenalectomised rats (Kramer et al 
1979, Mode et al 1981), showing that their effects are not 
dependent on the presence of intact adrenal glands.
From the effects of adrenalectomy on drug metabolism, 
the logical effect of glucocorticoid administration would be 
to increase hepatic metabolism. However, conflicting results 
have been reported with the effects of natural and synthetic 
glucocorticoids on this system. Tredger et al (1976) showed 
that whereas corticosterone reduced biphenyl hydroxylase and 
ethylmorphine N-demethylase activities, the synthetic
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glucocorticoid, dexamethasone markedly increased these 
enzyme activities. Further, total cytochrome P-450 content 
was increased by dexamethasone treatment and unaffected by 
corticosterone. The author explained this discrepancy by 
showing that natural glucocorticoids such as corticosterone 
were rapidly metabolised in vivo whereas the synthetic 
glucocorticoids were more slowly metabolised, and therefore 
longer-acting. This does not however explain why 
corticosterone inhibited, while dexamethasone stimulated 
drug metabolism.
The induction profile of pregnenolone-16a-carbonitrile 
(PCN) on drug-metabolising enzymes was first reported by Lu 
et al (1972) to be distinct from that of either 
phenobarbital or 3-methylcholanthrene (Horada and Omura 
1981). Although PCN administration increased total 
cytochrome P-450 content by 2-fold, cytochrome P-450pcn 
levels were induced more than 20-fold (Elshourbagy et al 
1981, Heuman et al 1981). Dexamethasone, which gives a 
greater than 30-fold induction of cytochrome P-450pcn 
appeared to be the most potent inducer of this isoenzyme 
(Schuetz et al 1984). Due to the relative inactivity of 
other steroids, together with the excessively high dose of 
dexamethasone required for P-450pcn (P-450 IIIA1) induction 
as compared to other glucocorticoid functions such as 
stimulation of tyrosine aminotransferase, it was proposed 
that dexamethasone was acting by a mechanism distinct from 
that of the classical glucocorticoid receptor pathway 
(Scheutz and Guzelian 1984). In addition, the 
dexamethasone-induced increases in P-450pcn were unaffected
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in the presence of glucocorticoid antagonists that abolished 
tyrosine aminotransferase activation (Schuetz et al 1984).
Glucocorticoids are known to influence a number of 
components of the hepatic drug- and steroid-metabolising 
system. A reduction in NADPH-cytochrome P-450 reductase 
activity (Castro et al 1970) and a decrease in cytochrome 
P-450 levels (Yago and Ichii 1969) was reported following 
adrenalectomy. Hamrick et al (197 3) showed that 
administration of cortisone acetate resulted in an increase 
in NADPH cytochrome c reductase, but cytochrome P-450 levels 
were reduced. Further, Tredger et al (1976) reported that 
whilst the synthetic glucocorticoid dexamethasone stimulated 
both of the above parameters, corticosterone exhibited no 
such effects.
Adrenalectomy has also been reported to increase haem 
oxygenase activity, and thus the degradation of cytochrome 
P-450 (Sardana et al 1980). This would explain the reduction 
in cytochrome P-450 content in response to adrenalectomy.
1.3.7 ROLE OF THYROID HORMONES
The thyroid hormones are known to influence the 
metabolism of drugs and steroids by the hepatic cytochrome 
P-450 system. A great deal of work has been carried out by 
Kato and coworkers in this respect.
Kato and Gillette (1965) reported that the effects of 
thyroxine on drug metabolism exhibited both sex- and 
substrate-dependent effects in rats. Whereas metabolism of 
the androgen-dependent substates aminopyrine and
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hexobarbital was impaired by thyroxine in adult male rats, 
metabolism of the sex-independent substrate aniline was 
slightly increased. Drug metabolism was enhanced upon 
thyroxine administration to female rats.
The effects of thyroxine on steroid metabolism were 
also sex-dependent and reported to be similar to those on 
drug metabolism. Thyroxine administration to adult male rats 
resulted in a decrease in the hydroxylation of progesterone 
(Kato et al 1970b) and testosterone (Kato et al 1970a), and 
increased progesterone and hydrocortisone reduction (Kato et 
al 1970c). Both cytochrome P-450 content and substrate 
interaction with cytochrome P-450 were reduced upon 
treatment with thyroxine. In contrast, thyroxine exhibited 
no effects in females, except for a slight decrease in the 
reductive metabolism of testosterone and hydrocortisone.
Thyroidectomy of male rats (Kato et al 1970b) resulted 
in a decrease in the hydroxylation of testosterone and 
progesterone, but no effects were observed on either 
reductase activity or upon thyroidectomy of female rats. 
Thyroidectomy also had no apparent effects upon either 
cytochrome P-450 content or on substrate interaction with 
cytochrome P-450 in females.
Both thyroxine and thyroidectomy were reported to 
influence several components of the cytochrome P-450 system. 
Kato and Takahashi (1968) showed that thyroxine increased 
NADPH oxidase and NADPH cytochrome c reductase activities in 
male and female rats, although the increase was reported to 
be greater in females. Cytochrome P-450 content was only 
increased in male rats.
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The metabolism of aminopyrine, hexobarbital and 
aniline, and the activities of NADPH oxidase, NADPH 
cytochrome c reductase and NADH oxidase were decreased upon 
thyroidectomy of male and female rats, although NADH 
cytochrome c reductase, cytochrome b 5 and P-450 content 
remained unchanged. The administration of triiodothyronine 
to thyroidectomised females was reported to reverse all the 
effects of thyroidectomy, but cytochrome P-450 content and 
drug metabolism remained low in males.
Studies of cytochrome P-450 binding spectra (Kato et al 
1970a) led to the conclusion that the reason for the 
reduction in the metabolism of aminopyrine and hexobarbital 
in male rats in response to thyroxine administration was due 
to an impaired binding capacity of cytochrome P-450 for 
these substrates, together with the direct effects of 
thyroxine observed on cytochrome P-450 content and binding 
capacity, and other components of this system (Kato and 
Takahashi 1968). A similar explanation was offered for the 
effects of thyroidectomy.
The relative specificity of thyroxine and thyroidectomy 
for male-specific functions suggested an involvement of 
androgens in this system. The authors therefore suggested 
that the actions of thyroxine may involve the gonadal 
hormones, since the effects of thyroxine were abolished in 
castrated rats, but restored in androgen-treated castrates 
(Kato and Gillette 1965). Further, the effects of thyroxine 
in androgen-treated females were reported to be identical to 
those in males (Kato et al 1970c), indicating a dependency 
of androgens in the actions of thyroxine. Hence the effects
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of thyroxine on steroid and drug metabolism may be due to an 
impairment of androgen action. In addition, Colby et al 
(1973) showed that thyroxine failed to affect steroid 
metabolism in orchiectomised rats. On the basis of these 
findings, the authors concluded that thyroxine antagonised 
the stimulatory effects of androgens on hepatic microsomal 
metabolism, but in the absence of androgens, thyroxine 
increased hepatic metabolism.
The studies carried out by Kato's group, have, however 
been disputed by several authors due to their use of 
thyrotoxic doses of the thyroid hormones. Rumbaugh et al 
(1978) showed that administration of physiological doses of 
thyroxine stimulated drug metabolism in hypophysectomised 
male and female rats, whereas larger doses of thyroxine 
inhibited metabolism of some substrates in a sex-dependent 
manner. In addition, thyroxine produced marked 
dose-dependent decreases in hepatic cytochrome P-450 content 
and increases in NADPH cytochrome c reductase activity in 
hypophysectomised males and females (Colby and Rumbaugh 
1985). Thus the effects of physiological doses of thyroxine 
do not appear to correlate with changes in cytochrome P-450 
levels (although specific isoenzymes may have increased), 
but rather follow the changes in NADPH cytochrome c 
reductase activity.
Under normal circumstances, the stimulatory effects of 
physiological doses of thyroxine are in agreement with the 
finding that thyroidectomy results in a decrease in drug 
metabolism. In addition, numerous clinical reports have 
shown that hypothyroidism increased while hyperthyroidism
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decreased the plasma half-life of drugs (Vesell et al 1975, 
Saenger et al 1976).
That the effects of thyroxine were exhibited in 
hypophysectomised rats shows that thyroxine acts directly on 
the liver, and not via pituitary hormones. In contrast to 
the conclusions of Kato, Colby and Rumbaugh (1985) proposed 
that the effects of thyroxine were not dependent on the 
gonadal status of the animal, and that thyroxine stimulated 
hepatic metabolism irrespective of the presence or absence 
of oestradiol and androgen.
In dispute with the above results, Skett and Weir 
(1983) demonstrated sex- and substrate-dependent effects of 
physiological doses of thyroxine, and further showed that 
thyrotoxic doses resulted in a marked decrease in cytochrome 
P-450 content in males together with the abolition of the 
sex-dependent effects observed on drug metabolism. In 
addition, thyroidectomy was also reported to exhibit sex 
differences in drug metabolism, and replacement thyroxine 
treatment of thyroidectomised rats reversed some effects of 
thyroidectomy whilst enhancing others. The existence of sex 
differences in steroid metabolism in response to 
thyroidectomy has previously been documented (Lax et al 
1979) .
Skett and Weir (1983), in an attempt to explain the 
discrepancies in the effects of thyroxine, suggested that an 
optimal concentration of thyroxine existed for exhibiting 
maximal effects on hepatic metabolism, and that deviations 
from this optimum, either in the direction of hypo- or 
hyperthyroidism, resulted in loss of enzyme activity.
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More recently, it has been suggested that the thyroid 
hormones may function as regulatory hormones in the 
expression of constitutive levels of cytochrome P-450a (gene 
IIA1), catalysing the 7a-hydroxylation of testosterone 
(Arlotto and Parkinson 1989) since thyroidectomy resulted in 
an increase in cytochrome P-450a (gene IIA1) expression that 
was restored upon treatment with thyroid hormones.
Previous studies have already documented a role of the 
thyroid hormones in the regulation of liver microsomal 
cytochrome b5 , NADPH cytochrome P-450 reductase and haem 
oxygenase (Phillips and Langdon 1962, Hoch et al 1980, Smith 
et al 1982, Kriz et al 1982).
1.3.8 ROLE OF INSULIN
The role of insulin in the regulation of cytochrome 
P-450-dependent drug and steroid metabolism has been 
indirectly implicated by the marked effects of both 
spontaneous and chemically-induced diabetes.
Dixon et al (1961) first reported that alloxan-induced 
diabetes in male rats decreased the metabolism of 
hexobarbital, codeine and chlorpromazine in vitro and 
prolonged hexobarbital sleeping time in these animals. 
Subsequent studies have confirmed this initial report. Kato 
and Gillette (1965) showed that the metabolism of 
aminopyrine and hexobarbital by male rat liver microsomes 
was impaired upon treatment with alloxan, while aniline 
metabolism was enhanced. In contrast, the metabolism of 
these substrates was enhanced in alloxan-treated females.
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The authors reported that the effects of alloxan were only 
evident in the presence of androgens, which may explain why 
alloxan only affected sex-dependent substrates such as 
aminopyrine and hexobarbital. It was subsequently suggested 
in a further report (Kato et al 1970e) that the stimulant 
effect of androgens on oxidative metabolism in male rat 
liver microsomes was blocked by alloxan or starvation, 
resulting in a decrease in drug oxidations. This was further 
supported by the observation that metabolism of the 
androgen-independent substrate aniline was not decreased by 
alloxan in male rats, or in female rats. In addition, Kato 
et al (1970f) demonstrated that the binding capacity of 
cytochrome P-450 for androgen-dependent substrates in male 
rats was decreased by alloxan, and so the authors postulated 
that this decrease was as a direct consequence of an 
impairment of the ability of androgen to stimulate the 
binding capacity of cytochrome P-450 with these substrates.
Several groups have documented that the effects of 
alloxan on drug metabolism may be due to its toxicity rather 
than diabetogenic effects (Hoftiezer and Carpenter 1973). 
Streptozotocin (STZ), a selective p-cell toxin was 
subsequently used to induce diabetes in experimental 
animals, and was reported to cause a decrease in 
hexobarbital and an increase in aniline metabolism (Ackerman 
and Liebman 1977). Since these effects were reversible upon 
insulin therapy, it was concluded that STZ was exerting 
diabetogenic effects on drug metabolism.
The sex-dependent effects of STZ-induced diabetes have 
more recently been demonstrated by Skett and Joels (1985).
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Whereas male-specific enzyme activities responsible for the 
metabolism of diazepam, lignocaine and imipramine were 
decreased, non-sex-specific enzyme activities were 
unaffected in male rats. Further, a time-dependency was also 
observed in the effects of STZ on drug metabolism in that 
acutely (3-day) STZ-treated rats exhibited all of the above 
effects whereas no changes were observed in chronically 
(21-day) rats. In contrast, STZ elicited no changes in drug 
metabolism in females.
Skett (1986) subsequently showed that the effects of 
STZ treatment on hepatic steroid metabolism were 
sex-dependent and similar to those observed with drug 
metabolism. The effects of diabetes were only observed in 
the male, and exhibited an abolition of the sex differences 
observed in hepatic steroid metabolism. Female-specific 
activities were increased and male-specific activities 
decreased by diabetes, which is characteristic of the 
feminisation effect observed with continuous growth hormone 
infusion (Mode et al 1981). Since insulin-deficient 
conditions led to the feminisation of steroid metabolism, it 
was proposed that insulin may be exerting a "masculinising" 
influence on hepatic metabolism in vivo (Skett 1986).
Insulin administration to isolated rat hepatocytes 
resulted in a general stimulation of hepatic 
steroid-metabolising enzymes (Hussin and Skett 1987) without 
altering total cytochrome P-450 content. The possibility of 
the stimulation of individual isoenzymes was, however, not 
examined. It was further shown that, whereas hepatocytes 
from 3- and 21-days STZ-diabetic rats were resistant to the
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stimulatory effects of insulin (Hussin and Skett 1988), 
insulin-treated diabetics indicated only a partial 
restoration of the response with insulin, implying that 
other factors may also be important for the restoration of 
the response to insulin.
Skett et al (1984) showed that the effects of 
STZ-diabetes and castration in the male rat were similar, 
and found that STZ had little effects in castrated rats. 
Further, the effects of STZ in castrated rats could be
restored upon treatment with androgen, suggesting a certain
degree of interaction between the two effects. The results 
on drug metabolism in this study did not however, correlate 
with changes in serum testosterone. The involvement of 
androgens in the diabetic state has also been suggested by 
Kato and Gillette (1965). It was therefore proposed that 
there was an interaction between androgens and insulin in 
this system that was mediated via a common mediator, growth 
hormone (Skett et al 1984). Tannenbaum (1981) has shown that 
STZ-diabetes resulted in marked depression of the pulsatile 
GH secretory pattern in male rats, and further suggested a
role of somatostatin in this effect. Certainly, the
somatotrophs of diabetic rats are relatively resistant to 
somatostatin, as well as elevated growth hormone-releasing 
hormone levels (Welsh and Szabo 1988). It has further been 
suggested that the effects of diabetes on the growth hormone 
secretory pattern may be as a consequence of the low 
circulating levels of thyroid hormone in these animals 
(Ortiz-Caro et al 1984), since growth hormone levels were 
decreased in thyroidectomised rats (Coiro et al 1979).
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The effects of diabetes at the biochemical level have 
been documented by numerous authors, and a diabetes- 
dependent form of cytochrome P-450 has been isolated. Past 
and Cook (1982) isolated a 5 2K cytochrome P-450 by SDS-PAGE 
from the microsomal fraction of alloxan-treated diabetic 
rats. They showed that this band was not present in control, 
3-methylcholanthrene- or phenobarbital-treated rats, or from 
insulin-treated diabetic rats. It was therefore suggested 
that the increase in this form of cytochrome P-450 in 
diabetes was reponsible for the increased metabolism of 
aniline (Kato and Gillette 1965).
More recently, Bellward et al (1987) have demonstrated 
increased levels of cytochrome P-450j (gene IIE1) in 
spontaneously diabetic BB rats, as well as increases in 
cytochrome P-450j-catalysed activities, aniline 
hydroxylation and N-nitrosodimethylamine N-demethylation. 
These effects were all reversible upon replacement insulin 
therapy. In contrast, cytochrome P-450f (gene IIC7) levels 
remained unchanged between diabetic and non-diabetic 
conditions.
It has recently been reported that levels of cytochrome 
P-450 forms RLM3 (gene IIC13) and RLM5 (gene IIC11) were 
markedly decreased, and RLM5b and RLM 6  (gene IIE1) increased 
within three weeks of the onset of STZ diabetes, and 
restored by insulin therapy (Favreau and Schenkman 1988a), 
whereas RLM5a (gene IIC 6 ) levels remained unchanged.
The results observed with STZ-induced diabetics were 
later confirmed in a subsequent study carried out in 
spontaneously diabetic rats (Favreau and Schenkman 1988b).
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The induction of cytochrome P-450ac (gene IIE1) was also 
reported in STZ-diabetic, alloxan-diabetic and BB/Wor rats 
(Dong et al 1988), which correlated well with the observed 
increase in P-450ac mRNA, possibly as a result of mRNA 
stabilisation and enhanced protein stabilisation due to the 
high level of acetone produced (Song et al 1987). Further, 
it has recently been shown that both actinomycin D (inhibits 
RNA synthesis) (Peng et al 1983) and cycloheximide (inhibits 
protein synthesis) (Tu et al 1983) reduced the effects of 
fasting on drug metabolism, and so diabetes may be exerting 
its effects in a similar manner.
Experimentally-induced diabetes has also been reported 
to reduce the expression of the inhibitory G-protein (Gi ) 
(Gawler et al 1987). Since insulin is thought to interact 
with G-proteins during its action (Houslay et al 1989), the 
impairment of many of the effects of insulin in diabetes may 
be as a direct consequence of this effect.
1.3.9 SEX-DEPENDENCY AND DEVELOPMENTAL REGULATION OF
CYTOCHROME P-450
Although the lower level of total microsomal cytochrome 
P-450 protein in the female as compared to the male rat is 
adequate to explain the overall slower metabolism of 
xenobiotics in female rats, it does not explain the large 
sex differences obtained in hepatic metabolism. The 
metabolism of endogenous steroids, such as
androst-4-ene-3,17-dione, is sex-specific in nature in that 
certain enzymes display higher activity in male rats while
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others are more active in females (Table 1).
TABLE 1 : SEX-SPECIFIC METABOLISM OF TESTOSTERONE AND 
ANDROST-4-ENE-3,17-DIONE (Gustafsson and Stenberg 1974)
ENZYME SEX-SPECIFICITY
5a-reductase male < female
3a-hydroxysteroid dehydrogenase male = female
30-hydroxysteroid dehydrogenase male > female
17a-hydroxysteroid dehydrogenase male = female
170-hydroxysteroid dehydrogenase male > female
60-hydroxylase male > female
7a-hydroxylase male < female
16a-hydroxylase male > female
steroid sulphate 150-hydroxylase male < female
Sex-related differences in the metabolism of drugs and 
steroids have now been attributed to the presence of male- 
and female-specific isoenzymes of cytochrome P-450 (Lu and 
West 1980, Morgan et al 1985b).
Recently, a number of groups have isolated and purified 
various forms of cytochrome P-450 (Waxman 1984, Kamataki et 
al 1983, Morgan et al 1985b, Funae and Imaoka 1987) which 
would explain these sex-differences observed in hepatic 
metabolism. Kamataki et al (1981) isolated two forms of 
cytochrome P-450 from male and female rats, which they 
termed cytochrome P-450-male and cytochrome P-450-female 
respectively. Cytochrome P-450-male metabolised aminopyrine 
and benzphetamine more efficiently than the female form, 
whereas ethylmorphine was metabolised to an equal extent by 
both forms (Kamataki et al 1981). Further, using specific 
antibodies against these cytochrome P-450 forms, they showed
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that cytochrome P-450-male was only present in male rats, 
and that its levels were markedly reduced upon castration 
and restored to normal levels upon treatment with 
testosterone. Similarily cytochrome P-450-female was only 
detected in female rats and abolished upon ovariectomy.
Kamataki et al (1985) have recently studied the 
developmental profile of these two forms and have shown that 
both cytochromes P-450-male and P-450-female are virtually 
undetectable prepubertally in male and female rats. However, 
the onset of puberty at approximately 25 days of age was 
shown to parallel the appearance of cytochromes P-450-male 
and P-450-female in male and female rats respectively, and 
correlated well with the changes observed in hepatic drug 
and steroid metabolism.
Male-specific enzymes have also been isolated by 
numerous other groups. Morgan et al (1985a) isolated 
cytochrome P-450 RLM5 (gene IIC11) from male rats, and 
correlated this with catalysing the hydroxylation of 
steroids in the 16a position. Further, it was shown in the 
same study and by Pasleau et al (1981) that the expression 
of cytochrome P-450!6a (gene IIC11) was only observed in the 
male after the onset of puberty, and not in prepubertal male 
or female rats.
Immunochemical studies have shown the existence of 
cytochromes P-4502c/ut-a (gene IIC11) in adult male rat 
liver and P-4502d/UT_1 (gene IIC12) in adult females (Waxman
1984). Characterisation of these forms of cytochrome P-450 
(Waxman et al 1985) showed that the male-specific cytochrome 
P-4502c/ut_a (gene IIC11) was the major microsomal steroid
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16a-hydroxylase of uninduced male rat liver, and activity 
was increased about 30-fold at the onset of puberty. 
Similarly, cytochrome P-4502d/ut-: (gene IIC12) was 
developmentally induced in female rats at puberty, 
corresponding with an increase in 15{3-hydroxylase activity 
(Waxman et al 1985, MacGeoch et al 1984). Postpubertal 
castration of male animals did not affect cytochrome 
P-450 ! 5 0  (gene IIC12) levels, whereas neonatal castration 
significantly increased cytochrome P-450i5p (gene IIC12) 
content. Administration of oestradiol valerate also 
feminised male cytochrome P-450!5p (gene IIC12) levels. From 
this it was concluded that cytochrome P-450i5P (gene IIC12) 
is suppressed by neonatal androgen and is therefore not 
expressed in male rats (MacGeoch et al 1985).
Cytochrome P-4502a/pcN_E (gene IIIA2), catalysing >85% 
of microsomal steroid 6 p-hydroxylation (Waxman et al 1985) 
was also male-specific. This was, however, due to the 
suppression of 6{3-hydroxylase activity in mature females 
rather than an induction in mature males rats at puberty.
Neonatal gonadectomy and hormone replacement studies 
have established that neonatal androgen is responsible for 
the imprinting of cytochrome P-4502c (gene IIC11), for the 
maintenance of cytochrome P-4502a (gene IIIA2), and for the 
suppression of cytochrome P-4502d (gene IIC12) in male rats 
(Waxman et al 1985).
The female-specific enzyme microsomal 5a-reductase was 
also expressed significantly in female rats at puberty 
(Waxman et al 1985). The regulation of the two 
female-specific enzymes 5a-reductase, and 15p-hydroxylase,
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has been studied in greater detail by Dannan et al (1986), 
who showed that, although enzyme activities were unaffected 
by oestrogen treatment, postpubertal androgen administration 
resulted in a marked suppression of the two activities.
Cytochrome P-4503/UT_F (gene IIAl) and its 
corresponding steroid 7a-hydroxylase activity was present at 
much higher levels in adult females than males (Waxman et al
1985). This was thought to be due to the rapid decrease in 
expression in male rats rather than an induction in female 
rats at puberty. Guengerich et al (1982) have reported a 
similar age-dependent cytochrome P-450 (P-450pb_x/PB_C )
(gene IIC 6 ) catalysing warfarin 7a-hydroxylase activity, 
which was present in both uninduced male and female rats.
1.4 STEROID METABOLISM
1.4.1 CYTOCHROME P-450 NOMENCLATURE
Since the original idea proposed by Lu and West in 
1980, that the cytochromes P-450 exist in the form of 
isoenzymes with distinct yet overlapping substrate 
specificities, numerous authors have subsequently isolated, 
purified and characterised a whole spectrum of cytochrome 
P-450 isoenzymes.
Isoenzymes isolated by different authors have been 
designated using their own nomenclature systems, resulting 
in a collection of names for each isoenzyme.
Nebert and Gonzalez (1987) have subsequently introduced 
a universal nomenclature system for different isoenzymes
-41-
based on their primary amino acid sequences. The cytochromes 
P-450 are grouped into a gene superfamily, which is 
subdivided into gene families and into gene subfamilies.
Gene families are designated by Roman numerals, and 
currently characterised hepatic drug-metabolising enzymes 
are categorised into gene families I to IV. Extrahepatic 
cytochromes P-450 catalysing steroid biosynthesis have been 
classified into gene families XVII (steroid 
17a-hydroxylase), XIX (cytochrome P-450aromatase) and XXI 
(steroid 21-hydroxylase). The mitochondrial, yeast and 
bacterial cytochrome P-450 gene families are referred to as 
XI, LI/LII and CI/II respectively. Gene subfamilies are 
denoted by capital letters, followed by Arabic numbers to 
identify genes within a subfamily. Gaps have been left 
throughout to allow for new cytochromes that may be 
isolated. The nomenclature system of Nebert and Gonzalez 
(1987) is summarised in Table 2.
TABLE 2 : HEPATIC CYTOCHROME P-450 NOMENCLATURE (adapted 
from Nebert and Gonzalez 1987,Gonzalez 1989)
Family/subfamily Characterisation
P-450I (polycyclic aromatic compound inducible) 
P-450IA1 Rat c, rabbit 6 , mouse F1,
P-450IA2 Rat d, rabbit 4, mouse P 3 ,
P-450II (major)
P-450IIA subfamily
P-450IIA1 Rat a
P-450IIA2 RLM2
P-450IIA3 Human P-450(1), mouse 15a
•-450IIB subfamily (phenobarbital-inducible)
P-45 0IIB1 Rat b, rabbit 2, human MP
P-450IIB2 Rat e
P-450IIB3 Rat
P-45 0IIB4 Rabbit LM2
P-450IIB5 Rabbit HP1
P-450IIB7 Human
P-450IIB8 Human
P-450IIB9 Mouse pf26
P-450IIB10 Mouse pf3/46
'-450IIC subfamily
P-450IIC1 Rabbit PBcl
P-450IIC2 Rabbit PBc2, K, pHP2
P-450IIC3 Rabbit PBc3, form 3b
P-450IIC4 Rabbit PBc4, form pl - 8 8
P-450IIC5 Rabbit 1
P-450IIC6 Rat PB1, PB-C, k
P-450IIC7 Rat f
P-450IIC8 Human form 1
P-450IIC9 Human MP-4
P-450IIC10 Chicken PB15, Human MP - 8
P-450IIC11 Rat M-l, h, 2c, 16a
P-450IIC12 Rat i, 2d, 15{3
P-450IIC13 Rat g
P-450IIC14 Rabbit pHP
P-45 0IIC15 Rabbit b32-3
'-450IID subfamily
P-450IID1 Rat dbl, human dbl
P-450IID2 Rat db2
P-450IID3 Rat
P-45 0IID4 Rat
P-450IID5 Rat
P-450IID6 Human dbl
P-450IID7 Human
P-450IID8 Human
P-45 0IID9 Mouse. 16a
’-450IIE subfamily (ethanol-inducible)
P-450IIE1 Rat j, rabbit 3a, human j
P-450IIE2 Rabbit gene 2
■450III (steroid-inducible)
P-450IIIA1 Rat pcnl
■450IIIA2 Rat pcn2
P-45 0IIIA3 Human p
P-450IIIA4 Human nf
P-450IIIA5 Human PCN
human P 
human P
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P-450IIIA6 Rabbit 3c
P-450IV (peroxisome proliferator-inducible) 
P-450IVA1 Rat LAw
P-450XI (mitochondrial proteins)
P-450XIA subfamily 
P-450XIA1 Bovine and human see
P-450XIB subfamily 
P-450XIB1 Bovine and human lip
P-450XVII 'steroid 17a-hydroxylase)
P-450XVIIA1 Bovine and human 17a
P-450XIX
P-450XIXA1 Human aromatase
P-450XXI (steroid 21-hydroxylase)
P-45 0XXIA1 Bovine, mouse and human C21A
P-450XX1A2 Bovine, mouse and human C21B
P-450LI (plant P-450)
P-450LIA1 Yeast Ian
P-450CI (prokaryote P-450)
P-450CIA1 Pseudomonas putida cam
-44-
1.4.2 STRUCTURAL SIMILARITY OF CYTOCHROME P-450
ISOENZYMES
The cytochromes P-450 catalyse the metabolism of a 
diverse range of drugs and steroids owing to the presence of 
isoenzymes showing greater specificity towards certain 
substrates than others. Steroid hormones have proved to be 
very useful in this respect for distinguishing between these 
multiple isoenzymes since they often yield unique metabolic 
profiles (Figure 3). The most widely studied steroids have 
been androstenedione and testosterone (Woods et al 1983, 
Waxman et al 1983, Sheets and Estabrook 1985, Sonderfan et 
al 1987), and so the characterisation of cytochrome P-450 
isoenzymes in this section will, for the greater part, be 
restricted to the metabolism of these two substrates. The 
recognition of the presence of multiple isoenzymes with 
unique yet overlapping substrate specificities was 
attributed to the presence of a family of structurally 
related cytochrome P-450 proteins (Lu and West 1980).
A variety of techniques have been employed in the 
identification of different isoenzymes :
i) Immunochemical cross-reactivity - useful in the 
determination of similarities between different isoenzymes, 
and also different species eg rat-human.
ii) Protein sequencing - Black and Coon (1986) have 
determined the amino acid sequences of a number of 
cytochromes P-450, which has subsequently led to the gene 
designations of Nebert and Gonzalez (1987).
iii) DNA sequencing - to determine similarities amongst
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P-450 genes. In general, similarity is greater among P-450 
genes in protein coding regions than in non-coding regions.
iv) Substrate specificity - eg Cytochromes P-45016a 
(Pas.leau et al 1981), P-4502 c (Waxman 1984) and P-450-male 
(Kamataki et al 1983) have been shown to catalyse the same 
hydroxylation reaction. Also important in the determination 
of major and minor reactions catalysed by a particular 
isoenzyme.
Although the nomenclature system used by the various 
authors will be sustained in the following discussion of 
their results, the gene designation given to that particular 
isoenzyme will also be given. Isoenzymes relevant to this 
study are discussed in detail, but all, together with their 
specific activities, are summarised in Table 3.
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TABLE 3 : CYTOCHROME P-450 ISOENZYMES (modified from Waxman 
1988)
Waxman Levin Guengerich Schenkman Wolf other GENE
PB-1 k PB-C RLM5a PBlb --- IIC6
PB-inducible warfarin 7a-hydroxylase; hormone independent
2a           IIIA2
Male-specific testosterone 6p-hydroxylase
PB-2a p PCN-E ---  -----  --- IIIA1
Synthetic steroid-inducible testosterone 6p-hydroxylase
2c h UT-A RLM5 PB2a male IIC11
Male-specific testosterone 2a/16a-hydroxylase
2d i UT-1 fRLM4---- female IIC12
Female-specific steroid sulphate 150-hydroxylase
3 a UT-F ----- UT1 --- IIA1
Steroid hormone 7a-hydroxylase
PB-4 b PB-B PBRLM5 PB3a ---  IIBl
Major phenobarbital-inducible testosterone 160-hydroxylase
PB-5 e PB-D PBRLM6 PB3b ---  IIB2
97% homologous to PB-4 (IIBl)
Constitutive form, cross-reacts with PB-4 (IIBl)
BNF-B c BNF-B------ ------ MClb --- IA1
Major 3-methylcholanthrene-inducible form
ISF-G d ISF-G------ ------ MCla --- IA2
Major isosafrole-inducible form
  f         IIC7
Constitutive form, cross-reactive with PB-4 (IIBl)
  g   RLM 3     IIC13
Male-specific, strain dependent
  j   RLM 6     IIE1
Ethanol-inducible nitrosamine demethylase
- 4 7 -
1.4.3 RAT CYTOCHROME P-45 0 ISOENZYMES
a_)_ 7g-HYDROXYLASE (P-450 IIA1)
Ryan et al (1979) isolated cytochrome P-450a (MW 48000) 
which has been reported to catalyse the 7a-hydroxylation of 
testosterone, progesterone and androstenedione (Wood et al 
1983, Waxman 1984, Waxman et al 1985, Nagata et al 1986). 
Arlotto and Parkinson (1989) have recently described the 
purification of two structurally related cytochrome P-450 
isoenzymes, P-450a (gene IIAl) and P-450m , which catalysed 
the 7a-hydroxylation of testosterone in a reconstituted 
system. Cytochrome P-450a (gene IIAl) (Arlotto et al 1989) 
appeared to be solely responsible (>96%) for the 
7a-hydroxylation in rat liver microsomes, and cytochrome 
P-450m only a minor pathway in testosterone oxidation. A 
similar form of cytochrome P-450 has been purified from dog 
liver microsomes (Duignan et al 1988).
Cytochrome P-450a (gene IIAl) was present in one week 
old male rats (Arlotto and Parkinson 1989), and 
7a-hydroxylase activity appreciably declined with age. In 
contrast, 7a-hydroxylase activity did not decline in mature 
female rats, resulting in higher levels of this activity in 
adult female than male rats (Waxman et al 1985).
Neonatal castration of males and neonatal exposure of 
females to androgens had little effects on cytochrome P-450a 
(gene IIAl) levels, indicating that 7a-hydroxylase activity 
is not regulated by neonatal androgen exposure, and is 
regulated by nongonadal factors (Waxman et al 1985).
Cytochrome P-450a (gene IIAl) was reported to be
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induced by 3-methylcholanthrene or phenobarbital (Guengerich 
et al 1982, Dannan et al 1983, Ryan et al 1984).
b) 16Q-HYDR0XYLASE (P-450 IIC11)
Ryan et al (1984) isolated cytochrome P-450 forms f, g 
and h catalysing the hydroxylation of testosterone. 
Cytochromes P-450f (gene IIC7) and P-450h (gene IIC11) 
catalysed the 16a-hydroxylation of testosterone. Cheng and 
Schenkman (1983) reported that the 16a-hydroxylation of 
testosterone was a major activity of cytochrome P-450 RLM5 
(gene IIC11) in rat liver microsomes. Cytochrome P-450UT_A 
(gene IIC11) also accounts for the minor pathway of 
2a-hydroxylation of testosterone in rat liver microsomes 
(Waxman 1984, Cheng and Schenkman 1983). This cytochrome 
P-450 form has also been purified by numerous other groups 
(Dannan et al 1986, Kamataki et al 1983, Mode et al 1981, 
Morgan et al 1985a, Ryan et al 1984, Waxman 1984), and 
exhibited steroid 16a-hydroxylase activity.
Regulation of this isoenzyme has been extensively 
studied (Pasleau et al 1981), and it is now believed that 
cytochrome P-4502c (gene IICll) corresponds to the 
male-specific 16a-hydroxylase activity of rat liver induced 
at puberty (Waxman 1984), and that its expression is 
imprinted by neonatal androgens (Dannan et al 1986). In 
addition, expression of cytochrome P-450-male, which was 
reported to be approximately 20-fold higher in adult male 
rats (Morgan et al 1985a), was decreased upon hypophysectomy 
(Kamataki et al 1985), and further decreased upon continuous 
infusion of GH into hypophysectomised male rats (Kato et al
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1986). In contrast, intermittent GH administration into 
hypophysectomisad males resulted in an increased expression 
of cytochrome P-450-male (Kato et al 1986). This implies 
that the level of expression of cytochrome P-45016a (gene 
IIC11) is regulated by the secretory pattern of GH (Morgan 
et al 1985a, Strom et al 1988). Both neonatal and 
postpubertal castration of male rats decreased cytochrome 
P-450!6a (gene IIC11) levels, and these were restored by 
neonatal or postpubertal testosterone treatment (Kamataki et 
al 1985, Waxman et al 1985, Dannan et al 1986).
Administration of 0-naphthoflavone• phenobarbital, PCN 
and isosafrole led to the suppression of cytochrome P-4502c 
(gene IIC11) and its associated 16a-hydroxylase activity 
(Waxman et al 1985, Guengerich et al 1982) and was virtually 
abolished by polybrominated biphenyl compounds (Dannan et al
1983). Decreases in the expression of male-specific forms of 
cytochrome P-450 by inducers, and therefore abolition of sex 
differences in drug and steroid metabolism, have been 
documented extensively (Kamataki et al 1986, Emi and Omura 
1988, Shimada et al 1989).
c) 60-HYDROXYLASE (P-45 0 IIIA2)
The major isoenzyme responsible for the 
60-hydroxylation of testosterone in a reconstituted system 
was shown to be cytochrome P-450 RLM3 (gene IIC13) (Cheng 
and Schenkman 1983) and cytochrome P-450 PB-1 (gene IIC6) 
(Imaoka et al 1988). Cytochrome P-4502a/PCN_E (gene IIIA2) 
was reported to mediate >85% of the 60-hydroxylation of 
testosterone (Waxman et al 1985).
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Significant levels of cytochrome P-4506p (gene IIIA2) are 
present in males irrespective of age of the animal. In 
contrast, cytochrome P-4506p (gene IIIA2)levels decreased 
markedly in the female at the onset of puberty (Waxman et al 
1985).
Neonatal androgen secretion was reported to play an 
essential role in imprinting the age and sex dependency of 
the expression of cytochrome P-4506P (gene IIIA2) and is 
also required for the maintenance of cytochrome P-450 PB2a 
(gene IIIA1) during adult life.
Cytochrome P-450sp (gene IIIA2) was induced in both 
sexes by PCN and dexamethasone (Heuman et al 1982, Scheutz 
et al 1984) and by phenobarbital (Heuman et al 1982, 
Guengerich et al 1982, Waxman 1988). The enzyme was reported 
to be increased >70-fold in female rats upon phenobarbital 
administration (Waxman et al 1985), thereby abolishing the 
sex differences in 60-hydroxylation between male and female 
animals.
Waxman et al (1988b) have recently reported that 
60-hydroxylation is the major pathway of metabolism of 
testosterone, androstenedione and progesterone in humans, as 
compared to the multiple hydroxylative pathways that exist 
in the rat. Antibodies to cytochrome P-450NF (gene IIIA4) 
and TAO (characteristic of gene subfamily IIIA) established 
that cytochrome P-450NF is the major 60-hydroxylase in human 
liver (Guengerich et al 1986), and is 75% similar to rat 
cytochrome P-450pcn (gene IIIA1) (Gonzalez et al 1985).
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1.4.4 CYTOCHROME P-45O-INDEPENDENT STEROID METABOLISM
a) 5a-reductase
5a-reductase is a microsomal membrane-bound enzyme, and 
although it does not contain cytochrome P-450, it is thought 
to act in a similar manner to the monooxygenase system and 
consists of coenzyme Q10 and NADPH-cytochrome oxidoreductase 
(Golf and Graef 1978). Thus electons are transferred from 
NADPH to coenzyme Qx0 by NADPH-cytochrome oxidoreductase, 
and from coenzyme Q10 to substrate by 5a-reductase.
5a-reductase activity has been reported to be higher in 
female rats (Yates et al 1958, Gustafsson and Stenberg 
1976), and its developmental profile showed that 
5a-reductase activity was induced at puberty in female rats 
(Waxman et al 1985).
The hepatic expression of 5a-reductase activity was 
increased upon exposure of male rats to oestrogens (Berg and 
Gustafsson 1973), but the expression of this female-specific 
enzyme was only partially affected by ovariectomy or 
oestrogen treatment of female rats. 5a-reductase activity 
was fully suppressed upon postpubertal androgen exposure 
(Dannan et al 1986, Rumbaugh and Colby 1980), whilst 
castration increased 5a-reductase activity (Yates et al 
1958, Berg and Gustafsson 1973).
Hypophysectomy reduced 5a-reductase activity markedly 
in female rats (Miller and Colas 1982, Colby et al 1974, 
Kramer and Colby 1976), and was restored upon continuous GH 
administration (Mode et al 1981). Continuous GH infusion of 
male rats also led to the expression of this female-specific
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enzyme (Mode et al 1980). Thus the increase in 5a-reductase 
activity in female rats correlates well with the continuous 
secretory pattern of GH at puberty, showing that 
5a-reductase activity is regulated by the GH secretory 
pattern. The suppression of 5a-reductase activity by 
testosterone therefore explains the relative absence of this 
enzyme in male animals (Dannan et al 1986).
b) 17-oxosteroid oxidoreductase
17a/170-oxosteroid oxidoreductase and 3a/3S-oxosteroid 
oxidoreductase (Penning et al 1987) are also cytochrome 
P-450-independent microsomal enzymes. The mechanism of 
action of these enzymes is not clear as yet, although a 
mechanism for testicular 170-oxosteroid oxidoreductase 
(Inano and Tamaoki 1986) and 170-oxosteroid oxidoreductase 
from rabbit liver (Antoun et al 1985) has been discussed.
1.5 GROWTH HORMONE
1.5.1 STRUCTURE AND VARIANTS OF GROWTH HORMONE
Growth hormone (GH), in all species studied, is now 
known to be a protein of molecular weight 21kDa containing 
a single polypeptide chain of about 200 amino acids. Li et 
al (1966) first determined the complete amino acid sequence 
of growth hormone, although errors have subsequently been 
noticed using molecular biology techniques. The primary 
structure of the growth hormone molecule contains two 
disulphide bridges, one of which links distant parts of the
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molecule whilst the other forms a small loop near the 
C-terminus. In addition, 50-60% of the growth hormone 
polypeptide chain exists in the a-helical conformation 
(Moore et al 1980).
A considerable amount of variation in the amino acid 
sequence of growth hormone has been determined between 
different species (Wallis 1981), resulting in differences in 
physicchemical properties. For instance, bovine growth 
hormone (bGH) is a fairly basic protein (pl=8), whereas 
human growth hormone (hGH) is acidic (pl=5). There is also 
virtually no immunological cross-reaction between hGH and 
bGH.
The 20K variant of hGH, which has a single chain that 
is 15 residues shorter than the normal 22K form of hGH, has 
been the subject of a recent review (Lewis et al 1987). The 
20K variant accounts for 10-15% of pituitary hGH and lacks 
residues 32 to 46 as compared to 22K hGH. While the 20K 
variant retains full growth-promoting and diabetogenic 
activity (Kostyo et al 1985), and stimulates somatomedin 
production, it binds to growth hormone receptors with a 
lower affinity as compared to 22K hGH.
Mondon et al (1988) have recently demonstrated that a 
peptide representing this deleted region in 20K hGH 
(residues 32-46) may be responsible for the insulin-like 
activity of growth hormone, and therefore may explain 
previous reports that 20K hGH had impaired insulin-like 
effects. Salem (1988) has also reported that the effects of 
a naturally occurring pituitary peptide, hGH (1-43) 
potentiated the effects of insulin in normal, diabetic and
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hypophysectomised rats.
1.5.2 SYNTHESIS AND SECRETION OF GROWTH HORMONE
1.5.2.1 BIOSYNTHESIS
Growth hormone is synthesised and secreted in the 
pituitary by a group of acidophilic cells termed 
somatotrophs (Bancroft et al 1976). In male animals, these 
are the predominant cells of the pituitary, whereas 
somatotrophs and lactotrophs (secrete prolactin) exist in 
equal numbers in female rats. Within the somatotroph, growth 
hormone is stored in the form of 300-400nm diameter granules 
prior to secretion. Growth hormone is derived from a larger 
precursor peptide, pre-growth hormone, of molecular weight 
28kDa, first documented by Sussman et al in 1976. The amino 
acid sequence of preGH has been determined, and shown to be 
a 26 amino acid extension of the growth hormone molecule at 
the N-terminus, as has been observed with insulin.
1.5. 2.2 SECRETION
It is now widely accepted that growth hormone secretion 
is episodic in nature. Eden (1979) demonstrated that the 
pattern of growth hormone secretion in adult rats was 
sexually differentiated, in that adult males exhibited an 
irregular growth hormone secretory profile, whereas growth 
hormone was secreted in a more continuous manner in adult 
females. Mode et al (1982) have shown that the secretory
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pattern of growth hormone was an important determinant of 
the sex differences observed in hepatic steroid metabolism, 
and on the effects on body growth (Jansson et al 1985, Clark 
et al 1985, Isaksson et al 1978, Norstedt and Palmiter
1984) .
No apparent sex differences have been reported in the 
secretory pattern of growth hormone secretion in humans. 
Albertsson-Wikland and Hosberg (1988) recently showed that 
although growth hormone secretion correlated well with 
height, there was no correlation between growth hormone 
secretion and the age and sex of children.
The human growth curve can, however, be divided into 
three distinct phases. There is a period of rapid and 
rapidly decelerating growth during infancy, followed by a 
period of steady and slowly decelerating growth during 
childhood. Growth appears to be completed by the adolescent 
growth spurt which, due to its greater magnitude in males 
than females, results in the sex differences in adult height 
(Brook et al 1988).
Normal adults secrete approximately 44pg growth hormone 
daily, whereas young adults secrete about 700pg.The basal 
growth hormone levels in man are about 2ng/ml, and increase 
episodically to about 10-30ng/ml. The bulk of growth hormone 
secretion in children occurs during sleep, especially during 
the first hour of onset (Sassin et al 1972).
Growth hormone in the circulation is now thought to be 
associated with a binding protein (Baumann et al 1988a and
b), and a considerable amount of growth hormone circulates 
as a dimer in man.
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The secretion of growth hormone is regulated and 
maintained by a balance between two hypothalamic hormones, 
growth hormone-releasing hormone and somatostatin.
1.5.2.3 GROWTH HORMONE RELEASING HORMONE (GHRH)
Although the presence of GHRH has been postulated for 
several years now, it was not isolated and characterised 
until 1982. Two groups independently showed that peptides 
with growth hormone-releasing activity, isolated from 
patients with pancreatic tumours, had given rise to 
acromegaly due to excessive growth hormone secretion 
(Guillemin et al 1982, Vale et al 1983). Guillemin et al 
(1982) isolated a peptide comprising of 44 amino acids and 
an amidated C-terminus, whereas Vale et al (1983) isolated 
GHRH containing 40 amino acids and a free C-terminus. Both 
molecules appeared to be equipotent in their function.
The precursor of GHRH has also been identified and is 
considerably larger than the GHRH molecule. Proteolytic 
cleavage of this molecule is thought to release other 
biologically active peptides in addition to GHRH (Gubler et 
al 1983).
1.5.2.4 SOMATOSTATIN
Somatostatin was first isolated and characterised by 
Brazeau et al in 1973 during the search for GHRH. This 
growth hormone release-inhibitory factor was shown to be a 
peptide consisting of 14 amino acid residues, and has been
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isolated from the pancreatic D cells and the gut, in 
addition to the hypothalamus. Somatostatin appears to be 
synthesised in the form of a precursor protein containing 
about 120 amino acids with the somatostatin sequence at the 
C-terminus (Shen et al 1982).
Somatostatin has also been shown to inhibit the 
secretions of thyrotrophin, insulin, glucagon, pancreatic 
enzymes, gastric acid and other gut hormones, as well as 
growth hormone (Brazeau et al 1978). Tannenbaum et al (1978) 
assigned a physiological role to somatostatin exclusively as 
a growth hormone release-inhibitory hormone by the use of 
anti-somatostatin.
1.5.2.5 CONTROL OF GROWTH HORMONE SECRETION
The episodic release of growth hormone was shown to be 
principally controlled by an interaction between GHRH 
(Plotsky and Vale 1985) and somatostatin (Tannenbaum 1985, 
McIntosh et al 1988). Clark et al (1987) have demonstrated 
that whereas the underlying pattern of GHRH secretion was 
the same in rats, the somatostatin secretory pattern varied, 
resulting in the characteristic secretory profiles of growth 
hormone in male and female rats. In contrast, other authors 
have previously shown that GH secretion predominantly 
reflects the pulsatile release of GHRH, and that the trough 
levels of GH are mainly influenced by somatostatin 
(Tannenbaum et al 1983, Wehrenberg et al 1982, Sato et al 
1988). Further, GH pulses may also be accompanied by reduced 
somatostatin secretion (Tannenbaum and Ling 1984, Plotsky
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and Vale 1985).
In addition it has been suggested that growth hormone 
can regulate its own secretion by a negative feedback 
mechanism. Krulich and McCann (1986) first demonstrated that 
bGH administration into rats reduced pituitary growth 
hormone content, and this feedback inhibition has 
subsequently been confirmed by other authors (Groesbeck et 
al 1987, Willoughby et al 1980, Tannenbaum 1980).
It has further been shown that growth hormone does not 
inhibit its secretion at the pituitary level (Richman et al 
1981, Goodyer et al 1984), and may act at the level of the 
hypothalamus to either increase somatostatin secretion 
and/or decrease GHRH release. Certainly, evidence exists 
that growth hormone increases somatostatin release (Chihara 
et al 1981), and that somatostatin inhibits growth hormone 
release in rats (Brazeau et al 1974, Tannenbaum 1985). Clark 
et al (1988) have more recently confirmed that growth 
hormone inhibits its own release in concious rats, and 
further showed that the feedback effects of growth hormone 
involve an inhibition of GHRH release rather than an 
increase in somatostatin secretion, and take place at the 
level of the hypothalamus.
While GHRH is thought to act via both cyclic AMP- (Ray 
and Wallis 1988, Dana and Karin 1989) and protein kinase 
C-dependent (Ohmura et al 1988, French et al 1989) 
mechanisms, somatostatin is thought to alter calcium levels 
in somatotrophs (Holl et al 1988). The regulation of GH 
secretion has recently been reviewed by Thorner (1989).
Noguchi et al (1989) have suggested that IGF-I may
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regulate growth hormone feedback at the level of the 
pituitary and hypothalamus since a substance that 
cross-reacted with IGF-I was detected in bovine anterior 
pituitary cells.
Glucocorticoids are reported to increase, and thyroid 
hormones to decrease growth hormone secretion by adult 
human (Bridson and Kohler 197 0, Mulchahey et al 1988) and 
rat (Oosterom et al 1983) pituitary cells, although the 
effects of glucocorticoids are documented to be inhibitory 
in vivo (Nakagawa et al 1973). The effects of the gonadal 
hormones on growth hormone secretion were also reported to 
be opposite in vivo and in vitro (Dieguez et al 1988). 
Nakagawa et al (1987) have reported that the suppressing 
effect of glucocorticoids on growth hormone release in vivo 
was at least partially due to the increase in hypothalamic 
somatostatin release, together with a decrease in GHRH 
release, and that these effects probably overwhelmed the 
potentiating effect of glucocorticoids on growth hormone 
release at the pituitary level, thereby resulting in a net 
inhibitory effect in vivo.
These observations are further supported by the finding 
that glucocorticoids increased gene transcription (Tushinski 
et al 1977) and that the activated glucocorticoid receptor 
protein binds to the first intron of the hGH gene (Moore et 
al 1985).
Growth hormone synthesis and secretion also appears to 
be dependent on thyroid hormones, which mediate their 
effects by regulation of the transcriptional rate of the 
growth hormone gene (Dieguez et al 1988).
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However, it has recently been suggested that both 
thyroid hormones and glucocorticoids influence GH secretion 
by affecting the responsiveness of the somatotroph to GHRH 
(Edwards et al 1989). In addition, the secretion of GH was 
impaired in animals with a deficiency of androgen receptors. 
Thus GH secretion was highest in females, lowest in males 
and intermediate in testicular-feminised rats, therefore 
indicating a partial masculinisation response as compared to 
normal animals (Batson et al 1989).
Growth hormone secretion is also regulated by a certain 
degree of metabolic control. Glucose administration lowered 
growth hormone secretion in normal subjects, whereas 
hypoglycemia is known to stimulate growth hormone release.
A protein-rich meal or infusion of amino acids is also 
reported to cause growth hormone release. Paradoxically, 
protein deficient states also result in growth hormone 
release. Fatty acids suppressed growth hormone responses to 
certain stimuli, including amino acid infusion and 
hypoglycemia. Fasting is documented to stimulate growth 
hormone secretion, possibly as a means of mobilising fat as 
an energy source and preventing protein breakdown (Holly et 
al 1988) .
The neural control of growth hormone secretion has been 
reviewed recently by Dieguez et al (1988).
1.5.3 GROWTH HORMONE RECEPTORS
Studies on the growth hormone receptor have recently 
been reviewed by Hughes and Friesen (1985) and Roupas and
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Herington (1989).
Growth hormone receptors have been characterised in a 
number of tissues (Hughes and Friesen 1985), although the 
most widely studied tissue has been the liver (Ranke et al
1976) since growth hormone has many actions on hepatic 
tissue. In addition, many of the actions of growth hormone 
are mediated by the somatomedins which are produced by the 
liver. The liver also contains lactogenic receptors for 
prolactin (Posner 1976), and much confusion has arisen in 
the past owing to the lactogenic and somatogenic properties 
of human GH (hGH). In contrast, rat growth hormone (rGH) and 
bovine growth hormone (bGH) specifically bind to somatogenic 
receptors, and rat prolactin (rPRL) to lactogenic receptors.
GH binding sites have been identified in male rat 
hepatocytes (Ranke et al 1976), and the covalent binding of 
radiolabelled GH to these binding sites studied (Donner 
1983, Yamada and Donner 1984). Affinity chromatography 
studies identified the GH receptor as a 220,000 daltons 
molecule (Waters and Friesen 1979). The growth hormone 
receptor from rabbit liver appears to have a subunit 
molecular weight of 50,000-80,000 daltons on SDS-PAGE, 
whereas that from rat and human liver has been estimated at 
100,000-110,000 daltons. Leung et al (1987) have recently 
cloned (Wallis 1987) and sequenced the rabbit growth hormone 
receptor and reported its molecular weight to be 130,000 
daltons.
Biochemical characterisation of the growth hormone 
receptor has shown that it contains carbohydrate residues 
(binds to concanavalin A), but does not contain sialic acid
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residues (unafffected by neuraminidase). In addition, 
galactose residues may be required for receptor activity, as 
shown by abolition of receptor responsiveness after 
treatment with galactosidase. Studies with phospholipase C 
revealed that phospholipids are not of any importance to the 
growth hormone receptor (Hughes and Friesen 1985).
Disulphide bonds in the membrane appear to be 
intimately involved in the maintenance of a receptor 
structure necessary for growth hormone binding. In addition, 
disruption of the disulphide bonds resulted in increased 
dissociation and displacement of bound hormone, indicating a 
possible role in the irreversible nature of growth hormone 
binding, which may be the irreversible component previously 
identified in hormone-receptor interactions (Moore et al
1983).
There is now evidence for the existence of a 
heterogenous population of growth hormone receptors in 
rabbit liver (Hughes and Friesen 1985). It has been proposed 
that three receptor populations existed in this tissue :
i) GHR-1 (1%) binds rat, rabbit and human growth 
hormone and the 2OK variant of human growth hormone.
ii) GHR-2 (85%-90%) binds human growth hormone with 
high affinity and other forms with low affinity.
iii) PRLR (10-15%) binds both 20K and 22K human growth 
hormone, as well as prolactin.
Different GH-receptor populations are involved in the 
insulin-like and lipolytic actions of GH in adipocytes 
(Chipkin et al 1989), which is supported by previous reports 
that higher GH concentrations are required for the
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insulin-like effect of GH.
Male hepatocytes bind approximately 2000 hormone 
molecules per cell with a dissociation constant of 3xlO~10M. 
Female rat hepatocytes bind 5-10 times more growth hormone 
at the same concentration (Postel-Vinay and Desbuquois
1977) .
A large proportion of the receptors in rabbit liver are 
membrane-bound. Although receptors associated with the 
plasma membrane are probably involved with the initiation of 
the growth hormone response, receptors on intracellular 
membranes (eg endoplasmic reticulum) do not appear to have 
an obvious role. These may represent either newly 
synthesised or spare receptors, or receptors that have been 
recently internalised. These cytosolic growth hormone 
receptors have identical binding characteristics to those of 
the plasma membrane. In addition, a cytosolic binding 
protein has recently been identified and is thought to be a 
cleaved form of the growth hormone receptor. Baumann et al 
(1988) have recently reported that a substantial fraction of 
circulating hGH in man circulates in the form of a growth 
hormone-binding protein complex. The binding protein has a 
native molecular weight of approximately lOOkDa and a 
binding subunit of about 60kDa (Hughes and Friesen 1985).
The GH binding protein has recently been cloned and 
sequenced (Leung et al 1987) as a 51kDa molecule. In 
addition, it has recently been demonstrated that the growth 
hormone receptor from rabbit liver and the binding protein 
from rabbit serum have the same N-terminal amino acid 
sequence, indicating that the binding protein corresponds to
-64-
the extracellular hormone-binding domain of the liver 
receptor (Leung et al 1987). This finding therefore 
confirmed the suggestion that the serum growth hormone 
binding protein may be derived from the membrane-bound 
growth hormone receptor (Daughaday et al 1987). Measurement 
of the growth hormone binding protein levels in serum has 
been proposed as a noninvasive tool to study the ontogeny of 
growth hormone receptors in humans (Daughaday et al 1987).
The regulatory factors affecting growth hormone 
receptors have been extensively documented in a recent 
review (Roupas and Herington 1987).
Both hGH and rGH were capable of inducing PRL and GH 
receptors in hypophysectomised male and female rats (Mode et 
al 1983, Baxter and Zaltsman 1984), although rPRL did not 
induce GH receptors (Baxter et al 1984).
Baxter et al (1980) have suggested that GH receptor 
number is either directly or indirectly dependent on the 
presence of GH, oestradiol and insulin. Hepatic GH receptors 
were decreased in diabetic rats, as was serum GH (Scott and 
Baxter 1986). Hepatic GH-binding was also decreased in 
STZ-diabetic rats (Baxter et al 1980). The partial 
restoration of this effect by insulin indicated a regulatory 
role of insulin in the control of GH binding (Baxter and 
Turtle 1978).
Hypophysectomy has been shown to increase liver 
GH-binding sites (Picard and Postel-Vinay 1984), an effect 
that was reversible upon GH administration (Posner 1984). 
Maes et al (1983a) have also reported a decrease in 
circulating GH concentrations in hypophysectomised rats,
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which correlated well with an increase in GH receptor 
number.
Baxter and Zaltsman (1984), however, reported a 
sex-differentiated effect of hypophysectomy on GH receptors. 
Whereas hypophysectomy reduced the number of GH receptors in 
females, receptor content was increased in male rats. This 
discrepancy in receptor content upon removal of the GH 
influence may be related to the sex difference in the GH 
secretory pattern (Eden 1979).
Intermittent growth hormone administration (Maiter et 
al 1988a), mimicking the male secretory pattern, resulted in 
greater increases in body weight and serum somatomedin 
levels than continuous growth hormone infusion. As would be 
expected, continuous growth hormone infusion increased 
growth hormone receptor number markedly whereas intermittent 
administration had no effects. This would suggest that a 
continuous presence of growth hormone is required for the 
upregulation of its receptors. Further, only continuous 
growth hormone infusion stimulated prolactin receptor 
content, indicating that the regulation of growth hormone 
and prolactin receptors may be linked (Norstedt 1982, 
Norstedt et al 1981). In a subsequent study, Maiter et al 
(1988b) demonstrated that whereas the administration of 
growth hormone over short time periods led to a time- and 
dose-dependent down-regulation of its receptors, stimulatory 
effects were observed upon prolonged exposure (Baxter et al 
1984, Baxter and Zaltsman 1984), which is consistent with 
ligand-induced internalisation and degradation of the 
receptor.
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Bullier-Picard et al (1989) reported that 125I-labelled 
hGH was internalised by male rat hepatocytes with a 
sequential association with plasma membranes and endocytotic 
structures distinct from golgi elements, and degraded in 
lysosomes (Wakai et al 1984). In addition, growth hormone is 
thought to be internalised by two endocytotic compartments 
(Husman et al 1988) prior to lysosomal degradation.
Insulin-like growth factor 1 (IGF-I) levels are low in 
rats at birth (Sara et al 1980) despite high growth hormone 
levels (Ojeda and Jameson 1977). At puberty there is a 
progressive rise in these growth factor levels (Eden 1979) 
associated with increased growth and growth hormone 
secretion. The discrepancy at birth and correlation during 
puberty between somatomedin and growth hormone levels 
suggest ontogenic variations in the responsiveness of the 
liver to growth hormone.
Maes et al (1983a) have reported on the development of 
growth hormone receptors in male and female rats and showed 
that there was a rise in receptor number before puberty in 
male and female rats (Postel-Vinay and Desbuquois 1977), 
which preceded the increase in growth velocity and plasma 
growth hormone levels by about one week. Whereas growth 
hormone receptor concentration continued to increase until 
120 days in females, male rat livers showed a significant 
decrease by day 50. Similarity, prolactin receptor content 
remained constant in male rat liver but increased in 
females, and with an inverse relationship to plasma 
testosterone levels. Pregnancy also caused marked changes in 
GH binding (Postel-Vinay and Desbuquois 1977).
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Contrary to the induction of GH receptors upon GH 
administration to rats (Baxter and Zaltsman 1984), a 
decrease in receptor number has been reported in human IM-9 
lymphocytes exposed to GH (Lesniak and Roth 1976). This 
down-regulation of GH receptors by GH that is observed in 
humans (Palmer and Wallis 1989) has not yet been
demonstrated in rats, not even upon administration of high
doses of GH to rats bearing pituitary tumours (Baxter et al 
1982) .
1.5.4 POST-RECEPTOR ACTIONS OF GROWTH HORMONE
Very little is known about the mechanism of growth
hormone action (reviewed by Isaksson et al 1985). Although 
it is well established that many of the effects of growth 
hormone, particularly on skeletal muscle, are mediated by 
the somatomedins (see section 1.5.5), the direct effects 
following stimulation of growth hormone receptors are 
relatively unknown.
Many direct effects of growth hormone on protein 
synthesis and lipid metabolism, DNA synthesis and enzyme 
activity have been reported, but these are all late events. 
It is now well known that the effects of growth hormone in 
the diaphragm are mediated by increased amino acid 
incorporation and protein synthesis, and due to an increase 
in RNA transcription in the perfused rat liver (Kostyo 1968, 
Kostyo and Nutting 1973, Rillema and Kostyo 1971). This 
stimulation of protein synthesis by growth hormone is 
thought to be due to its insulin-like action (Cameron et al
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1988). The effects of growth hormone on carbohydrate and 
lipid metabolism have recently been reviewed by Davidson 
(1987). In general, growth hormone shows anti-insulin-like 
effects in the long term and insulin-like effects over
shorter periods, as has been confirmed both in vivo and in
vitro (Betley et al 1989).
Attempts to link growth hormone receptor stimulation 
with adenylate cyclase in response to GH have given 
conflicting results. Some studies have demonstrated the 
inhibition of adenylate cyclase (Albertsson-Wikland and 
Rosberg 1982) while others failed to show this effect
(Hughes and Friesen 1985). Leppert et al (1981) showed that
growth hormone restored glucagon-stimulated increases in 
adenylate cyclase activity in hypophysectomised rats. In 
addition, the increased adenylate cyclase activity was 
reported to reside in the catalytic subunit (Hung and Moore
1984). Several studies have, however, reported an indirect 
effect of adenylate cyclase in growth hormone action 
represented by alterations in intracellular cyclic AMP 
levels.
Cyclic AMP levels were unchanged by hypophysectomy of 
male rats (Isaksson et al 1974). In addition, administration 
of growth hormone to these hypophysectomised animals 
elicited no change in intracellular cyclic AMP levels, 
showing that cyclic AMP was not involved (Isaksson et al 
1974, Klingensmith et al 1980). In contrast, Thompson et al 
(1973) demonstrated that hGH administration to 
hypophysectomised rats resulted in the activation of cyclic 
AMP phosphodiesterase, thus implying a role of the cyclic
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AMP system in the mechanism of action of growth hormone. 
Similarily, cyclic AMP-dependent protein kinase activity was 
stimulated by GH (Byus et al 1978).
The lipolytic action of growth hormone in adipocytes 
(reviewed by Goodman et al 1987, Schaffer 1985) was reported 
to involve both protein synthesis and an accumulation of 
cyclic AMP (Moskowitz and Fain 1970, Fain et al 1971).
Growth hormone was also reported to stimulate both lipolysis 
and cyclic AMP levels in perifused fat cells (Sengupta et al 
1981, Solomon et al 1987). The ability of theophylline, 
which inhibits cyclic AMP phosphodiesterase, to abolish the 
effects of growth hormone on amino acid transport and 
protein synthesis suggested that growth hormone may be 
acting by decreasing cyclic AMP levels (Payne and Kostyo 
1970, Rillema et al 1973).
A recent report showed that physiological 
concentrations of growth hormone enhanced guanylate cyclase 
and cyclic GMP systems in vitro (Vesely 1981), and may 
therefore be a possible mechanism of action of growth 
hormone. Guanylate cyclase, however, was not activated by 
growth hormone in the diaphragm (Ahren et al 1976).
Grief et al (1982) demonstrated that both thyroxine and 
growth hormone stimulated the efflux of calcium from rat 
liver mitochondria.
Smal et al (1989), using an inhibitor of protein kinase 
C known as acridine orange, demonstrated that growth hormone 
stimulated lipogenesis in rat adipocytes by protein kinase C 
activation. It has further been proposed that growth hormone 
stimulated protein kinase C by means of diacylglycerol
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formation (Doglio et al 1989).
Some evidence exists that the activated growth hormone 
receptor may act as a protein kinase, but again this data 
has been conflicted. Binding of growth hormone to rat 
hepatocytes led to a rapid (<10minutes) phosphorylation of 
several cellular proteins, including one of molecular weight 
46kDa (Yamada et al 1987).
Thus there appears to be no overall consensus on the 
intracellular mediator of growth hormone action.
1.5.5 INSULIN-LIKE GROWTH FACTORS
Salmon and Daughaday (1957) first proposed that the 
anabolic effects of growth hormone on cartilage were 
mediated by a putative sulphation factor, now known as 
somatomedin (Daughaday et al 1972). It is now evident that a 
whole family of somatomedins exist. IGF-I (molecular weight 
8000-9000 kDa) is a single chain polypeptide containing 70 
amino acid residues and three intrachain disulphide bridges, 
and is identical to somatomedin C (Klapper et al 1983). 
IGF-II is thought to be identical to multiple stimulating 
activity (MSA). Both insulin-like growth factors (IGF) I and 
II are reported to show marked amino acid sequence homology 
to insulin. In addition, the somatomedins mimic many of the 
metabolic effects of insulin (Froesch et al 1985, Zapf et al
1981).
The somatomedins are produced in the form of a large 
precursor molecule by, but not stored in, the liver, kidney 
and several other tissues (Hintz 1987). The perfused liver
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has been a commonly used tissue for the study of IGF-1 as it 
is its major site of synthesis (Schalch et al 1979).
Although there is no evidence that somatomedins act by an 
endocrine mechanism (ie synthesised by the liver and 
released into the general circulation), an autocrine or 
paracrine mechanism of action has been demonstrated 
(D’Ercole et al 1984, Holly and Wass 1989). This is 
supported by the observation that growth hormone stimulated 
growth and tissue IGF-I levels without corresponding 
increases in circulating IGF-I levels, thereby implying that 
autocrine or paracrine IGF-I mediated the effects of growth 
hormone in young animals (Orlowski and Chernausek 1988).
Phillips et al (1976) reported a high molecular weight 
circulating form of IGF-I, which either represented the 
IGF-I precursor, or IGF-I bound to an additional molecule. 
Somatomedins are now known to circulate in association with 
high molecular weight specific binding proteins (Zapf et al 
1975, Moses et al 1976, Moses et al 1979, Ooi and Herington 
1988). At least two binding proteins have been detected with 
molecular weights of 40-60kDa and 150kDa (Kaufmann et al 
1978, Moses et al 1976, Binoux et al 1982), although three 
categories of binding proteins have been documented 
according to their binding specificities (Forbes et al 
1988). Growth hormone appears to stimulate the production 
of the 150K binding protein (Kaufmann et al 1978, Moses et 
al 1976), whereas the 40-60K binding protein appears to be 
regulated in a growth hormone-independent manner (Binoux et 
al 1982). At least six growth hormone-dependent binding 
proteins have been isolated (D'Ercole et al 1984). The
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growth hormone-independent binding protein is particularly 
abundant during foetal life (D'Ercole et al 1980), in 
hypophysectomised animals (Hintz et al 1981) and in growth 
hormone-deficient patients (D'Ercole et al 1984). Their 
function, as yet, appears to be the extension of serum 
somatomedin half-life (Smith 1984, D'Ercole et al 1984) 
which, in its free form is metabolised in about ten minutes 
(Cohen and Nissley 1976). In addition, the binding proteins 
also appear to modulate the biological activity of IGF-I 
(Zapf et al 1979) directly by supporting IGF-binding at the 
cell surface (Clemmons et al 1986, Barenton et al 1988).
Growth hormone administration is known to stimulate 
IGF-I production by the liver in vitro (Daughaday et al 
1976, Binoux et al 1982, Scott et al 1985a & 1985b). Hepatic 
production of IGF-I in vivo correlates with serum IGF-I 
levels (Schwander et al 1983), which correlates well with 
IGF-I mRNA levels. It therefore appears that the metabolic 
regulation of IGF-I is at the mRNA level (Goldstein et al
1988). Further, Norstedt and Moller (1987) showed that 
growth hormone could directly induce IGF-I mRNA in 
hepatocyte cultures.
It is now well established that the effects of growth 
hormone on skeletal growth are mediated by IGF-I (Froesch et 
al 1985). However, it is not yet fully clear as to which of 
the other effects of growth hormone are direct and which are 
mediated by somatomedins.
IGF-I levels are lower in hypophysectomised than normal 
rats (Scott et al 1985a;b, Miller et al 1981). Infusion of 
growth hormone to hypophysectomised rats in a .intermittent
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manner resulted in greater increases in serum IGF-I levels 
and IGF-I mRNA levels than continuous administration 
(Isgaard et al 1988), thus confirming the observations of 
previous studies (Jansson et al 1982, Clark et al 1985). In 
addition, both local (Phillips et al 1980) and hepatic IGF-I 
(Isaksson et al 1982, Isgaard et al 1986) are reported to 
stimulate growth in hypophysectomised rats (Schoenle et al 
1982). Conversely, IGF-I expression was increased in 
transgenic mice (GH fusion genes) (Mathews et al 1988) and 
tumour-bearing rats (Scott et al 1985) together with 
elevated growth hormone levels, which correlated with 
increased IGF-I levels and increased growth.
Insulin deprivation also interferes with growth 
hormone-dependent IGF-I synthesis and secretion (reviewed by 
Holly et al 1988). IGF-I levels were reduced in diabetic 
rats, and could be accounted for either directly by reduced 
IGF synthesis or indirectly by reduced GH secretion or 
receptor content (Scott and Baxter 1986). Plasma IGF-I 
levels are reported to be reduced in diabetes (Maes et al 
1983b), possibly as a result of impaired synthesis by the 
liver (Miller et al 1981). Since IGF-I levels in diabetics, 
are not restored by treatment with growth hormone, it was 
suggested that the diabetic liver may be resistant to growth 
hormone (Phillips et al 1976), possibly due to a reduction 
in growth hormone receptors (Scott and Baxter 1986). In 
contrast, Maes et al (1986) found no changes in receptor 
content in diabetes and suggested that the low serum 
somatomedin levels were due to a defect distal to binding of 
growth hormone to its receptor. In rats made mildly diabetic
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with streptozotocin, insulin restored serum IGF-I levels, 
as well as growth parameters in the diabetic animals (Maes 
et al 1983, Taylor et al 1987). This reversal was, however, 
only observed when insulin was administered via the hepatic 
portal vein, and not the jugular vein, indicating that the 
liver was the target organ in mediating the growth-promoting 
effects of insulin (Griffen et al 1987). This is consistent 
with previous observations that insulin stimulates IGF-I 
production by the isolated perfused liver (Kogawa et al
1982) and cultured hepatocytes (Binoux et al 1982, Kogawa et 
al 1983, Scott and Baxter 1986). In addition, insulin also 
stimulated the accumulation of IGF-I mRNA transcripts in 
cultured hepatocytes (Johnson et al 1989).
The mechanism by which growth hormone stimulates IGF-I 
production is unknown, but it is clear that an action of GH 
on the expression of the IGF-I gene is involved, since 
growth hormone specifically increases IGF-I mRNA 
transcription in liver (Mathews et al 1986, Johnson et al
1989) and adipose cells (Doglio et al 1987). Further, Scott 
et al (1985a) showed that although IGF-I production was 
inhibited by cycloheximide, actinomycin D was less 
effective, thereby suggesting that continuous protein 
synthesis is required (Murphy and Luo 1989) and that a 
stable species of mRNA was present. In addition, the 
increase in expression of IGF-1 in response to growth 
hormone was suggested to be mediated by phospholipase C 
(Doglio et al 1989).
IGF-I receptors show structural similarity to the 
insulin receptor (section 1.8.1) (Rechler et al 1980,
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Chernausek et al 1981, Massague and Czech 1982, Watanabe et 
al 1987) and are thought to contain two extracellular a and 
two transmembrane p polypeptide chains joined by disulphide 
bridges, and also appear to bind insulin quite effectively. 
In addition, the a-subunit contains the IGF-I binding site 
and a cysteine-rich region, whereas the p-subunit contains a 
ligand-activated tyrosine kinase domain and 
autophosphorylation sites. The IGF-I receptor, in analogy 
with the insulin receptor, is associated with a protein 
kinase which is activated upon binding to IGF-I, and leads 
to phosphorylation of tyrosine residues of cellular 
proteins. The human IGF-I receptor has also been 
characterised (Steele-Perkins et al 1988). The IGF-II 
receptor appears to only contain a single transmembrane 
polypeptide chain (Morgan et al 1987) and does not bind to 
insulin.
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1.6 MECHANISM OF ACTION OF GLUCOCORTICOIDS
Glucocorticoid action is initiated by entry of the 
steroid into the cell and binding to the cytosolic 
glucocorticoid receptor proteins. The resulting steroid 
hormone receptor complexes then undergo activation (or 
transformation) and are translocated to the nucleus where 
they interact with nuclear chromatin acceptor sites (Pfahl
1986). The phosphorylation of steroid hormone receptors has 
also been implicated in the interaction between 
hormone-receptor complexes and DNA components (Auricchio 
1989). The activated glucocorticoid receptor appears to have 
a high affinity for the arginine-rich histones 3 and 4 (Ueda 
et al 1989). Activated hormone-receptor complexes then bind 
to DNA regulatory sequences, glucocorticoid responsive 
elements (GRE) (reviewed by Beato et al 1989), of specific 
genes leading to the specific transcription and expression 
of these genes. Both human and rat growth hormone genes have 
a GRE in the structural gene, and are therefore 
glucocorticoid-responsive (Perry et al 1988).
Hormone-receptor complexes are known to be enhancers of 
transcription. The resulting complexes effect the 
glucocorticoid response, which may be inhibitory or 
stimulatory, depending on the system involved. For instance, 
dexamethasone stimulated tyrosine aminotransferase activity 
but reduced the expression of HMG-CoA reductase mRNA, and 
adrenalectomy increased its expression (Simonet and Ness 
1989) .
Although the passage of steroids through the plasma
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membrane has been assumed to occur by simple diffusion due 
to their lipophilic nature, several authors have proposed 
the presence of a glucocorticoid binding-site at the plasma 
membrane that is responsible for the transport of steroids 
into the cell cytoplasm (Plas and Duval 1986). Howell et al 
(1989) have recently identified a 45K dexamethasone-binding 
site on the plasma membrane that may be responsible for the 
active transport of glucocorticoids into the cell.
Rousseau et al (1972) proposed that liver hepatoma 
cells contained a single class of cytoplasmic glucocorticoid 
receptors which were similar to the Type II corticosteroid 
receptors identified in the kidney. At least four forms of 
glucocorticoid receptors, the active and inactive steroid 
binding forms of the unoccupied receptor and the activated 
and unactivated forms of the occupied receptor, are now 
thought to exist (Harmon et al 1988). The proposed model of 
the structure of the glucocorticoid receptor has at least 
three functionally distinct domains (Carlstedt-Duke et al 
1982) : a protein that binds glucocorticoid, a region that
binds to DNA, and a modulating (immunoreactive) domain whose 
function is not clear as yet. Sequencing and expression of 
cDNA clones of the glucocorticoid receptor have revealed 
that the DNA-binding region is rich in cysteine, arginine 
and lysine residues, and contains a cys-X2-cys region that 
probably forms metal-binding fingers. Such fingers are well 
suited for binding specific sequences in DNA. Mutants of the 
glucocorticoid receptor containing insertions that disrupt 
the cys-X2-cys region bind hormone, but do not activate 
transcription, showing that this region is important for
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glucocorticoid action.
Hydrocortisone administration to male rats caused a 
down-regulation of the glucocorticoid receptor which 
correlated well with a decrease in tyrosine aminotransferase 
activity, a characteristic glucocorticoid function (Yi-Li et 
al 1989). A similar effect has been reported in mice (Svec
1988) .
Permissive hormones such as the glucocorticoids have 
been reported to modulate the actions' of hormones that act 
through cyclic AMP (Malbon et al 1988, Hems and Whitton 
1980), and adenylate cyclase (Davies and Lefkowitz 1984). 
Further, adrenalectomy affected the steady-state amounts of 
the components of the hormone-sensitive adenylate cyclase 
system : a 30% decrease in the amount of the a-subunit of Gs 
and a 50% decrease in the amount of the {3-subunit of Gs (Ros 
et al 1989) was observed, an effect that was reversed upon 
dexamethasone replacement therapy. However, adenylate 
cyclase activity was markedly reduced and {3-receptor 
expression increased with the same treatment (Ros et al
1989).
The expression of the {3-adrenergic receptor, which is 
coupled to adenylate cyclase via guanine-nucletide binding 
proteins (G-proteins), is stimulated by glucocorticoids 
(Graziano and Gilman 1987), whereas receptor sensitivity is 
reduced by adrenalectomy or depletion of adrenal steroids 
(Davies et al 1981). The regulation of G-protein-linked 
receptors by these hormones remains obscure. The gene for 
the mammalian {3-adrenergic receptor has recently been 
isolated (Dixon et al 1986) and glucocorticoid responsive
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elements (GRE), which are DNA sequences that mediate 
transcriptional regulation by glucocorticoids, have been 
identified in the 5'-coding (Kobilka et al 1987), coding and 
3'-noncoding regions of this gene (Chung et al 1987). 
Further, the GREs in the 5'-noncoding region of the hamster 
{32-adrenergic receptor appear to be responsible for the 
stimulation of its mRNA and expression by glucocorticoids 
(Malbon and Hadcock 1988). Actinomycin D, a potent inhibitor 
of transcription, abolished the dexamethasone-induced 
increase in {3-adrenergic receptor expression, showing that 
dexamethasone exerted its effects by influencing gene 
transcription (Hadcock and Malbon 1988).
Corticosteroids also interact directly with the GH gene 
to stimulate transcription (Evans et al 1982, Spindler et al 
1982, Yaffe and Samuels 1984, Diamond and Goodman 1985,
Gertz et al 1987).
The diabetic state is characterised by a fall in serum 
somatomedin levels and increased levels of glucocorticoids, 
it was recently reported that both adrenalectomised-diabetic 
and adrenalectomised-non-diabetic rats displayed decreases 
in serum somatomedin levels irrespective of glucocorticoid 
status (Hofert et al 1989). Conversely, Levinovitz and 
Norstedt (1989) reported that glucocorticoids play an 
important role in the expression of insulin-like growth 
factor II (IGF-II), since dexamethasone administration 
specifically and irreversibly reduced IGF-II expression in 
newborn rats.
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1.7 MECHANISM OF ACTION OF THYROID HORMONES
The unbound thyroid hormones (triiodothyronine, T3 and 
thyroxine, T4 ) enter the cell by diffusion. However, 
increasing evidence is now accumulating to support the claim 
that transport of thyroid hormone into rat hepatocytes is an 
energy-dependent and saturable process (Hennemann et al 
1986, Blondeau et al 1988, Docter et al 1988), rather than 
simple diffusion, since transport could be inhibited by 
specific monoclonal antibodies (Rao et al 1981).
Internalised hormone then binds to cytosolic binding 
proteins (CBP), forming a hormone-CBP complex. The T3-CBP 
complex remains in a reversible equilibrium with a very 
small amount of free T3 in the cytoplasm. T4 is normally 
converted to T3 before it acts in the nucleus. Unlike the 
steroid hormones, T3 can directly interact with its nuclear 
receptor (KD = 10_9M), and cytoplasmic receptors are 
apparently not directly involved in the activation of the 
nuclear receptor.
The nuclear receptors are associated with chromatin, 
and are nonhistone proteins with a molecular weight of about 
50K. The receptors can bind to DNA, which accounts for their 
presence in chromatin. Free T3 does not combine with the 
DNA, so that the presence of these receptor proteins 
accounts for the observed association of T3 with cell nuclei 
(Bernal and Refetoff 1977, Aprilletti and David-Inouye
1984) .
Thyroid hormone receptors also appear to be present in 
the cytoplasm, inner mitochondrial membrane and plasma
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membrane of the cell.
The physiological and developmental effects of the 
thyroid hormones are mediated by a family of thyroid hormone 
receptors. Three human thyroid hormone receptors have been 
characterised from skeletal muscle (Nakai et al 1988).
Thyroid hormone-receptor complexes function as 
trans-acting transcriptional factors and exert their effects 
by binding to specific DNA sequences in thyroid 
hormone-responsive genes (TRE). Messenger RNA formation and 
an increase in protein synthesis appear to follow receptor 
interaction (Bernal and Refetoff 1977).
The thyroid hormones, like the glucocorticoids, also 
exert permissive effects on the actions of hormones that act 
via cyclic AMP (Malbon et al 1988). It has been shown that 
thyroid hormones can differentially regulate the 
steady-state amounts of several G-protein subunits such as 
a-Gi (a-G41), a-G0 (a-G39) and {3-G35/36 in adipocytes 
(Malbon et al 1985, Saggersen 1986, Milligan et al 1988, Ros 
et al 1989). In the liver, both thyroid status and 
adrenalectomy modulated the steady-state amounts of 
G-proteins (Stiles et al 1981, Garcia-Sainz et al 1988) and 
the {3-adrenergic receptor (Wolfe et al 1976, Rajerison et al 
1974).
Thyroid hormone responsive elements (TRE) have recently 
been identified on the growth hormone gene, and may account 
for the stimulation of this gene by thyroid hormones. The 
sequences mediating thyroid hormone stimulation are thought 
to be located in the 5 '-flanking regions of the rGH gene (Ye 
and Samuels 1987), between -208 and -160 bp (Larson et al
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1986, Brent et al 1989, Copp and Samuels 1989). Thus T3 acts 
directly with the GH gene to stimulate transcription (Evans 
et al 1982, Spindler et al 1982, Yaffe and Samuels 1984, 
Diamond and Goodman 1985).
1.8 INSULIN
1.8.1 INSULIN RECEPTOR
1.8.1.1 RECEPTOR STRUCTURE
The insulin signal is initiated upon binding of insulin 
to its receptor. The structure of the insulin receptor has 
been identified by a multitude of techniques such as a) 
cross-linking of radiolabelled insulin to its receptor and 
then analysing the labelled proteins, b) receptor 
purification followed by sequencing of the isolated protein, 
and c) immunoprecipitation of the insulin receptor (reviewed 
by Jacobs and Cuatrecasas 1981, Goldfine 1987). .
The purification of the insulin receptor has recently 
been documented extensively (Hughes and Friesen 1985). Based 
on these studies, a model for the insulin receptor has been 
proposed. The insulin receptor is a tetramer consisting of 
two 125-135K a- and two 95K {3-subunits linked together by 
disulphide bonds (reviewed by Czech 1985). Thus the 
glycoprotein configuration is (p-S-S-a)-S-S-(a-S-S-p), and 
contains two type I and one type II disulphide bonds.
The insulin binding site resides in the a-subunit of 
the receptor and is exposed to the extracellular
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environment. Since no region of uncharged amino acids long 
enough to span the membrane has been identified in the a 
chain, it is unlikely to be transmembrane in nature (Yip et 
al 1988). The a-subunit has 15 potential asparagine-linked 
glycosylation sites and is rich in cysteine residues. In 
fact, the cysteine-rich region between residues 155 and 312 
of the a chain could either constitute the insulin receptor 
binding site or may be involved in receptor-receptor 
cross-linking. Similar high-cysteine regions have also been 
identified in the IGF-I receptor.
The {3-subunit is the transmembrane protein and is 
therefore exposed to both the extracellular and cytosolic 
surfaces of the cell. The {3-subunit has 4 potential 
asparagine-linked glycosylation sites and 4 extracellular 
cysteine residues. The transmembrane domain is probably 
represented by a long sequence of hydrophobic amino acids.
Insulin binding to the a-subunit of its receptor is 
thought to induce a conformational change (Schenker and 
Kohanski 1988), which in turn activates an intrinsic 
tyrosine kinase in the {3-subunit which autophosphorylates 
the receptor. Several lines of evidence have indicated that 
this tyrosine-specific phosphorylation is an obligatory step 
in insulin action. An additional requirement for 
autophosphorylation appears to be the association of the a{3 
insulin receptor heterodimer into the a2{32 heterotetrameric 
form (Wilden et al 1989, Kubar and van Obberghen 1989).
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1.8.1.2 RECEPTOR BIOSYNTHESIS
Pulse chase experiments have led to to the elucidation 
of receptor biosynthesis. The a- and {3-subunits are derived 
from a common precursor of the insulin receptor and is 
synthesised on the endoplasmic reticulum as a 1370 amino 
acid 190K molecule (Forsayeth et al 1986). Asparagine 
residues are co-translationally N-glycosylated, yielding the 
high-mannose form of the receptor. Sugar moieties appear to 
play an important role in insulin binding since tunicamycin 
blocked both N-glycosylation and insulin-binding. The 
receptor is then transferred to the golgi where the mannose 
residues are replaced by other sugars such as glucosamine 
and fucose, forming the 210K receptor species. The 210K form 
is then slowly proteolytically split to form the a' (125K) 
and {3' (83K) chains, immediately before insertion of the
subunits into the plasma membrane, sialic acid residues are 
acquired, giving rise to the mature a (135K) and {3 (90K) 
subunits (Forsayeth et al 1986).
Cloning of the insulin receptor has further led to the 
characterisation of the insulin receptor. The insulin 
receptor gene codes for the entire a- and {3-subunits of the 
receptor in the form of a single precursor molecule. At the 
start of the a-subunit there is a 27 amino acid N-terminal 
signal sequence sequence which allows the receptor to enter 
the endoplasmic reticulum, and is subsequently cleaved. Next 
a sequence for the 719 amino acid a-subunit follows, then a 
4-amino acid proteolytic cleavage site (arg-lys-arg-arg), 
and finally a sequence specifying the 620 amino acid
{3-subunit.
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1.8.1.3 RECEPTOR INTERNALISATION
Upon binding of insulin to its membrane receptor, the 
hormone-receptor complex has been shown to migrate and 
congregate at coated pits in the membrane. These coated pits 
are plasma membrane invaginations lined with protein 
clathrin on their cytoplasmic side, which is responsible for 
mediating the internalisation of activated hormone-receptor 
complexes. On entry into the coated pit, vesicularisation 
occurs, leading to the formation of an endosome vesicle.
From here, the receptor can either be degraded via the 
lysosomes or alternatively recycled to the plasma membrane 
by interaction with the golgi system (Jones et al 1988, 
McClain and Olefsky 1988). This is thought to be the major 
pathway undertaken by the insulin-receptor complex, and 
althogh insulin itself is degraded in the process, its 
receptor is recycled intact to the plasma membrane.
An insulin-degrading enzyme has been implicated in the 
intracellular degradation of insulin, and has recently been 
identified as a cytosolic enzyme (Akiyama et al 1988).
Insulin-stimulated internalised receptors remained in a 
phosphorylated state until after the dissociation of 
insulin, and were dephosphorylated prior to their return to 
the plasma membrane. Thus the phosphorylated state of 
internalised receptors may also be regulated by insulin 
(Backer et al 1989).
The kinetics of insulin-receptor internalisation have
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recently been described (Caro et al 1982).
Endocytosis of receptors appears to be a possible mechanism 
of reducing the number of insulin receptors at the cell 
surface through the lysosomal degradative pathway. Thus the 
potential of cell desensitisation to the action of insulin 
may be brought about by the down-regulation of the number of 
insulin receptors available. Receptor down-regulation may be 
caused by either an increased rate of receptor 
internalisation or an increased rate of removal of receptors 
from the plasma membrane. Although receptor down-regulation 
appears to be blocked by cycloheximide, receptor synthesis 
is not thought to be a contributory factor. It has, however, 
been suggested that protein synthesis may be involved in 
receptor recycling, blockage of which would result in 
receptor down-regulation. In addition, proteolysis of the 
insulin receptor at the plasma membrane may also be an 
important contributary factor in receptor degradation and 
down-regulation (Lipson et al 1988).
1.8.2 MECHANISM OF INSULIN ACTION
1.8.2.1 TYROSINE KINASE ACTIVATION
The 95kDa p-subunit of the insulin receptor is an 
insulin-regulated tyrosine kinase that is capable of 
autophosphorylation upon receptor activation (reviewed by 
Reddy and Kahn 1988, Kasuga et al 1982). Autophosphorylation 
of the p-subunit may then be responsible for activation of 
kinase activity for exogenous substrate phosphorylation.
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Insulin stimulated the phosphorylation of tyrosine residues 
on a novel 60kDa G-protein (O'Brien et al 1989) in mouse 
NIH-3T3 cells.
Autophosphorylation occurs at several tyrosine residues 
in the p-subunit, although the regulatory tyrosine has not 
yet been identified (Czech 1985). Tyrosine 1150 has been 
proposed here. The insulin receptor is phosphorylated at 13 
tyrosine residues in the p-subunit located in three 
clusters. Tyrosine kinase activation is an essential step in 
the action of insulin, and it has been reported that 
replacement of tyrosine for phenylalanine residues reduced 
both tyrosine kinase activity and glucose transport. The 
function of tyrosine phosphorylation appears to be the 
induction of a conformational change in the receptor that is 
then transmitted to the next step in insulin action 
(reviewed by Houslay 1985).
The tyrosine kinase domain begins 50 residues from the 
end of the insulin receptor transmembrane domain. Beginning 
at amino acid 991, this region has a Gly-x-Gly-x-x-Gly 
consensus sequence which is thought to be the ATP-binding 
site (Hunter and Cooper 1985). In addition, a lysine residue 
at position 1018 attracts the negatively charged third 
phosphate of ATP and directs it to tyrosine residues. An 
additional 90 residues distal to the carboxyl terminus of 
the tyrosine kinase domain are thought to regulate kinase 
activity (Hunter and Cooper 1985).
Insulin receptor tyrosine kinase activity appears to be 
regulated by tyrosine autophosphorylation in the p-subunit. 
Upon autophosphorylation of the insulin receptor kinase, the
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presence of insulin is not required for its continued 
activity.
The role of tyrosine phosphorylation in insulin action 
is further supported by the apparent reduction in receptor 
autophosphorylation in STZ-diabetic rats, and in 
erythrocytes from insulin-resistant patients.
In addition to autophosphorylation of tyrosine residues 
(Kasuga et al 1982), the insulin receptor appears to 
phosphorylate other cellular proteins. In purified, 
solubilised receptor preparations, insulin predominantly 
phosphorylated at serine residues (White et al 1985). In 
contrast, insulin only phosphorylated at tyrosine residues 
in vitro, but in intact cells, serine and threonine residues 
were also phosphorylated. Serine phosphorylation was thought 
to decrease insulin action. It has been suggested that this 
phosphoseryl-specific kinase is activated by the receptor 
tyrosine kinase, and may account for insulin-stimulated 
phosphorylation observed at serine residues elsewhere. This 
is further supported by the finding that the tyrosine kinase 
is activated before serine phosphorylation occurs (Czech 
1985). The phosphorylated receptor is capable of being 
dephosphorylated by endogenous protein phosphatases. This is 
supported by the finding that vanadate, which inhibits 
tyrosine-specific phosphatases, increased receptor 
phosphorylation. Further, phosphotyrosyl residues are 
rapidly inactivated in intact cells, showing the presence of 
protein phosphatases (Sefton et al 1980). Seven forms of 
phosphotyrosyl-protein phosphatases have been purified from 
bovine brain (Jones et al 1989), and were distinct from the
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type 1 and type 2 serine/threonine-protein phosphatases. 
Further, regulatory mechanisms for the control of these 
serine/threonine-protein phosphatases have been 
demonstrated. For instance, calcium ions activated pyruvate 
dehydrogenase phosphatase, and three heat-stable inhibitors 
of serine/threonine phosphatases are known to exist. Two 
inhibitor proteins of phosphotyrosyl-protein phosphatase 
have recently been identified and may be involved in their 
regulation (Ingebritsen 1989).
1.8.2.3 GUANINE NUCLEOTIDE REGULATORY PROTEINS
A number of guanine nucleotide regulatory proteins 
(G-proteins) have been isolated and characterised (Milligan
1988). For instance, Gs links the stimulation and Gi the 
inhibition of adenylate cyclase activity to the hormone 
receptors. G-proteins consist of three distinct subunits a,
P and 7. The a-subunit comprises the GTP-binding site, sites 
that interact with the receptor and target systems and a 
Mg2+-binding site. The a-subunits of G.j and Gs can be 
identified separately using cholera and pertussis toxins, 
which cause the NAD+-dependent ADP-ribosylation of Gs and G^  
respectively (Houslay 1985).
Activation of G-proteins by hormone-receptor complexes 
results in the release of the activated a-subunit of the 
G-protein. In the case of the Gs , the activated a-subunit 
interacts with and activates the catalytic unit of adenylate 
cyclase. G^  is thought to inhibit adenylate cyclase activity 
by two mechanisms. Firstly, by releasing an activated
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a-subunit which binds to the catalytic subunit of adenylate 
cyclase, and secondly by releasing its p - 7  complex. This 
complex, which is structurally very similar to that in Gs , 
inhibits Gs dissociation, thereby inhibiting its stimulatory 
action on adenylate cyclase.
The a-subunits of all G-proteins also exhibit a GTPase 
activity, which is thought to be responsible for the 
deactivation of the dissociated and activated a-subunit.
More recently, phosphorylation of a-Gi has been 
demonstrated, concomitant with the functional inactivation 
of Gi to inhibit adenylate cyclase activity (Pyne et al
1989) .
Insulin has been shown to stimulate a GTPase activity 
in human platelets, and appears to be distinct from other 
G-proteins. Insulin is now thought to inhibit adenylate 
cyclase activity not via G,, but via Gins, a novel G-protein 
thought to mediate the effects of insulin on many systems 
(Houslay 1986). The a-subunit of Gins has been identified as 
a 25kDa molecule.
Other factors aside from Gins are also involved in 
mediating the ability of insulin to inhibit adenylate 
cyclase and activate cyclic AMP phosphodiesterases. 
Activation of the plasma membrane cyclic AMP 
phosphodiesterase appears to be as a result of 
phosphorylation of intrinsic serine residues. Although the 
mechanism of this activation is not yet known, Gins has been 
implicated (Heyworth and Houslay 1983, Heyworth et al 1983a 
& 1983b).
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1.8.2.4 SECOND MESSENGERS OF INSULIN ACTION
The ability of insulin to antagonise the actions of 
hormones such as glucagon, that act via cyclic AMP 
mechanisms, led to the belief that insulin may be mediating 
its effects by lowering cyclic AMP levels. The possibility 
that many of the effects of insulin are as a result of 
changes in intracellular cyclic AMP levels is a much debated 
area. Although the mechanism by which insulin may lower 
cyclic AMP exists, that is, inhibition of adenylate cyclase 
and stimulation of cyclic AMP phosphodiesterase, several 
studies have reported controversial results.
Kuo and De Renzo (1969) demonstrated an insulin- 
stimulated reduction in cyclic AMP levels in adipocytes in 
the presence of lipolytic agents (Fain et al 1971). Insulin 
was shown to activate membrane-bound high affinity cyclic 
AMP phosphodiesterase, but not cytosolic phosphodiesterase 
in vivo, although the same effects were not observed in 
vitro (Thompson et al 1973), and may therefore explain the 
reduction in cyclic AMP levels seen above. A similar 
reduction in cyclic AMP levels in response to insulin was 
noted in hepatocytes, although this was attributed to the 
alteration in adenylate cyclase activity (Iliano and 
Cuatrecasas 1972). The role of the G-proteins in 
insulin-stimulated activation of cyclic AMP 
phosphodiesterase and inhibition of adenylate cyclase is 
well documented (Houslay 1985). In contrast to these 
reports, Tarui et al (1976) reported that the effects of 
insulin on diaphragm muscle were not mediated by alterations
-92-
in either cyclic AMP or GMP levels.
More recently, protein kinase C activation has been 
implicated in the stimulation of lipogenesis by insulin in 
isolated rat adipocytes since the effect was abolished in 
the presence of the protein kinase inhibitor acridine orange 
(Smal et al 1989). Similarly, protein kinase C was activated 
in response to insulin in BC3H-1 myocytes (Acevedo-Duncan et 
al 1989). Further, insulin and phorbol esters phosphorylated 
several proteins that are markers of protein kinase C 
activation, suggesting that insulin acted via protein kinase 
C activation (Vila et al 1989). By the use of specific 
inhibitors, it was shown that diacylglycerol production was 
involved in the insulin-stimulated increase in protein 
synthesis in 3T3 fibroblasts (Hesketh et al 1988). Further, 
glucose transport, stimulated by insulin was 
dependent on protein kinase C activation (Cooper et al
1989) .
In contrast to these reports, however, Andersen et al 
(1988) have reported that PMA and insulin-stimulated 
processes acted in an additive manner, and were therefore 
proceeding by distinct mechanisms. Taylor et al (1985) 
showed that insulin did not influence phosphoinositide 
formation in isolated hepatocytes. However, insulin 
stimulated the de novo synthesis of phosphatidylinositol and 
phosphatidylinositol-4,5-bisphosphate, but had no effect on 
phosphoinositide breakdown in adipocytes (Pennington and 
Martin 1985), showing that protein kinase activation was not 
involved in insulin action. Farese et al (1988a & 1988b) 
have also demonstrated an increase in PIP2/ phosphatidic
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acid and diacylglycerol synthesis, an effect that was 
abolished by protein synthesis inhibitors. Thus insulin 
stimulated the biosynthesis of phospholipids, but not their 
hydrolysis, which is contrary to the findings of other 
reports.
1.8.3 INSULIN MEDIATOR HYPOTHESIS
The rapid responses observed upon insulin binding to 
its receptor are thought to be mediated by a second 
messenger or chemical mediator.
A chemical mediator of insulin action was first 
proposed by Larner et al (1979) who showed that a substance 
extracted from insulin-treated skeletal muscle inhibited 
cyclic AMP-dependent protein kinase. A similar extract 
stimulated pyruvate dehydrogenase (PDH) activity in 
adipocyte mitochondria (Jarett and Seals 1979). In addition, 
treatment of a mixture of plasma membranes and mitochondria 
with insulin also stimulated PDH activity (Seals and Jarett 
1980). This low molecular weight mediator (1000-2000kDa) was 
also generated upon treatment of liver plasma membranes with 
insulin, and stimulated both adipocyte and liver 
mitochondrial PDH activity (Saltiel et al 1981). Further, 
this effect was dependent on the concentration of insulin 
used to generate the mediator substance.
The insulin mediator substance has subsequently been 
isolated and purified from rat skeletal muscle (reviewed by 
Cheng et al 1984), plasma membranes (reviewed by Seals and 
Czech 1982), hepatocytes (reviewed by Saltiel 1987),
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adipocytes (Kiechle et all 1980), IM-9 lymphocytes (Jarett 
et al 1980), hepatoma cells (Parker et al 1982) and from 
human mononuclear cells and placental plasma membranes 
(Suzuki et al 1984a). In its purified form, all the putative 
insulin mediators isolated as yet appear to be low molecular 
weight (1000-2000kDa) carbohydrate compounds that are 
acid-and heat-stable (Saltiel 1987, Suzuki et al 1984b), but 
are reported to be susceptible to hydrolytic cleavage 
(Suzuki et al 1984b, Zhang et al 1983).
Reports of a biphasic effect (inhibitory and 
stimulatory) with different concentrations of the insulin 
mediator extract on numerous systems have led to the idea of 
the existence of a family of insulin mediators (Larner et al 
1979, Suzuki et al 1987). Dose-response experiments with the 
insulin mediator extract have supported this claim, and it 
was suggested that the stimulating effects of the mediator 
were more active at lower concentrations than was the 
inhibitory activity. The generation of multiple insulin 
mediators has further been supported by subsequent 
purification of the extract. Inhibitory and stimulatory 
activities have now been separated electrophoretically 
(Cheng et al 1985) and by column chromatography (Larner et 
al 1988). Further, multiple stimulatory activities with the 
same biological actions have also been detected (Romero et 
al 1988). The generation of different insulin mediators may 
be attributed to tissue differences.
Purification of the insulin mediator extracts have led 
to the partial characterisation of the structure of the 
inositol phosphate glycan (IPG). Although some differences
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have been reported (Larner et al 1988), the IPG consists of 
an inositol monophosphate linked to glucosamine, four 
residues of galactose and two additional phosphate groups 
that are not linked to inositol (Mato et al 1987b, Saltiel
1987). In addition, three different phosphorylated forms of 
the IPG have recently been purified, and it was shown that 
the biological activity of each of these was dependent on 
their phosphorylation state (Merida et al 1988).
The mechanism by which insulin elicits IPG generation 
is not fully clear as yet. Early reports led to the belief 
that a proteolytic reaction was involved (Larner et al 1982, 
Cherqui et al 1982), and although this theory has not been 
entirely disproved, it is not thought to be valid.
A mechanism by which treatment of various tissues with 
insulin generated the insulin mediator has recently been 
proposed by Saltiel and co-workers. Two chemically related 
carbohydrate substances and diacylglycerol were purified 
from an extract prepared by treatment of plasma membrane 
fractions with insulin (Saltiel and Cuatrecasas 1986,
Saltiel et al 1986). Further, this insulin mediator could 
also be generated from plasma membranes incubated with a 
phosphatidylinositol-specific phospholipase C (Pi-specific 
PLC ) from Staphylococcus aureus (S. aureus), which 
selectively hydrolyses glycosyl-phosphatidylinositol to 
release compounds that are covalently linked to the 
phosphatidylinositol moiety by a glycan anchor (Low and 
Saltiel 1988). This led to the suggestion that insulin 
activated an endogenous Pi-specific PLC which, upon 
hydrolysis of the phosphatidylinositol-glycan (Pl-glycan),
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resulted in the formation of the inositol phosphate-glycan 
(IPG) mediator of insulin action (Saltiel et al 1986). 
Myristate diacylglycerol (DAG) was also produced during the 
course of this reaction (Saltiel et al 1987), and was not as 
a result of de novo DAG synthesis, as was proposed by Farese 
et al (1988a). In addition, increased synthesis of 
phosphatidylinositol, phosphatidylinositol phosphate and 
phosphatidylinositol glycan by insulin may represent 
replenishing of the precursor stores that are hydrolysed by 
insulin (Farese et al 1988b), and further supports the role 
of the IPG in insulin action.
The finding that EGF and IGF-I also stimulate the 
release of IPG implies that tyrosine kinase activation may 
be involved in Pl-glycan hydrolysis (Farese et al 1988c).
The observation that IPG generation by liver plasma 
membranes is markedly stimulated in the presence of ATP and 
Mn2+, similar to the requirements for tyrosine kinase 
phosphorylation, supports the claim that tyrosine kinase 
rather than serine or threonine phosphorylation is involved 
(Suzuki et al 1987). Since insulin failed to stimulate IPG 
generation from diabetic livers (Amatruda and Chang 1983), 
its release appears to be a specific effect of insulin 
rather than of tyrosine kinase activation alone.
The precusor Pl-glycan has been isolated and 
characterised by several groups (Mato et al 1987a), and 
appears to be almost exclusively located on the external 
surface of the rat liver plasma membrane (Alvarez et al 
1988). In addition, treatment of this purified 
glycophospholipid with either insulin or Pi-specific PLC
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from liver plasma membranes (Fox et al 1987), S. aureus 
(Kelly et al 1986) or Bacillus cereus (Merida et al 1988) 
resulted in the release of its polar head group, the insulin 
mediator. A striking resemblance became apparent at this 
point between insulin mediator generation and other systems 
such as alkaline phosphatase and heparan sulphate, which are 
also anchored to the plasma membrane by glycan structures 
(Low and Saltiel 1988). In addition, a novel glycan 
Pi-specific PLC that catalyses the conversion of membrane 
form variant surface glycoproteins (mfVSG) has been isolated 
from Trypanosoma brucei (Fox et al 1986). The glycolipid 
moiety of mfVSG contains dimyristyl-phosphatidylinositol 
glycosidically linked to glucosamine, and it is coupled to 
the polypeptide by additional carbohydrate, phosphate and 
ethanolamine, and forms an amide linkage with the carboxy 
terminus amino acid residue (Ferguson et al 1985a and b).
The PLC has been reported to cleave a phosphodiester bond in 
this structure. A phospholipid labelled with 3H-inositol, 
3H-glucosamine and 3H-myristate was recently reported to be 
hydrolysed by insulin-stimulated PLC (Farese et al 1988c), 
which is consistent with the components of the IPG.
The Pi-specific PLC has also been purified. Fox et al 
(1986) purified the 40K PLC from T. brucei. The enzyme 
showed a specificity for molecules containing carbohydrate 
covalently linked to Pl-glycans. The enzyme did not require 
any specific ions for its activity, and was therefore 
calcium ion independent, and was stimulated by 
thiol-reducing agents and inhibited by thiol-chelating 
compounds. A 62kDa Pi-specific PLC has subsequently been
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characterised from liver plasma membranes (Fox et al 1987) 
which appears to be associated with membrane lipid, and 
showed identical properties to the PLC isolated from T. 
brucei (Fox et al 1986).
Numerous reports have accumulated showing the homology 
between the actions of insulin and its mediator on various 
systems. The effects of insulin that are mimicked by the 
insulin mediator are summarised in Table 4.
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TABLE 4 : "INSULIN-LIKE" EFFECTS OF THE INSULIN 
MEDIATOR
(adapted from Gottschalk and Jarett 1985, Cheng and Larner
1985)
SOURCE and METABOLIC SYSTEM EFFECT
MEDIATOR INSULIN
A) CELL-FREE SYSTEMS
CYTOPLASM
Cyclic AMP-dependent protein kinase
Glycogen synthase + +
Acetyl CoA carboxylase + +
CELL MEMBRANE
Adenylate cyclase (hormone-stimulated)
Ca2+,Mg2+-ATPase - +
Na+ ,K+-ATPase + +
ENDOPLASMIC RETICULUM
Cyclic AMP phosphodiesterase + +
Glucose-6-phosphatase
MITOCHONDRIA
Pyruvate dehydrogenase + +
Ca2+ transport + +
NUCLEUS
Transcription of p-casein gene +
RNA synthesis +, +
B) INTACT CELL SYSTEM
RAT ADIPOCYTE
Hormone-stimulated cAMP concentration 
Lipogenesis + +
Antilipolysis + +
Low Km cAMP phosphodiesterase + +
RAT HEPATOCYTE
Lipogenesis + +
Down-regulation of insulin receptor + +
Adenylate cyclase -
HUMAN MONOCYTES 
Glucose-6-phosphatase
IM-9 LYMPHOCYTES 
Adenylate cyclase
RAT LIVER
Phospholipid methyltransferase
Steroid metabolism + ?
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The IPG in general, appears to act by activation of 
protein kinases and phosphatases to modulate the 
phosphorylation state, and therefore activity of its target 
enzymes. Such a phosphorylation-dephosphorylation control 
mechanism has been proposed (Larner et al 1979).
Both cyclic AMP-dependent and independent effects of 
insulin were mimicked by the IPG (Alemany et al 1987), 
indicating that mediator generation occurred early in 
insulin action, prior to second messenger activation.
The effects of the insulin mediator on pyruvate 
dehydrogenase (PDH) activation have been documented 
extensively (Jarett and Seals 1979, Saltiel et al 1981). PDH 
is a multi-enzyme complex comprising the five enzymes 
pyruvate decarboxylase, dihydrolipoyl acetyltransferase, 
dihydrolipoyl dehydrogenase, a cAMP-independent protein 
kinase and a phosphoprotein phosphatase. The activity of the 
complex is regulated by the extent of phosphorylation of the 
a-subunit of the decarboxylase, which is in turn determined 
by the competing effects of the PDH kinase and PDH 
phosphatase. The dephosphorylated enzyme is the active form. 
Thus the mechanism by which insulin and insulin mediator 
stimulate PDH activity could be either by inhibition of the 
kinase or activation of the phosphatase. PDH activation was 
blocked in the presence of sodium fluoride, an inhibitor of 
PDH phosphatase, thus showing that both insulin and the 
insulin mediator stimulated PDH activity by activation of 
the PDH phosphatase (Suzuki et al 1984a), and therefore 
caused a dephosphorylation of the a-subunit. In addition, 
inhibition of the PDH kinase had no effects on the ability
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of insulin and insulin mediator to activate PDH, showing 
that the kinase was not involved (Macaulay and Jarett 1985). 
An ethanol-insoluble PDH inhibitor has also been identified 
in the insulin mediator extract, and is thought to be 
prevalent at higher concentrations of insulin mediator 
(Suzuki et al 1987, Saltiel et al 1982).
Both insulin and the insulin mediator are known to 
exert effects on the cyclic AMP system. Adenylate cyclase 
activity was inhibited by the insulin mediator (Pyne and 
Houslay 1988, Saltiel 1987, Malchoff et al 1987, Macaulay 
and Jarett 1985) by modulating its catalytic subunit 
(Malchoff et al 1987). The insulin mediator also inhibited 
the catalytic subunit of cAMP-dependent protein kinase, and 
at a site distinct from the ATP-binding sites (Villalba et 
al 1988, Malchoff et al 1987). Low Km , but not high Km , 
cyclic AMP phosphodiesterase activity was increased by the 
insulin mediator (Kiechle and Jarett 1981, Parker et al 
1982), but neither peripheral plasma membrane or 
dense-vesicle cyclic AMP phosphodiesterase were affected 
(Pyne and Houslay 1988).
Thus the mechanism exists for modulation of 
intracellular cyclic AMP levels by insulin. The insulin 
mediator has also been reported to lower glucagon-elevated, 
although not basal, cyclic AMP levels (Zhang et al 1983, 
Alvarez et al 1987).
The insulin mediator was reported to inhibit the 
stimulatory effects of isoprenaline on phospholipid 
methyltransferase activity in adipocytes (Kelly et al 1986,
1988) by inhibiting the isoprenaline-induced phosphorylation
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and therefore activation of phospholipid methyltransferase 
(Kelly et al 1987). In contrast to this, the same extract 
failed to mimic the stimulatory effects of insulin on 
glucose transport (Kelly et al 1987). Thus a dissociation of 
the effects of insulin and its mediator were observed 
(Jarett et al 1985). This discrepancy was resolved by 
Standaert et al (1988), who showed that diacylglycerol, its 
structural analogues and insulin all stimulated glucose 
transport in BC3H-1 myocytes, and therefore implied a role 
of protein kinase C activation in insulin-stimulated glucose 
transport.
1.8.4 PROPOSED MECHANISM OF INSULIN ACTION
Based on the various steps that follow the binding of 
insulin to its receptor, a possible pathway for insulin 
action has been proposed by Brautigan and Kuplic (1988) 
(Figure 4) :
Insulin binds to the a-subunit of its receptor, causing 
a conformational change, and activates an intrinsic tyrosine 
kinase in the p-subunit. This activated receptor kinase then 
phosphorylates a tyrosine residue in a regulatory G-protein, 
possibly Gins. The a-subunit of this G-protein then 
activates a specific phospholipase C, which in turn 
catalyses the phosphodiesteratic hydrolysis of a 
membrane-bound phosphatidylinositol-glycan to release 
myristate diacylglycerol and a carbohydrate inositol 
phosphate-glycan moiety. This IP-glycan is the proposed 
mediator of insulin action that presumably controls target
FIGURE 4 : PROPOSED MECHANISM OF INSULIN ACTION
Abbreviations : cAMP=cyclic AMP, cAMP PDE=cyc1ic AMP-dependent 
phosphodiesterase, DAG=diacylglycerol, Gins=guanine nucleotide 
regulatory protein specif ic  fo r  insulin, 1 PG=inositol phosphate 
glycan, PI-PLC=phosphatidylinositol-specif ic  phospholipase C, 
Tyr-P=insul in  receptor tyrosine kinase.
(adapted from Espinal 1987)
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enzymes by a phosphorylation-dephosphorylation mechanism. 
The role of serine/threonine phosphorylation by insulin in 
this pathway has not yet been recognised, although it has 
been suggested that the insulin mediator substance itself 
may be involved in the phosphorylation of serine/threonine 
kinases rather than the intrinsic tyrosine kinase (Czech et 
al 1988).
AIMS OF THE PRESENT PROJECT :
1) To observe the effects of GH administration to 
isolated hepatocytes on steroid metabolism and to relate 
this, to results reported in the intact animal.
2) To attempt to elucidate the mechanism of action,of 
GH on steroid metabolism.
3) To determine the effects of insulin on steroid 
metabolism and its interaction with GH.
4) To determine the effects of dexamethasone on steroid 
metabolism and its interaction with GH.
5) To determine the effects of thyroxine on steroid 
metabolism and its interaction with GH.
6) To determine the effects of GH on steroid metabolism 
in the presence of dexamethasone AND thyroxine.
7) To determine the effects of the insulin mediator on 
hepatic steroid metabolism and to correlate this with the 
results obtained with insulin.
8) To purify the insulin mediator extract and identify 
the constituents of the insulin mediator.
The primary aim of this project was therefore to
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elucidate the effects of GH on hepatic steroid metabolism, 
and to determine the culture conditions that would manifest 
the feminising effect expected of GH from in vivo studies. 
The second part of this study comprised of studies with the 
putative insulin mediator isolated from hepatocytes in an 
attempt to determine if this mediator was involved in 
insulin action on hepatic steroid metabolism.
MATERIALS AND METHODS
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MATERIALS AND METHODS
2.0 EXPERIMENTAL ANIMALS
Mature male Wistar rats bred in the department were 
used throughout this study. The animals were housed under 
light-and temperature-controlled conditions (lights on 
0800-2000; 19±1°C) and were allowed access to food (CRM 
Nuts, Labsure, Croydon) and water ad libitum. The rats were 
10-12 weeks old at the time of experimentation, and weighed 
between 350-400g.
2.1 PREPARATION OF RAT HEPATOCYTES
Hepatocytes were isolated using a modification of the 
two-step collagenase perfusion technique described by Seglen 
(1973). The animal was anaesthetised under 3.5% halothane : 
400ml/min oxygen : 800ml/min nitrous oxide using a MiniBoyle 
anaesthetic machine. The abdomen was then cut open and a 
cannula inserted into the hepatic portal vein, ensuring that 
it was placed before any branch points in the vein so as to 
allow adequate perfusion of the whole liver. The liver was 
perfused using a Watson-Marlow 501U perfusion pump with 
calcium-free Hank's balanced salt solution (HBSS) at a rate 
of 90ml/min until the liver reached twice its original size, 
at which point the vena cava was punctured. The liver was 
perfused for a further 7-8 minutes at a rate of 60ml/min. 
After 10 minutes, the perfusion was switched over to 
calcium-collagenase buffer (calcium-free HBSS supplemented
-106-
with 4mM calcium chloride and 0.5mg/ml collagenase). The 
calcium-collagenase buffer was recirculated for about 12.5 
minutes, until the liver appeared to be sufficiently 
digested, at which point the liver was removed from the 
animal. The cells were then gently "combed-out" in HBSS and 
the resulting cell suspension filtered through two layers of 
gauze to remove connective tissue and undigested liver, and 
centrifuged at 200g for 2min in a refrigerated DAMON/IEC DPR 
600 centrifuge to remove cell debris from liver parenchymal 
cells. The isolated hepatocytes were then resuspended in 
incubation medium (calcium-free HBSS, lg/1 glucose, lOOmg/ml 
MgS04 , lOOmg/ml MgCl2 and 185mg/ml CaCl2 ), and counted using 
a haemocytometer. Yield of cells was about 108 cells/g 
liver, and cell viability exceeded 90% in all cases, as 
assessed by the trypan blue exclusion method.
2.2 PREPARATION OF RAT LIVER MICROSOMES
The method used is a modification of that described by 
Berg and Gustafsson (1973). The animal was killed by C02 
asphyxiation, and the liver removed, rinsed in ice-cold 
0.25M sucrose, blotted dry and weighed. All buffers were 
kept at 4°C throughout. The liver was finely chopped, and 
portions of liver were homogenised in four volumes of 
sucrose buffer using a Potter-Elvehjem homogeniser with a 
loose-fitting Teflon pestle at 10,000 rpm. The homogenate 
was then centrifuged in a refrigerated SORVALL RC-5B 
centrifuge for 15 minutes at 12,500g to sediment 
mitochondria and nuclei. This leaves the postmitochondrial
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supernatant fraction. Calcium chloride is then added to this 
postmitochondrial supernatant at a final concentration of 
8mM, mixed thoroughly, and left to stand at 4°C for 5 
minutes. The microsomes are then pelleted by centrifugation 
at 27,000g for 20 minutes. The supernatant is then decanted, 
the pellet resuspended in 0.25M sucrose, and stored on ice 
until use. Tissue protein content was determined as 
described in Section 2.4.
2.3 PREPARATION OF RAT LIVER MITOPLASTS
The method used for the preparation of rat liver 
mitoplasts was as described by Saltiel (1984). The animals 
were killed by C02 asphyxiation and the liver was washed in 
20mM potassium phosphate buffer pH 7.4, homogenised in 10 
volumes of buffer A (0.075M sucrose, ImM Tris, 0.ImM EDTA, 
pH 7.2) and centrifuged at 500g for 10 minutes. The 
supernatant was then re-centrifuged at 500g for a further 10 
minutes. This pellet was homogenised in an equal volume of 
buffer A, and the two centrifugation steps repeated. The 
pellet from this step consisted of whoTe mitochondria. The 
outer mitochondrial membranes were then detached by swelling 
in 10 volumes of 20mM potassium phosphate pH 7.2 
supplemented with 0.02% bovine serum albumin (Buffer B), 
gradually added over 45 minutes at 4°C with gentle shaking 
every 5 minutes. This suspension was centrifuged at 40,000g 
for 20 minutes at 4°C in order to shear the outer membranes, 
and the resultant pellet resuspended in buffer B. This 
mixture of inner and outer mitochondrial membranes was then
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separated by further centrifugation at 1900g for 15 minutes. 
The resulting pellet, consisting of inner mitochondrial 
ghosts (mitoplasts) highly enriched in pyruvate 
dehydrogenase activity, was resuspended in 20mM potassium 
phosphate buffer pH 7.0, and stored at -20°C for up to two 
weeks with negligible loss of enzyme activity. Tissue 
protein content was determined as per Section 2.4.
2.4 DETERMINATION OF TISSUE PROTEIN CONTENT
Tissue protein content was determined by the method of 
Lowry et al (1951), and follows the formation of a coloured 
complex between the alkaline copperphenol reagent and the 
tyrosine and tryptophan residues of the protein measured 
spectrophotometrically at 750nm.
To 1ml sample of protein solution (containing 
approximately 150pg protein) is added 2ml of freshly 
prepared reagent (50 parts 4% w/v Na2C03 in 0.IN NaOH : 1 
part 1% w/v potassium disodium tartarate : 1 part 0.5% w/v 
hydrated copper sulphate) and left to stand for 10 minutes 
at room temperature. 0.3ml of IN Folin Ciocalteu reagent is 
then added, rapidly mixed, and left to stand for 30 minutes. 
Optical density was then determined at 750nm, and the 
protein content of the unknown samples calculated from a 
standard curve prepared using 0.2ml to 1.0ml aliquots of 
200pg/ml bovine serum albumin.
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2.5 PRETREATMENT OF HEPATOCYTES
2.5.1 PREINCUBATION OF HEPATOCYTES OVER 0-60 MINUTES
Hepatocytes (2xl07 cells/incubation) were incubated in 
glass tubes in hormone-free Ham's F-10 culture medium 
supplemented with 0.1% bovine serum albumin in a final 
volume of 10ml at 37°C in a rotary shaking waterbath. 
Hormones were subsequently added in the minimum volume 
possible, control incubations receiving an equivalent volume 
of drug vehicle alone. Hormonal additions were as follows :
a) 10"9M - 10"7M growth hormone in distilled water
b) 10_11M - 10“6M insulin in 0.IN HCl
c) 10“8M dexamethasone in acetone
d) 10"8M - 10"6M thyroxine in 0.01N NaOH
e) 10"1°M - 10"8M insulin-like growth factor I in H20
None of these additions altered the pH of the
incubation system significantly.
2.5.2 PREINCUBATION OF HEPATOCYTES OVER 24, 48 AND 72HR
Hepatocytes were plated (NUNCLON 9cm diameter petri 
dishes) at a cell density of 2xl07 cells/incubation in 10ml 
Ham's F-10 culture medium supplemented with lOOpg penicillin 
/ streptomycin and 2% Ultroser G (LKB), which is a serum 
substitute to promote cell attachment and monolayer 
formation, and incubated at 37°C under 95% air and 5% C02 in 
a humidified incubator (Forma Scientific Model 3028). After 
24h of incubation, the medium was replaced with Ham s F-10
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culture medium supplemented with 0.1% bovine serum albumin 
and lOOpg penicillin/streptomycin. Hormones were added to 
the plated cells (Section 2.5.1) after 24h of incubation, 
and incubated for a further 24, 48 and 72 hours, as 
described by Hussin and Skett (1986). In some cases, 
pretreated cells are then further incubated with growth 
hormone.
2.6 ASSAY OF STEROID METABOLISM
2.6.1 ASSAY OF STEROID METABOLISM IN HEPATOCYTES
After pretreatment with hormone, cell suspensions were 
centrifuged at 200g for 2min (4°C) and the supernatant was 
discarded. Hepatocytes were then washed and resuspended in 
incubation medium, and counted prior to assaying for 
steroid-metabolising activity.
The assay used is a modification of that described by 
Gustafsson and Stenberg (1974). Hepatocytes (6xl06) were 
incubated with 500pg 0.lpCi [4-14c3 -androst-4-ene-3,17-dione 
in a final volume of 3ml in incubation medium. Incubations 
were carried out in a rotary shaking waterbath at 37°C for 
30min in triplicate, after which the reaction was stopped by 
the addition of 5ml Folch solution (chloroform : methanol, 
2:1 v/v) and 1ml 0.9% NaCl to aid extraction of metabolites 
into the organic layer. The tubes were gently shaken and the 
two phases allowed to separate overnight. The tubes were 
then centrifuged at 500g for 5min in order to achieve 
complete separation of the two phases. The lower organic
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layer was then removed and dried under a stream of nitrogen 
at 40°C. The extract was redissolved in a few drops of 
chloroform and sonicated for about 30 seconds in an 
ultrasonic waterbath. Samples were then spotted onto 0.25mm 
Merck silica gel thin layer chromatography plates (20cm x 
10cm), and separation of metabolites was achieved by running 
the plates in a mobile phase consisting of chloroform : 
ethyl acetate (4:1 v/v) in tanks equilibrated with the 
solvent for at least one hour. The plates were then dried, 
and metabolites were located by autoradiography (Figure 5). 
The identity of the metabolites has previously been 
characterised by gas chromatography -mass spectrometry 
(Gustafsson and Stenberg 1974). Metabolites were then 
scraped into counting vials, suspended in 3ml of Ecoscint 
liquid scintillant and counted in a Packard Tri-Carb 2000CA 
Liquid Scintillation Analyser in dpm mode using a commercial 
quenched standard set.
2.6.2 ASSAY OF STEROID METABOLISM IN LIVER MICROSOMES
The assay was essentially as that described in section
2.6.1 except that cofactors were also included in the 
reaction system. Microsomes were incubated in 0.25M Sucrose 
- 0. 1M Tris buffer (pH 7.4) with 500pg, 0.lpCi 
[4-1 4cJ -andr0st-4-ene-3 ,17-dione and HOpl cofactor mixture 
(3mg NADP, 3.9mg sodium isocitrate, 6pg manganese chloride 
and lOpl isocitrate dehydrogenase added immediately before 
starting the incubation) in a final volume of 3ml. The 
incubation was carried out at 37°C for 30min, and metabolite
FIGURE 5 : THIN LAYER CHROMATOGRAPHY OF ANDROSTENEDIONE 
METABOLITES.
A. Start
B. Androst-4-ene-7ar-o l-3 ,1 7-dione
C. Androst-4 -ene-6/J-o l -3 ,1 7-dione
D. Androst-4 -ene- 16Qf-ol-5, 17-dione
E. Testosterone/Epitestosterone
F. 3* -androstane-3^)-o l- -17-d ione
G. Unchanged substrate (Andros t -4 -ene-3 ,17-dione)
H. 5o-androstane-3,17-dione
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formation was determined as detailed above.
2.6.3 EVALUATION OF ENZYME ACTIVITY
Activities of each of the enzymes was determined by the 
amount of metabolite formed, and then calculated using the 
following formula :
pmoles metabolite / minute / million cells (mg protein)
= S x cpmM x 1 x 1 x 1 
cpmT t n MW 
where S = pg substrate (500pg) 
cpmM = cpm metabolite 
cpmT = cpm total 
t = incubation time (30min)
MW = molecular weight of substrate (280) 
n = number of cells (millions) OR mg protein 
(microsomes)
Thus enzyme activity is expressed as pmoles/min/million 
cells (hepatocytes) or as pmoles/min/mg protein 
(microsomes). The actual calculation was performed using a 
custom-made computer program.
2.7 MEASUREMENT OF INTRACELLULAR CYCLIC AMP
The intracellular cyclic AMP concentration was 
determined by the radioimmunoassay described by Brooker et 
al (1979). Following incubation with growth hormone over 
various time periods, cell samples were pooled, counted and 
then centrifuged at 200g for 2min at 4°C. The supernatant
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was removed and the cells were resuspended in sodium acetate 
buffer to give an approximate concentration of 107 cells/ml 
(approximately 20nM cAMP). The cells were then placed in a 
boiling waterbath for 10-15 minutes to denature the protein 
and extract the cAMP into solution, and then centrifuged at 
4000g for lOmin. The supernatant was stored at -20°C prior 
to assaying for cyclic AMP content. Cyclic AMP standards 
(10-10 to 10~6nM were also prepared in triplicate in sodium 
acetate buffer.
Cyclic AMP content was determined in lOOpl aliquots of 
both standards and unknown samples. To each lOOpl aliquot is 
added :
1) lOpl of a freshly prepared mixture of triethylamine 
and acetic anhydride (2:1 v/v) to acetylate the samples 
thereby increasing sensitivity, followed rapidly by vortex 
mixing;
2) 150pl of a 10-4 dilution of anti-cyclic AMP 
antiserum (in 0.1% BSA) which was raised in goats treated 
with human serum albumin conjugated with succinyl cyclic 
AMP;
The specificity of the antiserum was tested by 
measuring the ability of a range of adenine and guanine 
nucleotides to compete with [j-2 5 ij -cyclic AMP for binding to 
the antiserum. The antiserum was relatively specific for 
cyclic AMP, with 103 fold (cGMP) and 104 fold (AMP, ADP,
ATP) higher concentrations of the other nucleotides required 
to produce 50% displacement of the Q 25ij-cyclic AMP.
3) lOOpl of a 1/7000 dilution of jj12 5 ij -cyclic AMP 
(3000cpm per sample).
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Samples were then mixed and incubated for 16h at 4°C. 
After this incubation, 0.5ml of a suspension of activated 
charcoal (1% w/v) in lOOmM potassium phosphate buffer pH 6.4 
containing 0.25% BSA was added to each of the samples in 
order to remove unbound nucleotide. The samples were then 
mixed and the charcoal sedimented by centrifugation at 4000g 
for lOmin at 4°C. 600pl of this supernatant was taken to 
assess the antibody-bound Q1 2 51]-cyclic AMP, and counted in 
a gamma counter (LKB 1275 Gamma counter).
Standard calibration curves were plotted as 
radioactivity bound (cpm) against concentration of cyclic 
AMP or as B/B0 against concentration of cyclic AMP, where B 
and B0 represent the amount of jj-2 5 Ij -cyclic AMP bound in 
the presence or absence of unlabelled cyclic AMP 
respectively. In the absence of cyclic AMP, approximately 
30% of the total added jj-2 5 ij -cyclic AMP was bound. Amounts 
oz cyclic AMP were then determined in the unknown samples by 
using the standard curve and expressed as pmoles of cyclic 
AMP per million cells.
2.8 PREPARATION OF THE INSULIN MEDIATOR EXTRACT
2.8.1 PREPARATION OF INSULIN MEDIATOR FROM RAT LIVER
MICROSOMES
The insulin mediator extract was prepared using the 
method of Suzuki et al (1987). Rat liver microsomes (2.5mg 
protein) were incubated with and without insulin in 50mM 
Tris-HCl buffer pH 7.4 supplemented with 0.01% BSA, ImM ATP,
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3mM MnCl2 , 1M CaCl2 at 37°C for 5min in a total volume of 
2ml. 2ml of 1M formic acid containing 5mM EDTA was then 
added to the reaction mixture and the tubes placed in a 
boiling waterbath for 5min. After centrifugation (15000g, 
lOmin, 4°C) the denatured precipitate was removed and the 
supernatant treated with 0.2mg/ml activated charcoal for 
lOmin at 4°C. The supernatant was then separated from the 
charcoal by centrifugation (15000g, lOmin, 4°C) and 
lyophilised at -50°C overnight. The resulting white powder 
was resuspended in 1ml of ImM formic acid pH 3.5 and 
labelled as the original insulin mediator extract.
These original extracts were then twice extracted with 
2ml of chloroform : methanol (2:1 v/v) at 4°C for lOmin. The 
soluble fraction was removed and the insoluble residue 
extracted with 2ml of ethanol at 4°C for lOmin. The soluble 
fraction was discarded and the insoluble precipitate was 
dried under a stream of nitrogen. This precipitate was 
redissolved in 1ml of ImM formic acid pH 3.5, and the 
insoluble residue removed by centrifugation. The resulting 
supernatant, consisting of the partially purified insulin 
mediator extract, was then applied to a 1x2cm AGlx8 
ion-exchange resin equilibrated with ImM formic acid pH 3.5. 
The column was then eluted sequentially with 6ml each of ImM 
formic acid; 0.025M, 0.1M, 0.2M, 0.5M, 1.0M ammonium formate 
and 1.0M formic acid. The eluates were collected, 
lyophilised at -50°C and redissolved in ImM formic acid pH 
3.5 immediately before assay.
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2.8.2 PREPARATION OF INSULIN MEDIATOR FROM RAT
HEPATOCYTES
The insulin mediator extract was prepared from rat 
hepatocytes essentially as described above in section 2.8.1, 
except that hepatocytes (1.2xl07 cells) were incubated with 
or without insulin in a final volume of 2ml of incubation 
medium supplemented with 0.1% BSA.
2.9 PRETREATMENT WITH THE INSULIN MEDIATOR EXTRACT
2.9.1 PRETREATMENT OF HEPATOCYTES WITH INSULIN MEDIATOR
Hepatocytes (2xl07 cells) were incubated at 37°C with 
varying doses of the insulin mediator extract in incubation 
medium supplemented with 0.1% BSA in a final volume of 5ml. 
After incubating for the required time (0 to 60min), the 
cell suspension was centrifuged (200g, 2min, 4°C) and cells 
resuspended in incubation medium prior to being assayed for 
steroid metabolism (Section 2.6.1).
2.9.2 PRETREATMENT OF LIVER MICROSOMES WITH INSULIN
MEDIATOR
Rat liver microsomes were incubated with varying 
concentrations of the insulin mediator extract for 30min and 
at 37°C in a final volume of 5ml in 0.25M Sucrose-0.25M Tris 
buffer pH 7.4. Steroid metabolism was then assayed as per 
section 2.6.2.
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2.10 ASSAY OF MITOCHONDRIAL PYRUVATE DEHYDROGENASE 
ACTIVITY
Mitochondrial pyruvate dehydrogenase activity was 
assayed by measuring the conversion of 14C -pyruvic acid to 
14C02, as described by Saltiel (1987).
Rat liver mitoplasts (2.5mg) protein were prepared as 
per section 2.3, and incubated with 0.2mM ATP for lOmin at 
37°C in the presence of 50pM CaCl2 and 50pM MgCl2 to convert 
the enzyme into its inactive phosphorylated form. Following 
this incubation the solutions were cooled to 4°C and twice 
washed free of unbound nucleotide by centrifugation and 
resuspension in lOmM potassium phosphate buffer pH 7.0.
Pyruvate dehydrogenase activity was assayed, in 
triplicate, by monitoring the conversion of 14C -pyruvic 
acid to 14C02 in 1.0ml containing 50pM coenzyme A, 50pM 
co-carboxylase, 50pM MgCl2 , 25p.M CaCl2 , ImM dithiothrietol,
0. 5mM p-NAD and 0. 5mM pyruvic acid (3000cpm) in 20mM 
potassium phosphate buffer pH 7.0. The reaction was started 
by the addition of this reaction mixture to vessels 
containing varying amounts of the insulin mediator extract 
and 2.5mg mitochondrial protein, and allowed to proceed for 
5min at 37°C. The reaction was then stopped by the addition 
of 1ml 2N H2S04 , and the release of 14C02 was determined by 
absorption to phenylethylamine-soaked filter paper squares 
(lcm2) suspended above the reaction system from the rubber 
stoppers capping the tubes. 14C02 was allowed to absorb onto 
the filter paper for 30min at room temperature, after which 
the radioactivity in the filter paper was counted by liquid
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scintillation counting in 3ml Ecoscint liquid scintillant. 
Pyruvate dehydrogenase activity was expressed as nmole /mg 
protein /minute.
2.11 CHROMATOGRAPHY OF THE ACID HYDROLYSED INSULIN 
MEDIATOR
Samples of the original insulin mediator extract were 
subject to acid-hydrolysis by incubating with 2ml of ION HC1 
for 2h at 100°C. Both hydrolysed and unhydrolysed mediator 
fractions were then spotted onto cellulose thin layer 
chromatography plates and onto 20x20cm squares of Whatman 
No. 1 filter paper. Samples of 5% standard solutions of 
galactose, mannose, glucosamine, galactosamine and inositol 
were also applied. The chromatograms were then placed in a 
TLC tank equilibrated with butanol : acetic acid : water 
(4:1:2) and the solvent front allowed to run about 1cm from 
the edge in each case. The chromatograms were left to dry 
overnight at room temperature, and then placed in an iodine 
vapour tank to locate the components of chromatography. 
Comparison of the insulin mediator to the standards allowed 
identification of the bands visualised.
2.12 CALCULATION OF RESULTS AND STATISTICS
Enzyme activities are expressed as pmoles product / 
minute / million cells or as pmoles product / minute / mg 
protein ± standard deviation of triplicate incubations. 
Absolute values are then expressed as percentages of
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relevant controls ± standard deviation and statistical 
analysis performed by means of Student's t-test. The level 
of significance has been set at p<0.05 in each case.
2.13 BUFFERS
1) Calcium-free HBSS (10% stock solution)
2.Og/1 
0.3g/l 
40g/l 
10.5g/l 
0.238g/l
2) Incubation medium
HBSS.....................................100ml (10% stock)
glucose.................................. l.,0g/l
MgCl2 . 6H20 .............................. 0.1g/l
MgS04 . 7H20 .............................. 0.1g/l
CaCl2 .6H2 ).............. ................0 .185g/l
3) Sodium acetate buffer
50mM sodium acetate solution adjusted to pH 5 using
acetic acid.
4) IQOmM Potassium phosphate buffer 
66.25ml of 200mM K2HP04
183.7 5ml of 200mM KH2P04
-made up to 500ml with distilled water and adjust to pH
6.4 using 10N HCl.
KCl................
KH2P04 (anhydrous).
NaCl...............
NaHC03 (anhydrous). 
Na2HP04 (anhydrous)
5) 0.25M Sucrose-0.1M Tris buffer pH 7.4
132g/l sucrose 
12.1g/l Tris base 
80ml/l IN HC1
2.14 MATERIALS LIST
Sigma Chemical Co. Ltd., Poole, Dorset, U.K. 
Androst-4-ene-3,17-dione 
Dexametasone-21-acetate 
L-thyroxine (sodium salt)
Tris buffers 
cyclic AMP
BCL Ltd., Lewes, East Sussex, U.K.
Collagenase
Bovine serum albumin
NADP
Isocitric acid
Isocitrate dehydrogenase
Gibco Ltd., Paisley, Strathclyde, U.K.
Ham's F-10 culture medium 
Penicillin/streptomycin
Novo Research Centre, Copenhagen, Denmark 
Porcine insulin 
LKB, Bromma, Sweden 
Ultroser G
KabiVitrum AB, Stockholm, Sweden
Human growth hormone
Kodak, France 
X-ray film (X-Omat S)
Developer (D-19)
Fixer (FX-40)
Amersham Int. pic, Aylesbury, Bucks., U.K.
^l-14 cj-androst-4-ene-3,17-dione 
[l-1 4 c]-pyruvic acid
Adenosine-3 15'-cyclic phosphoric acid 2 1-0-succinyl-3 Q 12 
iodotyrosine methyl ester r125a -CAMP
All other chemicals were of the highest grade available 
commercially.
RESULTS
3.0 RESULTS
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The assay used allows the measurement of the 
6 p-hydroxylase, 7a-hydroxylase, 1 6 0 -hydroxylase, 3 a/{3 - 
oxosteroid oxidoreductase, 17-oxosteroid oxidoreductase and 
5a-reductase activities. 3a/f3-oxosteroid oxidoreductase, 
however, does not metabolise the parent compound (Figure 3), 
but rather the metabolite subsequent to 5 a-reduction of 
androstenedione. Only primary metabolism of the substrate 
was studied, and so the 3a/(3-oxosteroid oxidoreductase 
product was measured with unchanged 5a-androstane-3,17-dione 
so as to determine total 5a-reductase activity.
The two female-specific activities (7a-hydroxylase and 
5a-reductase) are shown in the first graph, and the 
male-specific activities (6p-hydroxylase, 16a-hydroxylase 
and 17-oxosteroid oxidoreductase are shown in the second 
graph in each case. Results are illustrated as percentages 
of relevant controls and tabulated as absolute values in 
pmoles product/minute/million ceTIs ± standard deviation. 
Error bars have been omitted from the graphs for reasons of 
clarity, but significant pointc have been asterisked.
3.1 GROWTH HORMONE
3.1.1 DOSE-DEPENDENT EFFECTS OF GROWTH HORMONE
Hepatocytes were preincubated with 10"9 to 10_7M growth 
hormone for 30 minutes prior to assaying for 
steroid-metabolising activity (Table 5). As compared to
FIGURE 6 : Dose-response effects of 30 minute preincubation 
with 10~ 9M-10“7M GROWTH HORMONE on A) 7a-hydroxylase, B) 
5a-reductase, C) 6p-hydroxylase, D) 16a-hydroxylase and E) 
17-oxosteroid oxidoreductase activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 5
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TABLE 5 : Dose-response effects of 7a-, 6J3-, 
16a-hydroxylases (OHases), 17-oxosteroid oxidoreductase 
(17-OHSD) and 5a-reductase activities after 30 minute 
preincubation with 10~9M-10“7M GROWTH HORMONE.
Enzyme activities (pmoles/minute/million cells)
TREATMENT 7a-QHase 6p-OHase 16a-OHase 17-OHSD 5a-red
Control 36±4 38±4 36±4 60±7 100±2
10~9M GH 44±2* 39±6 29±3* 50±1* 96±8
10“8M GH (C) 32±2 35±4 33±3 47±1* 96±6
10"7M GH (D) 30±2* 34±3 32±5 46±2* 114±8*
Results are expressed as mean ± s.d. (N=3); *=P<0.05 as 
compared to relevant controls.
Duncan's Multiple Range Test : 
7a-0Hase D C A B
60-OHase D C A B
16a-OHase B D C A
17-OHSD D C B A
5a-red B C A D
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relevant control values, incubation with 10-9M growth 
hormone significantly increased 7a-hydroxylase (Figure 6A), 
but markedly decreased enzyme activity at the higher 
concentrations of growth hormone tested. The effects of 
growth hormone on 5a-reductase activity were not significant 
(Figure 6B), except in the case at 10-7M where a 14% 
increase was observed. Growth hormone had no significant 
effects on the male-specific enzyme activities 
6p-hydroxylase (Figure 6C) and 16a-hydroxylase (Figure 6D), 
but a significant reduction in 17-oxosteroid oxidoreductase 
activity was observed at all concentrations of growth 
hormone tested (Figure 6E).
3.1.2 TIME COURSE OF THE EFFECTS OF 1Q-9M GROWTH
HORMONE
Hepatocytes were preincubated with 10“9M growth hormone 
for 0,5,10,15 and 30 minutes (Table 6). Growth hormone had 
no significant effects on 7a-hydroxylase 'Figure 7A) and 
5a-reductase (Figure 7B) activities, although a slight 
increase was observed at the earlier incubation times. No 
significant effects of incubating with growth hormone were 
observed on 6p-hydroxylase activity (Figure 1C), except at 
15 minutes of incubation where a significant decrease was 
seen. Growth hormone significantly decreased both 
16a-hydroxylase (Figure 7D) and 17-oxosteroid oxidoreductase 
activities (Figure 7E) between 10 and 30 minutes of 
incubation.
Hepatocytes were preincubated with 10“9M growth hormone
FIGURE 7 : Time course of the effects of preincubation with 
10"9M GROWTH HORMONE on A) 7a-hydroxylase, B) 5a-reductase, 
C) 6p-hydroxylase, D) 16a-hydroxylase and E) 17-oxosteroid 
oxidoreductase activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 6
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TABLE 6 : Effects of preincubation with 10~9M GROWTH HORMONE 
over 0 to 60 minutes on la-, 6p~, 16a-hydroxylases (OHases), 
17-oxosteroid oxidoreductase (17-OHSD) and 5a-reductase 
activities.
Enzyme activities (pmoles/minute/million cells)
TIME(min) 7a-OHase 6p-OHase
oc 34±5 36±5
OGH 35±3 36±2
5C 34±8 34±6
5GH 38±7 34±4
10C 34±3 38±8
10GH 32±2 34±3
15C 30±2 34±1
15GH 30±4 3012*
30C 38±2 38±1
3 OGH 36±7 38±1
16a-OHase 17-OHSD 5a-red
34±6
35±2
58±7
59±5
106±9
105±7
30±7
30±1
58±8
52±8
100±10
104±3
32±1
2613*
38±1
4411*
92±5
106116
30±2
2612*
58±4
4612*
9814
10618
44±4
3216*
78±3
5618*
118112
118112
Results are expressed as mean ± s.d. (N=3); *=P<0.05 as 
compared to relevant control values (C=control).
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over 24,48 and 72 hours (Table 7) as described in Section 
2.5.2. Figure 8A shows that growth hormone significantly 
decreased 7a-hydroxylase activity after 24h of incubation, 
after which enzyme activity returned to basal levels. No 
significant effects of growth hormone were seen on 
5a-reductase activity (Figure 8B), except at 72h where 
enzyme activity was decreased to 70% of contol. No changes 
in enzyme activity were observed with 6p-hydroxylase (Figure 
8C) and 16a-hydroxylase activities (Figure 8D), whilst a 
significant increase in 17-oxosteroid oxidoreductase (Figure 
8E) activity was seen at 24 and 48h of incubation, an effect 
that was lost by 72h.
3.1.3 TIME COURSE OF THE EFFECTS OF 10~8M GROWTH 
HORMONE
Incubation of hepatocytes with 10_8M growth hormone 
(Table 8) exhibited no significant changes in 7a-hydroxylase 
(Figure 9A), 6p-hydroxylase (Figure 9C) or 17-oxosteroid 
oxidoreductase activities (Figure 9E) throughout the 30 
minutes of incubation. 5a-reductase activity (Figure 9B) 
was significantly increased after 5 minutes of incubation, 
and a significant decrease was observed in 16a-hydroxylase 
activity (Figure 9D) at 15 minutes of incubation.
Thus although some significant results were obtained 
by incubating hepatocytes with growth hormone, these effects 
were, firstly, not consistent over all experiments and, 
secondly the results obtained are not typical of those 
obtained by in vivo infusion of growth hormone (Mode et al
FIGURE 8 : Effects of preincubation with 10-9M GROWTH
HORMONE over 24, 48 and 72 hours on A) 7a-hydroxylase, B) 
5a-reductase, C) 6p-hydroxylase, D) 16a-hydroxylase and E) 
17-oxosteroid oxidoreductase activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 7
100  -
o
L-
£ZO
o
&€ 90 "
80
time (days)
Ffa-reductase100 i
90 "
o
80 -c
o
o
70 -
60
time (days)
% 
co
nt
ro
l 
 ^
co
nt
ro
l 
% 
co
nt
ro
l
130 i
120  -
10  -
100 -
90
4320
t ime (days)
16a-hydroxy1ase1 1 0  i
100  -
90
t ime (days)
17-OHSD130 n
120  -
110-
100
t ime (days)
TABLE 7 : Effects of preincubation with 10"9M GROWTH HORMONE 
over 24,48 and 72h on 7a-, 6p-, 16a-hydroxylases (OHases), 
17-oxosteroid oxidoreductase (17-OHSD) and 5a-reductase 
activities.
Enzyme activities (pmoles/minute/million cells) 
TIME (hrs) 7a-OHase 6p-OHase 16a-OHase 17-OHSD 5a-red
24h C 28±1 30±1 28±3 39±2 61±2
24h GH 23±2* 29±3 29±1 47±3* 60±1
48h C 23±2 22±3 26±3 42±4 62±6
48h GH 22±2 25±4 24±2 49±3* 54±6
72h C 17±3 24±3 27±3 52±1 54±2
72h GH 20±1 28±4 28±1 50±2 37±4*
Results are expressed as mean ± s.d. (N=3); *=P<0.05 as 
compared to relevant control values (C=control).
FIGURE 9 : Time course of the effects of preincubation with 
10~8M GROWTH HORMONE on A) 7a-hydroxylase, B) 5a-reductase, 
C) 6p-hydroxylase, D) 16a-hydroxylase and E) 17-oxosteroid 
oxidoreductase activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 8
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TABLE 8 : Effects of 30 minute preincubation with 10_8M 
GROWTH HORMONE on la-, 6p~, 16a-hydroxylases (OHases), 
17-oxosteroid oxidoreductase (17-OHSD) and 5a-reductase 
activities.
Enzyme activities (pmoles/minute/million cells) 
TIME (min) 7a-OHase 6p-OHase 16a-0Hase 17-OHSD 5a-red
oc 64±18 58±10 44±15 61±9 118±7
OGH 54±5 60±6 56±2 51±6 132±14
5C 52±18 62±6 54±3 45±7 115±6
5GH 54±4 60±4 48±2* 46±4 139±3
10C 44±6 47±4 47±7 48±5 100±2
10GH 44±4 54±7 50±2 42±5 98±8
15C 56±2 58±2 64±6 48±2 125±9
15GH 56±6 53±9 52±4* 45±4 102±5
30C 44±6 50±10 48±9 38±2 95±11
3 OGH 46±4 54±10 42±6 40±6 146±6
Results are expressed as mean ± s.d. (N=3); *-P<0.05 as 
compared to relevant control values (c=control).
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1982), as will be discussed in a later section.
3.1.4 EFFECTS OF GROWTH HORMONE ON INTRACELLULAR CYCLIC 
AMP
Table 9 shows that incubation of hepatocytes with 10_9M 
growth hormone over 0-30 minutes (Figure 10) and over 24,48 
and 72 hours (Figure 11) had no significant effects on 
intracellular cyclic AMP levels.
3.1.5 DOSE-DEPENDENT EFFECTS OF INSULIN-LIKE GROWTH
FACTOR 1
Incubation of hepatocytes with 10-10 to 10“8M 
insulin-like growth factor 1 (IGF-1) for 30 minutes (Table 
10) showed dose-dependent increases in all enzyme 
activities. Maximum effects of IGF-1 on 7a-hydroxylase 
activity (Figure 12A) were seen upon incubation with 10"9M 
IGF-1. 5a-reductase (Figure 12B), 6p-hydroxylase (Figure 
12C), 16a-hydroxylase (Figure 12D) and 17-oxosteroid 
oxidoreductase (Figure 12E) activities all exhibited 
dose-dependent effects with maxima at 10"8M IGF-1.
FIGURE 10 : Intracellular cyclic AMP content in hepatocytes 
treated with 10"9M GROWTH HORMONE over 0-120 minutes.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 9
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FIGURE 11 : Intracellular cyclic AMP content in hepatocytes 
treated with 10“9M GROWTH HORMONE over 24, 48 and 72 hours. 
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 9
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TABLE 9 : Effects of preincubation with 10~9M GROWTH HORMONE 
on intracellular cyclic AMP content.
TIME CONTROL io- 9M GH
Omin 2.0 + 0.23 1.8 + 0.21
5min 1.8 + 0.14 1.5 + 0.13*
lOmin 1.8 + 0.16 1.7 + 0.18
15min 1.9 + 0.21 1.8 + 0.24
3 Omin 1.7 + 0.18 1.6 + 0.08
6 Omin 1.6 + 0.09 1.4 + 0.12*
120min 1.2 + 0.10 1.3 + 0.15
24hr 0.84 + 0.06 0.53 + 0.05*
48hr 0.84 + 0.07 1.00 + 0.14
72hr 0.74 + 0.10 0.89 i 0.09
Results are expressed as mean ± s.d. of cyclic AMP levels in 
pmoles/million cells (N=3), and plotted as percentages of 
relevant control values.
FIGURE 12 : Effects of 30 minute preincubation with
10 1°M-10 8M INSULIN-LIKE GROWTH FACTOR 1 on A)
7a-hydroxylase, B) 5a-reductase, c) 6p-hydroxylase, D)
16a-hydroxylase and E) 17-oxosteroid oxidoreductase 
activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 1Q
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TABLE 10 : Effects of 30 minute preincubation with 
10-1 °M-10~ 8M IGF-1 on 7a-, 6f3-, 16a-hydroxylases (OHases), 
17-oxosteroid oxidoreductase (17-OHSD) and 5a-reductase 
activities.
Enzyme activities (pmoles/minute/million cells)
TREATMENT
Control 
10~1°M (B) 
10“ 9 M (C) 
10"8M (D)
7a-OHase 6{3-OHase 16a-0Hase 17-OHSD 5a-red
42±3
48±4
63±6*
54±3*
45±2
44±2
60±3*
60±5*
40±3
36±2
42±2
52±3*
81±4
78±5
120±8*
114±7*
126±3
120±7
152±9*
177±6*
Results are expressed as mean ± s.d. (N=3); *=P<0.05 as 
compared to relevant controls.
Duncan's Multiple Range Test
7a-0Hase A B D C
6p-OHase B A C D
16a-0Hase B A C D
17-OHSD B A D C
5a-red B A C D
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3.2 INSULIN
3.2.1 THE EFFECTS OF INSULIN AND THE INTERACTION OF
INSULIN AND 10" 9 M GROWTH HORMONE ON
ANDROST-4-ENE-3y17-DIONE METABOLISM
Hepatocytes were preincubated for 30 minutes with 10" 11 
to 10~7M insulin in the presence and absence of 10"9M growth 
hormone. Incubation of hepatocytes with insulin gave a 
dose-dependent stimulation of androst-4-ene-3,17-dione 
metabolism (Table 11A). 7a-hydroxylase (Figure 13A) and 
16a-hydroxylase (Figure 13D) activities showed maximum 
stimulation at 10"8M insulin. Maximum activities for 
5a-reductase (Figure 13B), 6j3-hydroxylase (Figure 13C) and 
17-oxosteroid oxidoreductase (Figure 13E) were observed with 
10"9M insulin. Thus insulin appears to be a non-specific 
stimulatory agent of steroid metabolism in that both 
male-and female-specific enzyme activities are affected in a 
similar fashion, as has been shown previously (Hussin and 
Skett 1987).
Incubation of hepatocytes with insulin and 10"9M growth 
hormone resulted in a marked decrease in enzyme activity as 
compared to the response with insulin alone (Table 11B).
This antagonism of the insulin response by growth hormone 
was more apparent at physiological concentrations of 
insulin, as is illustrated in Figure 13, and showed 
insignificant changes in enzyme activity with 10 M ins
These results therefore indicate that, although growth 
hormone exhibited consistent and significant effects in
FIGURE 13 : Dose-dependent effects of 30 minute
preincubation with 10~1i-M-lO-7M INSULIN in the presence and 
absence of 10~9M GROWTH HORMONE on A) 7a-hydroxylase, B) 
5a-reductase, C) 6p-hydroxylase, D) 16a-hydroxylase and E) 
17-oxosteroid oxidoreductase activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 11
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TABLE 11 : Dose-dependent effects of 30 minute preincubation 
with A) 10_11M-10-7M INSULIN and B) 10~11M-10-7M INSULIN + 
10_9M GROWTH HORMONE on 7a-, 6p-, 16a-hydroxylases (OHases), 
17-oxosteroid oxidoreductase (17-OHSD) and 5a-reductase 
activities.
A)
TREATMENT
Enzyme activities (pmoles/minute/million cells)
Control 
10'n M 
10" 1 °M 
10~ 9M 
10' 8M 
10" 7M
B)
(A)
(B)
(C)
(D)
(E)
(F)
TREATMENT
7a-OHase 6(3-OHase 16a-0Hase 17-OHSD 5a-red
45±2 52±1 47±3 84±2 112±4
46±1 6114* 49±3 7611* 127±1*
46±2 6414* 46±5 86±2 12011*
5315* 7514* 5814* 100±1* 13711*
6111* 8215* 54±6 107±13* 13413*
5113* 58±1 49±1 71±9* 13011*
Enzyme activities (pmoles/minute/millioni cells)
7a-OHase 6p-OHase 16a-OHase 17-OHSD 5a-red
Control I44±2
10"11M+GH 45±3
10“1°M+GH (C) 46±2 
10“ 9M +GH (D) 45±1 
10“ 8M +GH (E ) 45±2 
10-7M + G H 4 5 ± 4
Results are expressed 
relevant control values.
3812 3611 5012 10312
3011* 2813* 3011* 9513
3112* 3012* 2813* 9519
3611 3112* 2911* 10512
4112 3213* 2914* 9018*
4314 3614 4617 10816
as mean 1 s .d . (N=3); *=P<0 . 05 of
Duncan's Multiple Range Test : 
A)
7a-OHase A B C F D E
6p-0Hase A F B C D E
16a-OHase C A B F D E
17-OHSD F B A C D E
5a-red A C B F E D
B)
7a-OHase A B D E F C
6p-OHase B C D A E F
16a-OHase B C D E A F
17-OHSD C D E B F A
5a-red E B C A D F
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antagonising the stimulatory action of insulin, these 
effects were non-sex-specific in nature since both male- and 
female-specific activities were affected in an identical 
manner.
3.2.2 TIME COURSE OF THE INTERACTION BETWEEN lQ-^M
INSULIN AND 10~9M GROWTH HORMONE
Hepatocytes were pretreated with 10_11M insulin with or 
without 10~9M growth hormone over a period of 0-60 minutes. 
The effects of incubating hepatocytes with 10-11M insulin 
alone demonstrated maximal stimulation at 15 minutes of 
incubation (Table 12A), and enzyme activity remained 
elevated until 30 minutes of incubation for 5a-reductase 
(Figure 14B), 6p-hydroxylase (Figure 14C) and 
16a-hydroxylase (Figure 14D) activities. A I L  enzyme 
activities had returned to basal levels by 60 minutes of
incubation (Figure 14).
Pretreatment of hepatocytes with a combination of 
10-HM insulin and 10"9M growth hormone resulted in an 
antagonism of the stimulate:7 effects of insulin (Table 
12B) . This antagonistic action of growth hormone was evident 
from as early as 5 minutes of incubation, as is the case 
with 16a-hydroxylase and 1 7 -oxosteroid oxidoreductase 
activities (Figures 14D and 14E respectively), and from 10 
minutes with 7 a-hydroxylase, 5 a-reductase and 6p hydroxylase 
activities (Figures 14A, 14B and 14C respectively).
FIGURE 14 : Time course of the effects of preincubation with 
10-11M INSULIN in the absence and presence of 10-9M GROWTH 
HORMONE on A) 7a-hydroxylase, B) 5a-reductase, C) 
6p-hydroxylase, D) 16a-hydroxylase and E) 17-oxosteroid 
oxidoreductase activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 1 2
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TABLE 12 : Effects of preincubation with A) 10-^ M  INSULIN 
and B) 10 1:LM INSULIN + 10-9M GH over 0 to 60 minutes on 
7a-, 60-, 16a-hydroxylases (OHases), 17-oxosteroid 
oxidoreductase (17-OHSD) and 5a-reductase activities.
A ) Enzyme activities (pmoles/minute/million cells)
TIME(min) 7a-OHase 60-OHase 16a-OHase 17-OHSD 5a-red
OC 57±5 62±4 5113 7814 10713
OINS 58±4 8219* 4711* 11315* 109111
5C 62±7 71±10 4716 8719 90116
5INS 65±2 8312* 6417* 12014* 118116*
10C 51±3 81±6 5014 10712 9118
10INS 55±6 10611* 6911* 12212* 13317*
15C 61±9 6416 5518 9611 115122
15INS 8617* 6815 6214 129112* 139112
30C 69±7 6116 4613 11516 107116
30INS 70±4 80112* 5617 11815 143112*
60C 57±9 7614 4312 11116 107112
60INS 57±6 7517 4112 H214 120115
Enzyme activities (pmoles/minute/million cells)
TIME(min) 7a-OHase 60-OHase 16a-OHase 17-OHSD 5a-red
OC 49±8 4214 2616 95116 98112
OINS+GH 43±3 4414 2912 11111 12713*
5C 40±4 4115 3814 119111 12017
5INS+GH 40±2 5016* 3614 129113 15215*
10C 46±8 5617 3413 13214 12511
10INS+GH 56±4 ; 4812 3412 99121* 12116
15C 35±4 6712 3411 126118 117115
15INS+GH 38±5 4317* 3314 104118 12215
30C 45±3 7016 4111 84114 10811
30INS+GH 45±4 7018 ~ 4111 9116 11417
60C 41±1 5211 3713 11912 96110
60INS+GH 41±3 5613* 4014 10918* 8314*
Results are expressed as mean ± s.d. (N-3); *-P<0.05 as
compared to relevant control values (C=control).
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3.2.3 TIME COURSE OF THE INTERACTION BETWEEN 10“9M
INSULIN AND 1Q~9M GROWTH HORMONE
Hepatocytes were pretreated with 10_9M insulin in the 
absence or presence of 10" 9 M growth hormone over a period of 
0  to 60 minutes.
Incubation with 10-9M insulin (Table 13A) resulted in 
significant increases in all enzyme activities, as is 
illustrated in Figure 15, and this activity peaked after 30 
minutes of incubation, moving towards basal levels 
thereafter.
Preincubation with a combination of insulin and growth 
hormone (Table 13B) showed marked decreases in enzyme 
activity, as is shown in Figure 15. The effect of growth 
hormone in antagonising the stimulatory action of insulin 
was apparent early in the time course, and was maintained 
throughout the 60 minutes of incubation, except with 
17-oxosteroid oxidoreductase activity where this effect was 
lost after 60 minutes of incubation (Figure 15E).
3.2.4 TIME COURSE OF THE INTERACTION BETWEEN 10" 7M 
INSULIN AND 10“ 9 M GROWTH HORMONE
Table 14A shows the effects of pretreatment of 
hepatocytes with 10_7M insulin with or without the presence 
of 10_9M growth hormone for 0-60 minutes. Incubation with 
10“ 7M insulin exhibited significant increases in enzyme 
activity in all cases (Figure 16), showing maxima at 30 
minutes of incubation, except for 6 0 -hydroxylase activity
FIGURE 15 : Time course of the effects of preincubation with 
10"9 M INSULIN in the absence and presence of 10~9M GROWTH 
HORMONE on A) 7a~hydroxylase, B) 5a-reductase, C) 
6p-hydroxylase, D) 16a-hydroxylase and E) 17-oxosteroid 
oxidoreductase activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 13
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TABLE 13 : Effects of preincubation with A) 10-9M INSULIN 
and B) 10-9M INSULIN + 10"9M GROWTH HORMONE over 0-60 
minutes on 7a-, 6{3- and 16a-hydroxylases (OHases), 
17-oxosteroid oxidoreductase (17-OHSD) and 5a-reductase 
activities.
A) Enzyme activities (pmoles/minute/million cells)
TIME(min) 7a-OHase 6f3-OHase 16a-OHase 17-OHSD 5a-red
OC 38±4 66±5 36±1 52±5 91±12
0INS 32±6 57±1* 37±2 48±5 82±10
5C 32±1 6013 40±5 63±1 79±4
5 INS 2911* 56±4 44±1 60±3 91±1^ '
10C 28±2 57±2 48±1 46±2 83±4
10INS 3514* 58±1 5816* 56±4* 110±4*
15C 36±1 67±1 45±6 53±4 82±2
15INS 5011* 44±4* 5611* 63±1* 116±3*
30C 28±1 59±5 43±2 59±2 72±5
30INS 41±2* 8011* 6112* 78±7* 10811*
60C 29±2 54±5 57±2 62±2 7 6±12
60INS 3612* 6113* 6614* 65±4 92±5*
11 Enzyme activities (pmoles/minute/million cells)
TIME(min) 7a-OHase 6{3-OHase 16a-0Hase 17-OHSD 5a-red
OC 36±5 49±2 47±4 62±3 82111
0INS+GH 31±3 49±3 42±2 56±1* 7817
5C 30±1 54±5 40±1 53±1 83110
5INS+GH 2611” 56±1 43±2 56±4 8217
10C 43±3 60±2 50±2 64±4 9218
10INS+GH 3614* 58±2 51±1 55±6* 9414
15C 39i8 60±4 36±2 58±3 10114
15INS+GH 34±1 62±6 3012* 38±1* 10315
30C 40±3 72±5 50±4 48±2 9412
30INS+GH 36±4 5515* 44±1* 53±7 102110
60C 42±1 62±1 53±6 55±2 10315
60INS+GH 3612* 5514* 47±1 61±4* 9011*
Results are expressed as mean ± s.d. (N-3); *-P<0.05 as
compared to relevant control values (C=control).
FIGURE 16 : Time course of the effects of preincubation with 
10~7 M INSULIN in the absence and presence of 10“ 9M GROWTI 
HORMONE on A) 7a-hydroxylase, B) 5a-reductase, C) 
6{3-hydroxylase, D) 16a-hydroxylase and E) 17-oxosteroic 
oxidoreductase activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table “|4
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TABLE 14 : Effects of preincubation with A) 10" 7M INSULIN 
and B) 10-7M INSULIN + 10-9M GROWTH HORMONE over 0 to 60 
minutes on 7a-, 6J3-, 16a-hydroxylases (OHases), 
17-oxosteroid oxidoreductase (17-OHSD) and 5a-reductase 
activities.
hi Enzyme activities (pmoles/minute/million cells)
TIME(min) 7a-OHase 60-OHase 16a-0Hase 17-OHSD 5a-red
OC 78±6 64±1 55±10 54±9 120±1
OINS 75±3 54 + 5* 55±4 48±6 103+2*
5C 80+4 76±2 44±4 40±1 119±3
5INS 79±4 8012* 52±6 40±4 111±6*
10C 78±4 56±3 52±6 47±4 122±8
10INS 80±4 7215* 6412* 43±3 13715*
15C 78±8 48±1 48±2 44±2 113±8
15INS 73±6 5212* 54±8 45±5 142±15*
30C 59±1 59±1 46±6 42±2 119±9
30INS 6917* 63 + 2* 58±8 50+3* 139±12*
60C 88±4 62±2 38±1 72±9 116116
60INS 73 + 2* 62 + 7 37±4 64±10 12513
li Enzyme activities (pmoles/minute/million cells)
TIME(min) 7a-OHase 60-OHase 16a-OHase 17-OHSD 5a-red
OC 70±6 52±13 50±10 46±7 93 + 5
OINS+GH 84±3 56±4 57±5 44±5 110+5*
5C 88±9 65±3 46±10 52±6 103 + 6
5INS+GH 76±6 5017* 52±3 50±6 9017*
10C 78±3 62±6 68±3 46±3 98 + 2
10INS+GH 75±6 60±4 £0+5* 3915* 9519
15C 72 + 5 66±7 53±2 46±3 98 + 10
15INS+GH 71±3 5515* 41+4* 3 6 ± 3 * 90 + 5
30C 69±3 62±8 50±5 42±4 110+13
30INS+GH 80+7* 67±4 48±6 44±5 8417*
60C 74±9 56±3 63±4 62±6 8213
60INS+GH 82±5 58±7 60±4 41±5* 65 + 6*
Results are expressed as mean t s.d. (N=3); *=P<0.05 as
compared to relevant control values (C-controi;.
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(Figure 16C) where activity peaked after 10 minutes of 
incubation. The stimulatory effect of insulin was lost by 60 
minutes of incubation in all cases.
Growth hormone antagonised the stimulatory effect of 
10“7M insulin on all enzyme activities (Table 14B), and this 
inhibition was apparent at the earlier incubation times, as 
is illustrated in Figure 16. No significant effect was 
however observed with 7a-hydroxylase activity (Figure 16A).
3.3 DEXAMETHASONE
3.3.1 TIME COURSE OF THE EFFECTS OF 10“ 8M DEXAMETHASONE
AND ITS INTERACTION WITH GROWTH HORMONE
Preincubation of hepatocytes with the synthetic 
glucocorticoid dexamethasone at a concentration of 10~8M 
over 0-30 minutes caused marked increases in enzyme activity 
(Table 15). This stimulation of enzyme activity was 
non-specific in nature as both male- and female-specific 
activities were affected in the same way, as is illustrated 
in Figure 17. This stimulation of enzyme activity was 
optimal early in the time course, returning to basal levels 
by 30 minutes in most cases (Figure 17), except for 
16a-hydroxylase activity (Figure 17D) where the stimulatory
effect was maintained.
Inclusion of 10“9M growth hormone in the incubation 
medium in combination with 10“8M dexamethasone resulted in a 
marked reduction in enzyme activity with respect to the 
response obtained on incubation with dexamethasone alone
FIGURE 17 : Effects of preincubation with 10" 83
DEXAMETHASONE in the absence and presence of 10_9M GROWT 
HORMONE on A) 7a-hydroxylase, B) 5a-reductase, C 
6p-hydroxylase, D) 16a-hydroxylase and E) 17-oxosterob 
oxidoreductase activities.
Results are expressed as percentages of relevant contro 
values, where *=P<0.05 and N=3. Absolute data is given i: 
Table 15
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TABLE 15 : Effects of preincubation with 10"8M DEXAMETHASONE 
+/-10_9M GH over 5 to 30 minutes on 7a-, 6p-, 
16a-hydroxylases (OHases), 17-oxosteroid oxidoreductase 
(17-OHSD) and 5a-reductase activities.
Enzyme activities (pmoles/minute/millionl cells)
TIME(min) 7a-OHase 6p-OHase 16a-OHase 17-OHSD 5a-red
5C 56±2 68116 6016 8818 10215
5DEX 6818* 68114 4818* 11214* 122115*
10C 60±7 6418 68110 9617 120118
10DEX 7616* 9612* 8012 10416 180119*
15C 56±10 7218 6012 104120 10016
15 DEX 8012* 72110 7212* 8012 11417*
30C 76±1 68110 5218 92110 112112
30DEX 76±4 7218 6014 10014 106115
5C 7 6±7 7618 6817 112120 146114
5DEX+GH 76±8 8416 68112 10816 13814
IOC 84±12 8812 88110 12418 134112
10DEX+GH 80±12 7216* 6812* 10018* 14416
15C 84±5 76114 72110 12013 142122
15DEX+GH 7218* 80114 6012* 7212* 132120
30C 80±20 7212 6818 12011 11816
30DEX+GH 72±14 8012* 4812* 8812* 120122
Results are 
compared to
expressed
relevant
as mean + s.d. (N=3); *=P<0.05 
control values (C=control).
as
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(Table 15), as shown in Figure 17. Growth hormone appears to 
modify the stimulatory action of dexamethasone 
non-specifically since both male- and female-specific 
activities are affected in a similar manner.
3.3.2 A COMPARISON OF THE INTERACTION BETWEEN 10~eM 
DEXAMETHASONE AND DIFFERING CONCENTRATIONS OF GROWTH 
HORMONE
Table 16 shows the effects of incubation of hepatocytes 
with 10_8M dexamethasone, and the interaction observed 
between growth hormone at 10_9M and 10_8M. As illustrated in 
Figure 18, incubation with dexamethasone stimulated all 
enzyme activities significantly. Co-incubation with 10_9M 
growth hormone significantly reduced the stimulatory effects 
of dexamethasone in all cases (Figure 18) by up to 70%, as 
is the case with 6p-hydroxylase activity (Figure 18C). 
Incubation of hepatocytes with a combination of 10 8M 
dexamethasone and 10_8M growth hormone resulted in an 
enhancement of the interaction obtained with 10 9M growth 
hormone in that enzyme activities were further decreased by 
approximately 10-20% (Figure 18). Thus growth hormone 
appeared to display a certain degree of dose-dependency in 
its effect on the stimulatory response to dexamethasone.
FIGURE 18 : A comparison of the effects of preincubation
with 10_8M DEXAMETHASONE in the absence and presence of 
10" 9M or 10" 8M GROWTH HORMONE for 10 and 30 minutes on A) 
7a-hydroxylase, B) 5a-reductase, C) 6£-hydroxylase, D) 
16a-hydroxylase and E) 17-oxosteroid oxidoreductase 
activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 16
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TABLE 16 : Effects of preincubation with 10“ 8M 
DEXAMETHASONE in the absence or presence of 10“8M or 10“9M 
GROWTH HORMONE for 10 and 30 minutes on 7a-, 6J3-, 
16a-hydroxylases (OHases), 17-oxosteroid oxidoreductase 
(17-OHSD) and 5a-reductase activities.
Enzyme activities (pmoles/minute/million cells)
TREATMENT 7a-OHase 6p-OHase 16a-0Hase 17-OHSD 5a-red
10 C 30±1 45±7 42±8 45±4 101±2
10 DEX 3913* 66110* 54±4* 45±4 115±8*
10 C 60±15 66±2 57±4 66±6 116±4
10 DEX,-8GH 3012* 4212* 4212* 36±3* 82±2*
10 DEX,-9GH 4211* 6014* 4812* 45±6* 98±1
30 C 33±1 51±4 51±2 51±2 89±1
30 DEX ' 39±4 54±5 6011* 48±2* 96±2^
30 C 51±4 69±2 66±2 84±2 153125
30 DEX,-8GH 3914* 4214* 4812* 63±4* 113±10*
30 DEX,-9GH 48±6 4812* 5412* 51±1* 12114
Results are expressed as mean ± s.d. (N=3) ; *=P<0. 05 as
compared to relevant control values (C=control).
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3.3.3 PRETREATMENT OF HEPATOCYTES WITH DEXAMETHASONE 
FOR 24,48 AND 72h
Hepatocytes were pretreated with dexamethasone for 
24,48 and 72h as described in Section 2.5.2. Table 17 shows 
that incubation with dexamethasone markedly stimulated 
enzyme activity. 5a-reductase, 6p-hydroxylase and 
17-oxosteroid oxidoreductase (Figures 19B, 19C and 19E 
respectively) showed a gradual increase in activity with 
time, whilst 7a-hydroxylase (Figure 19A) and 16a-hydroxylase 
(Figure 19D) reached a peak at 24h of incubation that was 
maintained throughout the incubation period. Thus 
dexamethasone appears to be a potent inducer of steroid 
metabolism in cultured hepatocytes.
3.3.4 PRETREATMENT OF HEPATOCYTES WITH 10~8M
DEXAMETHASONE FOR 24,48 AND 72h FOLLOWED BY INCUBATION
WITH 10-9M GROWTH HORMONE OVER 0-60 MINUTES
Hepatocytes pretreated with 10_8M dexamethasone showed 
a marked stimulation of all enzyme activities (Table 17) as 
was shown in Figure 19. These dexamethasone-exposed 
hepatocytes were then incubated with 10_9M growth hormone 
over a further 0-60 minutes prior to being assayed for 
steroid-metabolising activity (Table 18).
Figure 20 shows that incubation with 10~9M growth 
hormone markedly reduced 7 a-hydroxylase activity to basal 
levels at all time points as compared to the response 
obtained with dexamethasone alone.
FIGURE 19 : Effects of preincubation with 10“ 8M
DEXAMETHASONE over 24, 48 and 72 hours on A) 7a-hydroxylase, 
B) 5a-reductase, C) 60-hydroxylase, D) 16a-hydroxylase and 
E) 17-oxosteroid oxidoreductase activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 17
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TABLE 17 : Effects of preincubation with 10“ 8M DEX over 
24,48 and 72h on 7a-, 60-, 16a-hydroxylases (OHases), 
17-oxosteroid oxidoreductase (17-OHSD) and 5a-reductase 
activities.
Enzyme activities (pmoles/minute/million cells)
TREATMENT 7a-OHase 6{3-OHase 16a-OHase 17-OHSD 5a-red
24 C 42±3 44±1 32±1 34±4 116±5
24 DEX 76±7* 60±6* 46±1* 44±1* 152±1*
48 C 46±3 48±2 80±2 52±5 123±9
48 DEX 80±3* 72±2* 118±2* 80±6* 200±7*
72 C 28±3 36±6 28±1 22±2 94±7
72 DEX 50±2* 68±3* 42±2* 40±2* 181±9*
Results are 
compared to
expressed
relevant
as mean ± s.d. (N=3); *=P<0. 
control values (C=control).
05 as
FIGURE 20 : Effects of preincubation with 10-8M
DEXAMETHASONE for A) 24 hours, B) 48 hours and C) 72 hours 
followed by incubation with 10-9M GROWTH HORMONE over 0 to 
60 minutes on 7a-hydroxylase activity.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 18
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FIGURE 21 : Effects of preincubation with 10 8M
DEXAMETHASONE for A) 24 hours, B) 48 hours and C) 72 hours 
followed by incubation with 10~9M GROWTH HORMONE over 0 to 
60 minutes on 6p-hydroxylase activity.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table18
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FIGURE 22 : Effects of preincubation with 10“ 8M
DEXAMETHASONE for A) 24 hours, B) 48 hours and C) 72 hours
followed by incubation with 10-8M GROWTH HORMONE over 0 to
60 minutes on 16a-hydroxylase activity.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 18
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FIGURE 23 : Effects of preincubation with 10~8M
DEXAMETHASONE for A) 24 hours, B) 48 hours and C) 7 2 hours 
followed by incubation with 10"9M GROWTH HORMONE over 0 to 
60 minutes on 17-oxosteroid oxidoreductase activity.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 18
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FIGURE 24 : Effects of preincubation with 10" 8M
DEXAMETHASONE for A) 24 hours, B) 48 hours and C) 72 hours 
followed by incubation with 1 0 - GROWTH HORMONE over 0 to 
60 minutes on 5a-reductase activity.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 18
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FIGURE 25 : Effects of preincubation with 10“ 8M
DEXAMETHASONE over 24, 48 and 72 hours followed by
incubation with 10~8M GROWTH HORMONE for 10 and 30 minutes 
on A) 7a-hydroxylase, B) 5a-reductase, C) 60-hydroxylase, D) 
16a-hydroxylase and E) 17-oxosteroid oxidoreductase 
activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 18
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TABLE 18 : Effects of preincubation with 10~8M DEX over 
24,48 and 72h followed by incubation with 10" 9 M GROWTH 
HORMONE for 0 to 60 minutes of A) 24h-pretreated, B) 
48h-pretreated and C) 72h-pretreated hepatocytes on 7a-, 
6(3-, 16a-hydroxylases (OHases), 17-oxosteroid oxidoreductase 
(17-OHSD) and 5a-reductase activities.
Enzyme activities (pmoles/minute/million cells)
TIME(min) 7a-OHase 6(3-OHase! 16a-0Hase 17-OHSD 5a-red
24h C 33±3 35±3 32±3 80±7 11716
24h DEX 6015* 4813* 46±3* 10316* 15317*
control 39±4 49±2 33±2 11814 12612
24DEX+0GH 2813* 3612* 28±2* 9419* 11619
control 23±2 33±1 30±2 8614 12415
24DEX+5GH 2812* 3612* -28±3 8612 11615
control 26±2 39±4 27±4 8711 11216
24DEX+10GH 27±1 3312* 26±2 8715 11412
control 28±4 34±1 24±1 9414 10614
24DEX+15GH 25±2 35±3 28±2* 8711* 116110
control 25±2 34±1 29±3 8611 12014
24DEX+30GH 23±3 35±1 26±3 8815 11912
control 29±1 32±1 34±3 9412 12115
24DEX+60GH 30±3 32±3 28±2* '8514* 11418
II Enzyme activities (pmoles/minute/million cells)
TIME(min) 7a-OHase 6(3-OHase 16a-0Hase 17-OHSD 5a-red
48h C 34±1 44±3 29±2 9617 133113
48h DEX 6014* 6614* 43±4* 14717* 217117*
control 28±5 33±3 28±3 8611 118110
48DEX+0GH 26±2 3912* 31±2 9612* 137112*
control 25±2 40±2 32±1 9911 11316
48DEX+5GH 26±2 37±1 26±2* 9811 145115*
control 26±2 38±1 29±2 8718 13416
48DEX+10GH 3513* 4413* 40±6* 9017 12715
control 26±3 34±2 27±2 8812 12815
48DEX+15GH 28±1 34±2 30±3 9815* 13016
control 31±1 34±2 28±2 8814 12517
48DEX+30GH 2811* 40±1* 30±3 8714 12714
control 27±4 41±1 30±1 9013 128110
48DEX+60GH 3711* 41±2 39±2* 9216 134110
91 Enzyme activities (pmoles/minute/million cells)
TIME(min) 7a-0Hase 6p-0Hase 16a-0Hase 17-OHSD 5a-red
72h C 27±3 34±2 32±3 80±4 109±4
72h DEX 48±5* 6415* 4813* 146110* 210111*
control 31±1 32±2 26±1 80±2 114±4
72DEX+0GH 30±1 3511* 28±3 57±6* 82±6
control 29±3 31±2 24±1 76±5 115±12
72DEX+5GH 25±2 32±3 24±1 78±1 80±3
control 2611 36±2 26±2 83±6 11215
7 2DEX+10GH 26±3 35±2 28±1 78±3 10117*
control 23±1 35±1 28±2 86±7 116112
7 2DEX+15GH 3213* 36±2 29±2 84±6 6613*
control 28±1 40±1 26±1 93±2 123114
7 2DEX+30GH 26±1 3512* 28±2 87±5 6914*
control 22±2 30±2 24±1 80±2 123114
7 2DEX+60GH 2511* 32±2 26±3 80±1 6913*
Results are 
compared to
expressed
relevant
as mean ± s.d. (N=3); *-P<0. 
control values (C=control).
05 as
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The effects of growth hormone on 6p-hydroxylase (Figure
21) were more marked with cells pretreated with 
dexamethasone for 72h, although a reduction was also 
observed with hepatocytes pretreated for 24 and 48h. Again 
this reduction in enzyme activity to basal levels was 
apparent early in the time course. Similarity, incubation 
of dexamethasone-pretreated hepatocytes with growth hormone 
resulted in a marked decrease in 16a-hydroxylase (Figure
22), 17-oxosteroid oxidoreductase (Figure 23) and 
5a-reductase activities (Figure 24) throughout the 60 minute 
time course.
Figure 25 summarises the above results. Thus the potent 
stimulatory effects of dexamethasone on these enzymes are 
strongly modulated by further incubation with growth 
hormone in a non-specific manner, as was observed with 
similar experiments over short incubation periods (section 
3.3.1) .
3.4 THYROXINE
3.4.1 DOSE-DEPENDENT EFFECTS OF THYROXINE
Hepatocytes were preincubated with 10-10M-10 6M 
thyroxine for 10 and 30 minutes (Tables 19A and 19B 
respectively). Incubation with 10_10M thyroxine for 10 
minutes caused no significant changes in the female-specific 
activities 7 a-hydroxylase (Fig 26A) and 5 a-reductase (Figure 
26B) , but significantly increased the male-specific 
6{3-hydroxylase, 1 6 a-hydroxylase and 17-oxosteroid
FIGURE 26 : Effects of 10 minute preincubation with
10_loM-10~6M THYROXINE on A) 7a-hydroxylase, B) 
5a-reductase, C) 6p-hydroxylase, D) 16a-hydroxylase and E) 
17-oxosteroid oxidoreductase activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 1 9 A
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FIGURE 27 : Effects of 30 minute preincubation with
10 M-10~6M THYROXINE on A) 7a-hydroxylase, B)
5a-reductase, C) 60-hydroxylase, D) 16a-hydroxylase and E) 
17-oxosteroid oxidoreductase activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 19g a
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TABLE 19 : Effects of preincubation with 10"10M-10-6M 
THYROXINE for A) 10 and B) 30 minutes on 7a-, 6£-, 
16a-hydroxylases (OHases), 17-oxosteroid oxidoreductase and 
5a-reductase activities.
A) Enzyme activities (pmoles/minute/million cells)
TREATMENT 7a-OHase 6{3-OHase 16a-OHase 17-OHSD 5a-red
Control (A) 65±7 63±7 42±5 138±4 122±13
10~ 1 °M (B) 64±4 74±5* 59±2* 166±8* 126±6
10~ 9 M (C) 51±2* 59±4 45±5 133±5 110±2
10~ 8M (D) 54±6* 56±3 49±5 139±1 105±4*
10~ 7M (E) 55±6 63±6 44±4 137±6 106±1*
10~ 6M (F) 55±2* 65±2 46±6 146±3* 112±12
B) Enzyme activities (pmoles/minute/million. cells
TREATMENT 7a-OHase 6p-OHase 16a-0Hase 17-OHSD 5a-red
Control (A) 57±1 67±5 49±4 137±3 114±6
10- 1 °M (B) 72±2* 71±2 68±6* 148±6* 114±5
10“ 9 M (C) 57±8 59±2* 48±2 124±14 97±8*
10“ 8M (D) 52±7 65±3 48±6 133±2 107±4
10" 7M ( F ^ 55±1* 57±2* 42±2* 123±10* 98±10'
10- 6M (F) 57±6 59±7
45±6 137±4 105±10
Results are expressed as mean ± s.d. (N=3); *=P<0.05 as
compared to relevant control values.
Duncan's Multiple Range Test :
A)
7 a-OHase C D E F B A
6{B-OHase D C A E F B
16a-OHase A E C F D B
17-OHSD C E A D F B
5a-red D E C F A B
B)
7a-OHase D E A C F B
6^-OHase E C F D A B
16a-OHase E F C D A B
17-OHSD E C D A F B
5a-red C E F D A B
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oxidoreductase activities (Figures 26C, 26D and 26E 
respectively). Incubation with higher concentrations of 
thyroxine significantly decreased female-specific activities 
(Figures 26A and 26B) whilst exhibiting no significant 
effects upon male-specific enzymes (Figures 26C, 26D and 
26E). Thus thyroxine appears to exhibit sex-specific effects 
at 10 minutes of incubation.
Incubation of hepatocytes with the above doses of 
thyroxine for 30 minutes (Table 19B) resulted in a similar 
response to that observed at 10 minutes above.
7a-hydroxylase activity (Figure 27A) was significantly 
increased with 10_10M thyroxine, thereafter significantly 
decreased to 90% of control with 10“8M thyroxine. 
5a-reductase activity (Figure 27B) was significantly 
decreased with all thyroxine concentrations used, except 
10_1°M, where enzyme activity remained unchanged. 
Male-specific activities (Figures 27C, 27D, 27E) were 
significantly increased with 10_10M thyroxine, after which 
point all activities returned to basal levels or below, and 
reached a significant reduction with 10“7M thyroxine in all 
cases.
Thus incubation with thyroxine appears to stimulate 
male-specific activities at low concentrations and reduced 
all activities at higher concentrations, thereby exhibiting 
some sex-specific effects on steroid metabolism.
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3.4.2 COMPARISON OF THE INTERACTION OF VARYING 
CONCENTRATIONS OF THYROXINE WITH 10"9M GROWTH HORMONE
Incubation of hepatocytes with 10“ 8M thyroxine (Table
20) for 30 minutes resulted in no significant changes in 
enzyme activity (Figure 28). Incubation with 10_6M thyroxine 
resulted in significant decreases in 6p-hydroxylase, 
16a-hydroxylase and 5a-reductase activities, whilst having 
no effects on either 7a-hydroxylase or 17-oxosteroid 
oxidoreductase activities (Figure 28).
Co-incubation with growth hormone resulted in 
significant reductions in enzyme activity in all cases, as 
is illustrated in Figure 28, except for in 7a-hydroxylase 
and 5a-reductase activities with 10~8M thyroxine.
3.4.3 TIME COURSE OF THE INTERACTION BETWEEN THYROXINE
AND GROWTH HORMONE
Hepatocytes were preincubated with 10“ SM thyroxine with 
or without 10“9M growth hormone for 10-30 minutes (Table
21). Incubation with thyroxine alone resulted in significant 
reductions in 6p-hydroxylase, 1 7 -oxosteroid oxidoreductase 
and 5a-reductase activities (Figures 29C, 29E and 29B 
respectively). Co-incubation with 10“9M growth hormone 
resulted in marked reductions in all enzyme activities 
(Figure 29). The decrease in enzyme activity is non-specific 
in nature since all activities were reduced upon incubation 
with growth hormone and thyroxine.
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FIGURE 28 : A comparison of the effects of 30 minute
preincubation with 10“8M or 10“6M THYROXINE in the absence 
and presence of 10" 9 M GROWTH HORMONE on enzyme activities. 
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 2 0
%
7G?-T4 
7CX-J4 + GH 
6j3~T4 
6fj-T4 + GH 
16QHT4 
16Q4T 4 + GH
170HSD-T 4 
170HSDT 4+GH
5GHT4
5QHT4 + GH
-8 log (thyroxine) -6
TABLE 20 : Effects of 30 minute preincubation with 10"8M or 
10"6M THYROXINE in the absence and presence of 10"9M GROWTH 
HORMONE on 7a-, 60-, 16a-hydroxylases (OHases), 
17-oxosteroid oxidoreductase (17-OHSD) and 5a-reductase 
activities.
Enzyme activities (pmoles/minute/million cells)
TREATMENT 7a-OHase 60-OHase 16a-0Hase 17-OHSD 5a-red
Control 32±2 56±6 50±2 30±1 108±11
-8 T4 36±4 58±4 50±3 32±1 114±14
-6 T4 32±1 50±1 42±5* 30±2 90±1*
Control 36±1 76±4 56±4 52±1 102±11
-8 T4 + GH 36±2 70±2* 36±1* 44±1* 97±6
-6 T4 + GH 30±2* 42±2* 40±1* 44±1* 82±9*
Results are 
compared to
expressed
relevant
as mean ± s.d. (N=3) 
control values.
; *=P<0. 05 as
FIGURE 29 : Effects of preincubation with 10~6M THYROXINE in 
the absence and presence of 10"9M GROWTH HORMONE on A) 
7a-hydroxylase, B) 5a-reductase, C) 6p-hydroxylase, D) 
16a-hydroxylase and E) 17-oxosteroid oxidoreductase 
activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 21
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TABLE 21 : Effects of preincubation with 10“6M THYROXINE in 
the absence or presence of 10“ 9M GROWTH HORMONE for 10 and 
30 minutes on 7a-, 6J3-, 16a-hydroxylases (OHases), 
17-oxosteroid oxidoreductase (17-OHSD) and 5a-reductase 
activities.
Enzyme activities (pmoles/minute/million cells)
TREATMENT 7a-OHase 6p-OHase 16a-OHase 17-OHSD 5a-red
10 C 42±4 61±6 76±6 117±1 117±6
10 t 4 39±5 53±1* 70±5 105±2* 98±6*
30 C 45±4 59±2 71±6 109±5 126±7
30 T4 41±4 62±1* 68±7 93±1* 96±5*
10 C 45±6 60±3 77±4 128±6 130±12
10 t 4 + GH 27±3* 43±2* 45±8* 69±6* 42±8*
30 C 51±2 56±7 82±9 124±4 142±16
30 T4 + GH 41±5* 48±2 49±6* 79±4* 45±2*
Results are expressed as mean ± s.d. (N=3); *=P<0. 05 as
compared to relevant control values (C=control).
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3.4.4 PREINCUBATION OF HEPATOCYTES WITH THYROXINE 
(IQ"6M) FOR 24, 48 AND 7 2 HOURS FOLLOWED BY INCUBATION 
WITH 10"9M GROWTH HORMONE OVER 0 TO 60 MINUTES.
Hepatocytes were preincubated with 10-6M thyroxine for 
24, 48 and 72 hours, followed by further incubation with 
10"9M growth hormone for 0-60 minutes, as detailed in 
Section 2.5.2.
Preincubation with thyroxine for (Table 22) showed no 
significant effects on enzyme activity after 24 and 48 hours 
of culture (Figure 30), except for a decrease in 
7a-hydroxylase (Figure 30A), and an increase in 
6p-hydroxylase (Figure 30C) activities. All enzyme 
activities were significantly reduced at 72h (Figure 30) as 
compared to relevant control values.
Further incubation with 10-9M growth hormone for 0 to 
60 minutes (Table 22) show that enzyme activity was 
modulated upon treatment with growth hormone. 7a-hydroxylase 
activity (Figure 31) was markedly increased as compared to 
the thyroxine alone response, being restored to basal levels 
as compared to relevant control incubations.
6p-hydroxylase activity remained relatively unchanged 
upon incubation with growth hormone after 24 and 48 hours of 
culture, but increased to near basal levels with hepatocytes 
pretreated with thyroxine for 72 hours (Figure 32).
Similar results were observed with 1 6 a-hydroxylase, 
17-oxosteroid oxidoreductase and 5 a-reductase activities 
(Figures 33, 34 and 35 respectively) as with 6 {3 -hydroxylase 
above.
FIGURE 30 : Effects of preincubation with 10_6M THYROXINE
over 24, 48 and 72 hours on A) 7a-hydroxylase, B)
5a-reductase, c) 6p-hydroxylase, D) 16a-hydroxylase and E) 
17-oxosteroid oxidoreductase activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in
Table 2 2
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FIGURE 31 : Effects of preincubation with 10"5M THYROXINE 
for A) 24 hours, B) 48 hours and C) 72 hours followed by 
incubation with 10“9M GROWTH HORMONE over 0 to 60 minutes on 
7a-hydroxylase activity.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in
Table 2 2
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FIGURE 32 : Effects of preincubation with 10"6M THYROXINE
for A) 24 hours, B) 48 hours and C) 72 hours followed by 
incubation with 10-9M GROWTH HORMONE over 0 to 60 minutes on 
6{3-hydroxylase activity.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 2 2
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FIGURE 33 : Effects of preincubation with 10~6M THYROXINE 
for A) 24 hours, B) 48 hours and C) 72 hours followed by 
incubation with 1 0 - GROWTH HORMONE over 0 to 60 minutes on 
16a-hydroxylase activity.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 2 2
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FIGURE 34 : Effects of preincubation with 10"6M THYROXINE
for A) 24 hours, B) 48 hours and C) 72 hours followed by 
incubation with 10“9M GROWTH HORMONE over 0 to 60 minutes on 
17-oxosteroid oxidoreductase activity.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 2 2
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FIGURE 35 : Effects of preincubation with 10"6M THYROXINE 
for A) 24 hours, B) 48 hours and C) 72 hours followed by 
incubation with 10~9M GROWTH HORMONE over 0 to 60 minutes on 
5a-reductase activity.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 2 2
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FIGURE 36 : Effects of preincubation with 10“6M THYROXINE
over 24, 48 and 72 hours followed by 30 minute incubation 
with 10 9M GROWTH HORMONE on A) 7a-hydroxylase, B) 
5a-reductase, C) 6p-hydroxylase, D) 16a-hydroxylase and E) 
17-oxosteroid oxidoreductase activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 2 2
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TABLE 22 : Effects of preincubation with 10" 6M THYROXINE for 
24, 48 and 72 hours followed by incubation with 10_9M GROWTH 
HORMONE over 0 to 60 minutes of A) 24h-pretreated, B) 
48h-pretreated and C) 72h-pretreated hepatocytes on 7a-,
6 p-, 16a-hydroxylases (OHases), 17-oxosteroid oxidoreductase 
(17-OHSD) and 5a-reductase activities.
A) Enzyme activities (pmoles/minute/million cells)
TIME (min) 7a-0Hase 6 p-OHase 16a-0Hase 17-OHSD 5a-red
24h C 
24h T 4
59±2
4811*
53±3
6413*
54±3
54±3
6 8 ± 1
72±6
100±3
109112
control 
24T4 +0GH
44±1
5113*
59±2
73±5
45±4
50±5
71±6
68±4
1 1 0 1 1 1
9614*
control 
24T4 +5GH
45±3
50±1
62±6
62±1
47±2
48±1
70±2
7412*
9917
9814
control 
24T4 +10GH
49±1
52±3
58±9
54±5
51±4
47±1
70±2
69±1
1 0 1 1 1 0
10216
control 
24T4 +15GH
45±1
43±1
56±5
61±4
50±1
47±5
70±4
76±4
9811
1 1 2 1 1 0
control
24T4+30GH
49±9
61±11
58±2
56±7
54±6
53±2
70±2
66±3
99117
9816
control
24T4+60GH
43±6
60±4
52±2
56±5
51±1
5011
70±2
71±5
8914
10213*
B) Enzyme activities (pmoles/minute/million cells)
TIME(min) 7a-OHase 63-OHase 16a-0Hase 17-OHSD 5 a-red
48h C 
48h T4
49±4
4213*
55±5
56±4
49±2
54±2
67±2
72±5
9018
10018
control 
48T4 +0GH
38±4
38±7
64±6
57±8
. 44±8 
54±4
76±6
76±2
9417
9518
control 
48T4 +5GH
4i±3
36±5
68±4
65±4
45±7
41±3
78±3
74±4
10217
9614
control
48T4+10GH
44±2
41±3
62±2
58±2*
42±2
48±6
80±8
77±6
9915
9516
control
48T4+15GH
38±3
36±5
58±4
62±5
44±4
48±5
78±3
82±2
10016
9218
control
48T4+30GH
39±9
43±5
70±2
60±6*
42±6
42±2
78±2
74±4
9614
9418
control 
48T4 +60GH
4 4 + 4
42±4
55±8
54±2
47±6
49±6
75±4
78±5
9917
9213
91 Enzyme activities (pmoles/minute/million cells;
TIME(min) 7a-0Hase 6S-0Hase 16a-0Hase 17-OHSD 5a-red
72h C 61±2 74±4 7313 11011 14214
72h T* 3312* 4713* 41110* 6912* 8913*
control 38±6 48±7 4115 6319 8419
72T4+0GH 35±3 53±6 4219 6512 8414
control 32±2 4612 4418 6014 8218
72T4+5GH 36±2* 5219 3917 6812* 8415
control 33±3 5915 3913 6012 9514
72T4+10GH 35±4 5311* 4714 6814* 8415*
control 34±7 5217 3814 6114 8814
72T4+15GH 36±7 5112 4416 6415 7916*
control 35±3 5512 4511 7016 62110
72T4+SGGH 34±3 6116 3214* 6814 8016
control 35±2 5911 4212 6816 8312
72T4+60GH 3 3 ±6 50110 3618 5615* 8616
Results are 
compared to
expressed 
relevant <
as mean 1 s.d. (N=3); *—P<0.05 
control values (C=control).
as
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Results given in Figures 30 to 35 are summarised in 
Figure 36. Growth hormone modulated the effects of thyroxine 
restoring all enzyme activities to basal levels.
3.4.5 PREINCUBATION OF HEPATOCYTES WITH THYROXINE
(IQ- 8M) FOR 24, 48 AND 72 HOURS FOLLOWED BY INCUBATION
WITH 10-9M GROWTH HORMONE OVER 0 TO 60 MINUTES
Incubation of hepatocytes with 10_8M thyroxine (Table 
23) resulted in no significant changes in enzyme activity 
(Figure 37) except for significant differences in 
60-hydroxylase activity (Figure 37C) and 16a-hydroxylase 
activity (Figure 37D).
Further incubation of thyroxine-treated hepatocytes 
with 10_9M growth hormone over 0 to 60 minutes resulted in 
no significant differences in 7a-hydroxylase activity 
(Figure 38). 60-hydroxylase activity (Figure 39) was 
significantly increased back to basal levels with 72h
thyroxine-pretreated hepatocytes upon incubation with growth 
hormone, although this effect was not significant with 
respect to relevant control incubations. No changes were 
exhibited upon further treatment of 24- and 48h pretreated
hepatocytes with growth hormone.
No significant changes were observed in 
16a-hydroxylase, 1 7 -oxosteroid oxidoreductase and 
5a-reductase activities (Figure 40, 41 and 42 respectively) 
upon further treatment with growth hormone as compared to
both the thyroxine response a 
The results from Figures
and relevant control values, 
s 37 to 42 are summarised in
FIGURE 37 : Effects of preincubation with 10~8M THYROXINE
over 24, 48 and 72 hours on A) 7a-hydroxylase, B)
5a-reductase, C) 6p-hydroxylase, D) 16a-hydroxylase and E) 
17-oxosteroid oxidoreductase activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 2 3
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FIGURE 38 : Effects of preincubation with 10_8M THYROXINE 
for A) 24 hours, B) 48 hours and C) 72 hours followed by 
incubation with 10-9M GROWTH HORMONE over 0 to 60 minutes on 
7a-hydroxylase activity.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 2 3
120 i 24hr. 7othudroxy1ase
-O- T4+GH 
T4
o
c
oo
90 -
80
60 80400 20
time (min)
105 -i 48hr. 7&-hudroxu1ase H3- T4+GH
1 00  -
95o1_
-t—'c
85 -
80
806040
time (min)
20
72hr. Xfr-hydroxulase2 0 0  -i HZf* T4+GH
50 -
o
L_
C
oo
50 -
806040
time (min)
20
FIGURE 39 : Effects of preincubation with 10"8M THYROXINE
for A) 24 hours, B) 48 hours and C) 72 hours followed by 
incubation with 10-9M GROWTH HORMONE over 0 to 60 minutes on 
6p-hydroxylase activity.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 2 3
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FIGURE 40 : Effects of preincubation with 10~8M THYROXINE 
for A) 24 hours, B) 48 hours and C) 72 hours followed by 
incubation with 10"9M GROWTH HORMONE over 0 to 60 minutes on 
16a-hydroxylase activity.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 2 3
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FIGURE 41 : Effects of preincubation with 10"0M THYROXINE
for A) 24 hours, B) 48 hours and C) 72 hours followed by 
incubation with 10~9M GROWTH HORMONE over 0 to 60 minutes on 
17-oxosteroid oxidoreductase activity.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 2 3
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FIGURE 42 : Effects of preincubation with 10~8M THYROXINE 
for A) 24 hours, B) 48 hours and C) 72 hours followed by 
incubation with 10~9M GROWTH HORMONE over 0 to 60 minutes on 
5a-reductase activity.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 2 3
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FIGURE 43 : Effects of preincubation with 10“8M THYROXINE
over 24, 48 and 72 hours followed by 30 minute incubation 
with 10"9M GROWTH HORMONE on A) 7a-hydroxylase, B) 
5a-reductase, C) 6£~hydroxylase, D) 16a-hydroxylase and E) 
17-oxosteroid oxidoreductase activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 2 3
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TABLE 23 : Effects of preincubation with 10"8M THYROXINE
for 24, 48 and 72 hours followed by incubation with 10-9M 
GROWTH HORMONE over 0 to 60 minutes of A) 24h-pretreated, B) 
48h-pretreated and C) 72h-pretreated hepatocytes on 7a-,
60-, 16a-hydroxylases (OHases), 17-oxosteroid oxidoreductase 
(17-OHSD) and 5a-reductase activities.
A) Enzyme activities (pmoles/minute/million cells)
TIME(min) 7a-OHase 60-OHase 16a-0Hase 17-OHSD 5a-red
24h C 
24h T4
38±3
38±5
43±2 
47 + 1*
39±4
37±5
110±4
115±5
8811
88+4
control 
24T4 +0GH
34±1
36±2
45±2
46±2
33±1
35±4
117±9
107±6
76+1
78+3
control 
24T4 +5GH
34±3
32±3
47±1
49±2
42±4
34+3*
121±9
113±6
76+8
80+9
control 
24T4 +10GH
34±1
38±4
52±1
49±6
34±2
37±3
110±3
114±7
86+6 
78 + 5
control 
24T4 + 15GH
38±3
36±6
46±2 
50 + 9
40±5
39±6
11916
125113
88+8 
76 + 2
control 
24T4 + 30GH
36±3
41±5
47±2
45±3
41±4
37±2
11815
123+12
88 + 7 
76 + 4
control 
24T4 +60GH
41±8
38±2
45 + 3 
57 + 6*
38±5
38±2
121+7 
132 + 9
86+8 
86 + 5
B) Enzyme activities (pmoles/minute/million cells)
TIME(min) 7a-OHase 60-OHase 16a-0Hase 17-OHSD 5a-red
48h C 
48h T4
31±3
2814
40±1
4311*
31±2
26±1*
92+2
92+2
66+6
65+5
control 
48T4 +0GH
26±3
25±2
39±1
3711*
30±1
2811*
91+4
9216
7014
59+2*
control 
48T4 + 5GH
29±3
24+2*
38±2
37±1
28±1
24+2*
97 + 6 
92+6
68+4
62+6
control 
48T4 +10GH
25±2
26±2
39±1
44+3*
29±1
26±4
9315
94+9
66+5 
62 + 6
control 
48T4 +15GH
28±2
25±3
37±4
43±3
28±2
29±3
89+3
9712*
63 + 1 
65 + 5
control 
48T4 +30GH
27±1
2511*
37±5
40±2
31±4
26±3
89+2
91+6
68 + 3 
61+4*
control 
48T4 +60GH
25±2 
32 + 2*
39±3
4615*
31±3
29±2
105 + 5 
112+4
63 + 2 
67 + 1*
Cl Enzyme activities (pmoles/minute/million cells
TIME(min) 7a-0Hase 60-OHase 16a-0Hase 17-OHSD 5a-red
72h C 38±2 51±2 41±1 114±7 8415
72h T4 38±2 4212* 4612* 11212 8618
control 32±1 46±5 34±6 11615 8014
72T4+0GH 2812* 52±4 35±2 11713 7715
control 35±7 45±5 37±2 11514 7214
72T4+5GH 32±6 50±1 34±2 12014 8014*
control 3012 53±4 36±5 12213 8315
72T4 +10GH 31±2 46±6 36±2 11216* 6713*
control 32±6 48±4 35±4 11414 8212
7 2T4 +15GH 27±3 50±1 35±2 10912 73111
control 35±1 48±6 35±5 11915 8612
72T4 +30GH 33±2 46±1 38±4 10713* 7313*
control 31±1 50±2 37±6 12113 8218
72T4+60GH 29±2 49±1 36±4 11116* 78110
Results are expressed as mean ± s.d. (N-3); *-P<0.05 as 
compared to relevant control values (C=control).
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Figure 43. Thus 10"8M thyroxine has no significant effects 
on enzyme activity, which are not markedly affected by 
further incubation with growth hormone.
3.5 DEXAMETHASONE AND THYROXINE
3.5.1 EFFECTS OF INCUBATION WITH 10" 9 M GROWTH HORMONE 
IN THE PRESENCE OF 10~8M DEXAMETHASONE AND 10" 6M 
THYROXINE
Hepatocytes were preincubated with 10" 9M growth hormone 
in the presence of both 10" 8M dexamethasone and 10" 6M 
thyroxine over two incubation times (Table 24).
As is illustrated in Figure 44A and 44B, the 
female-specific enzyme activities 7a-hydroxylase and 
5a-reductase were markedly increased at both 10 and 30 
minutes of incubation, whereas enzyme activity was 
significantly decreased in the absence of growth hormone.
The male-specific enzymes 6p-hydroxylase, 1 6 a-hydroxylase 
and 17-oxosteroid oxidoreductase (Figures 44C, 44D and 44E 
respectively) were significantly decreased with respect to 
the response observed in the absence of growth hormone
(which remained at basal levels).
Thus the feminising effects of growth hormone shown in
vivo by numerous workers (see Introduction) and typified y 
an increase in female-specific and a decrease 
male-specific activities has been demonstrated above in the
presence of both dexamethasone and thyroxin
FIGURE 44 : Effects of preincubation with 10“6M THYROXINE
and 10 8M DEXAMETHASONE in the absence and presence of 10_9M 
GROWTH HORMONE for 10 and 30 minutes on A) 7a-hydroxylase, 
B) 5a-reductase, C) 6p-hydroxylase, D) 16a-hydroxylase and 
E) 17-oxosteroid oxidoreductase activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 24
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TABLE 24 : Effects of preincubation with 10" 6M THYROXINE and 
10“ 8M DEXAMETHASONE in the absence and presence of 10“9M 
GROWTH HORMONE for 10 and 30 minutes on 7a-, 6p-, 
16a-hydroxylases (OHases), 17-oxosteroid oxidoreductase 
(17-OHSD) and 5a-reductase activities.
Enzyme activities (pmoles/minute/million cells)
TREATMENT 7a-OHase 6p-OHase 16a-0Hase 17-OHSD 5a-red
10 C 51±6 38±2 38±2 87±3 135±5
10 t 4/d e x 41±5* 44±2* 34±4 87±2 lllfl*
30 C 40±3 49±4 57±2 101±4 106±11
30 T4/DEX 33±2* 54±4 41±3* 94±5 134±4*
10 C 38±2 54±1 45±4 83±6 134±10
10 T4/D+GH 45±1* 45±3* 35±1* 97±3* 123±3
30 C 35±2 61±6 82±4 110±5 110±12
30 T4/D+GH 40±3* 54±3 35±2* 90±2* 148±5*
Results are 
compared to
expressed
relevant
as mean ± s.d. (N=3); *-P<0. 
control values (C=control)«
05 as
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3.5.2 A COMPARISON OF THE EFFECTS OF 10“8M AND 10"9M
GROWTH HORMONE IN THE PRESENCE OF 10~8M DEXAMETHASONE AND 
10-sM THYROXINE
The experiment was essentially identical to that in 
section 3 .5 . 1  except that the effects of a higher dose of 
growth hormone were also examined (Table 25).
7a-hydroxylase activity (Figure 45A) was significantly 
increased upon incubation with growth hormone in the 
presence of dexamethasone and thyroxine, the effect being 
more pronounced with 1 0 "9M than with 1 0 _8M growth hormone. 
This increase in enzyme activity was, however, not 
significant at 30 minutes of incubation.
5a-reductase activity (Figure 45B) was significantly 
reduced upon incubation with dexamethasone and thyroxine, 
and increased when growth hormone was included in the 
incubation medium. Again this increase was more marked up 
incubation with 10"9M than with 10_8M growth hormone, 
effect being more obvious after 30 minutes of incuba
The male-specific enzyme activities, 6 0 -hydroxylase, 
16a-hydroxylase and 17-oxosteroid oxidoreductase (Figures 
45C, 45D and 45E respectively), were all significantly 
decreased upon incubation with growth hormone in 
presence of dexamethasone and thyroxine. The 
growth hormone was, however, greater at 1 0  8M than at 
in contrast to the situation seen with the female-specific
enzymes above.
Thus growth hormone exhibited a feminisation of steroid 
metabolism when incubated together with dexamethasone and
FIGURE 45 : A comparison of the effects preincubation with
10" 6 M THYROXINE and 10~8M DEXAMETHASONE in the absence and 
presence of 10"9M or 10-8M GROWTH HORMONE for 10 and 30 
minutes on A) 7a-hydroxylase, B) 5a-reductase, C) 
6p-hydroxylase, D) 16a-hydroxylase and E) 17-oxosteroid 
oxidoreductase activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 25
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TABLE 25 : Effects of preincubation with 10-6M THYROXINE 
and 10“8M DEXAMETHASONE in the absence and presence of 10"9M 
or 10"8M GROWTH HORMONE for 10 and 30 minutes on 7a-, 6p-, 
16a-hydroxylases (OHases), 17-oxosteroid oxidoreductase 
(17-OHSD) and 5a-reductase activities.
Enzyme activities (pmoles/minute/million cells
TREATMENT 7a-OHase 6p-OHase 16a-0Hase 17-OHSD 5a-red
10 C 50±3 70±4 7 0±10 80±6 76±12
10 d t 4 40±3* 60±3* 80±7 90±4* 62±6
10 C 50±6 80±5 70±7 70±5 85±9
10 DT4/-8GH 50±4 80±7 65±4 55±3* 92±5
10 DT4/-9GH 65±2* 90±8* 75±4 75±4 91±2
30 C 75±5 70±3 80±8 80±10 169±4
30 DT4 65±3* 80±4* 95±10* 110±5* 75±4*
30 C 60±4 85±7 90±10 80±4 92±8
30 DT4/-8GH 65±5 75±5* 80±7 75±7 96±8
30 DT4/-9GH 55±6 90±3 90±3 65±4* 123±9*
Results are 
compared to
expressed
relevant
as mean ± s.d. (N=3); *-P<0. 
control values (C=control).
05 as
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thyroxine. This effect of growth hormone was more effective 
at 10"9M on female-specific enzymes, but 10-8M growth 
hormone appeared to be more potent with male-specific 
enzymes.
3.5.3 EFFECTS OF INCUBATION WITH 1Q-9M GROWTH HORMONE
ON HEPATOCYTES PRETREATED WITH 10~8M DEXAMETHASONE AND
10- 6M THYROXINE FOR 24, 48 AND 72 HOURS.
Hepatocytes were cultured with 10-8M dexamethasone and 
10" 6M thyroxine for 24, 48 and 72 hours, as described in 
section 2.5.2.
Table 26 shows that incubation of hepatocytes with a 
combination of dexamethasone and thyroxine over 24, 48 and 
72 hours had no significant effects on enzyme activity. 
Further incubation of pretreated hepatocytes with 10 9M 
growth hormone for 10 and 30 minutes showed that 
7a-hydroxylase was markedly increased with respect to 
hepatocytes not exposed to growth hormone (Figure 46A).
A significant increase was observed in 5 a-reductase 
activity (Figure 46B) upon incubation of pretreated 
hepatocytes with growth hormone, although this effect wa 
lost with hepatocytes pretreated for 72 hours.
Incubation of pretreated hepatocytes with 10 9M growth 
hormone caused a significant decrease in the male sp 
6p-hydroxylase, 1 6 a-hydroxylase and 17 oxosteroid 
oxidoreductase activities (Figures 46C, 46D and 
respectively), although this effect was not significant with 
16a-hydroxylase activity at 48h or with 1 7 -oxosteroid
FIGURE 46 : Effects of preincubation with 10~6M THYROXINE
and 10“ 8M DEXAMETHASONE over 24, 48 and 72 hours followed by
incubation with 1 0 - GROWTH HORMONE for 10 and 30 minutes
on A) 7a-hydroxylase, B) 5a-reductase, C) 60-hydroxylase, D)
16a-hydroxylase and E) 17-oxosteroid oxidoreductase 
activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 2 6
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TABLE 26 : Effects of preincubation with 10~6M THYROXINE and 
10" 8M DEXAMETHASONE over 24, 48 and 72h followed by 
incubation with 10~9M GROWTH HORMONE for 10 and 30 minutes 
on 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 
oxidoreductase (17-OHSD) and 5a-reductase activities.
Enzyme activities (pmoles/minute/million cells) 
TREATMENT 7a-QHase 6p-OHase 16a-0Hase 17-OHSD 5a-red
24C
24DexT4
24±2
20±1*
25±1
26±1
25±2
28±1*
22±2
21±1
125±18
122±10
control 
24DT4 +10GH
30±2
32±3
32±4
29±2
28±4
20±4*
32±2
36±4
60±7
70±9
control
24DT4+30GH
36±3
44±5*
30±2
18±2*
38±1
28±3*
44±3
44±4
60±5
79±4*
48C
48DexT4
20±2
16±1*
20±1
22±2
27±1 
21 ±2
13±1
14±1
137±14
133±15
control 
48DT4 +10GH
26±1
32±3*
38±1
20±1*
36±2
33±4
38±3
20±3*
57±4
93±6*
control
48DT4+30GH
28+2
38±6*
28±2
16±2*
34±3
28±3*
34±4
26±2*
65±5
79±2*
72C
72DexT4
15±1
16±1
25±2
25±3
21±2
23±2
18±2
21±2
164±12
164±15
control 
72DT4 +10GH
14±1
19±2*
24±3
15±1*
24±3
20±2
20±2
18±1
41±4
46±3
control
72DT4+30GH
14±2
16±2
19±2
9±1*
28±4
21±2*
21±1
15±2*
32±5
38±2
Results are expressed as mean ± s.d. (N-3); * P<0.05 as 
compared to relevant control values (C=control).
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oxidoreductase activity at 24h.
Thus the feminising effects of growth hormone are, as 
with the short incubation experiments, manifested by 
hepatocytes pretreated with dexamethasone and thyroxine over 
24, 48 and 72 hours.
3.6 INSULIN MEDIATOR
3.6.1 EFFECT OF INCUBATION OF RAT LIVER MITOPLASTS
WITH IQ- 11M-10~ 6M INSULIN ON MITOCHONDRIAL PYRUVATE
DEHYDROGENASE
Rat liver mitoplasts, highly enriched in pyruvate 
dehydrogenase activity, were prepared as detailed in section 
2.3, and incubated with insulin prior to assaying for 
stimulation of enzyme activity (section 2.10).
As is shown in Table 27, and illustrated in Figure 47, 
insulin significantly increased pyruvate dehydrogenase 
activity at all concentrations tested, except with 10-6M 
insulin. This increase in enzyme activity was 
dose-dependent, and exhibited maximum stimulation upon 
incubation with 10-9M insulin.
FIGURE 47 : Dose dependent effects of incubation of rat
liver mitoplasts with 10-HM-10-6M INSULIN on mitochondrial 
pyruvate dehydrogenase activity.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 27 -
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TABLE 27 : Dose-dependent effects of incubation of rat livei 
mitoplasts with 10"11- 1 0 " INSULIN on mitochondrial 
pyruvate dehydrogenase activity.
INSULIN C0NCN . Enzyme activity (nmoles/mg protein/minute)
Control (A) 0.72 + 0.089
10“ 1XM (B) 1.16 + 0.160*
10“ 1 °M (C) 1.36 + 0.059*
10“ 9M (D) 1.43 + 0.132*
10“ 8M (E)
(F)
1.27 + 0.033*
10“ 7M 1.06 + 0.039*
10“ 6M 0.76 + 0.045
(G)
Results are expressed as MEAN ± S.D. (N=3); *=P<0.05 as 
compared to control.
D u n c a n 's  M u l t i p l e  R a n g e  T e s t  :
A G F B E C D
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3.6.2 EFFECT OF INCUBATION OF RAT LIVER MITOPLASTS WITH
VARYING DOSES OF INSULIN MEDIATOR PRODUCED USING 10"9M 
INSULIN
Rat liver mitoplasts were incubated with various 
dilutions of the insulin mediator extract prepared from 
hepatocytes incubated with 10_9M insulin (Section 2.8.2).
As is shown in Table 28 and in Figure 48, incubation 
with the insulin mediator extract significantly increased 
pyruvate dehydrogenase activity at all dilutions tested. 
This stimulation of enzyme activity was maximal using a 
1:100 dilution of the original insulin mediator extract. 
Further ten-fold dilutions still resulted in a significant 
stimulation of enzyme activity, although not as marked as 
that caused by incubation with a 1:100 dilution. Incubation 
with more concentrated extracts also resulted in a 
stimulation of enzyme activity but exhibited a tailing o 
effect as mediator amount was gradually increased.
Thus incubation with various dilutions of a 10 9M 
insulin mediator extract resulted in a dose dependen 
increase in pyruvate dehydrogenase activity and a 
degree of amplification of the insulin response was 
exhibited in that a 1:100 dilution caused maximum 
stimulation. It therefore appears that the insulin medi 
extract prepared is active in stimulating pyru 
dehydrogenase activity and is therefore similar to the 
insulin mediator described by other workers (Suzuki et al
1987) .
FIGURE 48 : Dose-dependent effects of incubation of rat
liver mitoplasts with various dilutions of the INSULIN 
MEDIATOR extract prepared using 10~9M INSULIN on 
mitochondrial pyruvate dehydrogenase activity.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 2 8
200 i
-9  IM dose
TABLE 28 : Dose-dependent effects of incubation of rat liver 
mitoplasts with various dilutions of the INSULIN MEDIATOR 
extract prepared using 10-9M INSULIN on mitochondrial 
pyruvate dehydrogenase activity.
IM dilution Enzyme activity (nmoles/mg protein/minute)
control 0.68 + 0.087
1:10-4 0.80 + 0.080
control 0.76 + 0.099
1:10-3 1.00 + 0.096*
control 1.34 + 0.141
1:10-2 2.22 + 0.118*
control 1.98 + 0.039
1:10 3.12 + 0.077*
control 2.46 + 0.030
1:2 3.64 + 0.101*
control 2.60 + 0.119
1:1 3.58 + 0.178*
Results are expressed as MEAN ± S.D. (N=3); *-P<0.05 as 
compared to relevant control values.
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3.6.3 INSULIN MEDIATOR DOSE-RESPONSE CURVE
An insulin mediator extract was prepared by 
treating hepatocytes with 10-h m -10-7M insulin, as described 
in section 2.8.2. Hepatocytes were incubated with this 
extract for 30 minutes (section 2.9.1) prior to assaying for 
steroid metabolism.
Table 29 shows that the effects of the insulin mediator 
produced in response to different doses of insulin exhibits 
dose-related effects on enzyme activity. As is illustrated 
in Figure 49A, 49D and 49E respectively, the stimulation of 
7a-hydroxylase, 16a-hydroxylase and 17-oxosteroid 
oxidoreductase activities is maximal upon incubation with 
the insulin mediator extract prepared in response to 10 9M 
insulin, and with 10"8M insulin mediator for 6p-hydroxylase 
and 5a-reductase activities (Figure 49C and 49B 
respectively) . Enzyme activity is significantly reduced upon 
incubation with insulin mediator prepared using 
supraphysiological concentrations of insulin.
Thus the above data illustrates that the effects of the 
insulin mediator extract prepared using a range of insulin 
concentrations exhibit dose-dependency, and that this 
dose-related response is reminiscent of that observed upon 
incubation of hepatocytes with various concentrations
insulin.
Since physiological concentrations of insulin displayed 
maximum effects, insulin mediator prepared using 
insulin is used for future assays, unless otherwise 
indicated.
FIGURE 49 : Dose-dependent effects of 30 minute incubation 
of hepatocytes with 1:1 INSULIN MEDIATOR extract prepared 
using 10-11M-10~7M INSULIN on A) 7a-hydroxylase, B) 
5a-reductase, C) 6p-hydroxylase, D) 16a-hydroxylase and E) 
17-oxosteroid oxidoreductase activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 2 9
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TABLE 29 : Dose-dependent effects of 30 minute incubation of 
male rat hepatocytes with 1:1 INSULIN MEDIATOR extract 
prepared using 10-11M-10"7M INSULIN on 7a-, 60-, 
16a-hydroxylases (OHases), 17-oxosteroid oxidoreductase 
(17-OHSD) and 5a-reductase activities.
Enzyme activities (pmoles/minute/million cells)
TREATMENT 7a-OHase 60-OHase 16a-0Hase 17-OHSD 5a-red
Control 47±1 59±3 62±2 119±4 174±7
10-iiM (B ) 62±6* 59±1 66±7 143±11* 175±2
10“1°M (C) 70±5* 73±10* 69±2* 169±24* 207±14*
10“9M (D) 68±5* 79±6* 82±3* 164±26* 223±29*
10“8M 72±1* 83±4* 75±8* 164±15* 231±11*
io_?m 66±10* 61±1 65±1* 159±18* 211±17*
Results are expressed as MEAN ± S.D. (N=3); *=P<0. 05 as
compared to control.
Duncan's Multiple Ranqe Test :
7a-OHase
6f3-OHase
16a-OHase
17-OHSD
5a-red
A B F D C E
A B F C D E
A F B C E_ D_
A B F D E C
A B F C D E
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3.6.4 TIME COURSE OF INSULIN MEDIATOR GENERATION
Hepatocytes were pretreated with 10-9M insulin for 0.5, 
1, 2, 5, 10 and 15 minutes in order to determine the time of 
incubation optimal for mediator production. Hepatocytes were 
then incubated with these insulin mediator extracts (1:2 and 
undiluted extract) for 30 minutes prior to assaying for 
steroid-metabolising activity (Table 30).
Figure 50 illustrates the effects of incubation of 
these extracts (1:2 dilution) on enzyme activities. Enzyme 
activity was low in each case upon incubation of hepatocytes 
with mediator produced by 0.5, 1 and 2 minutes exposure to 
insulin, and was rapidly increased to maximum levels with 
mediator produced by 5 minute exposure to insulin. Mediator 
produced by exposure to insulin for longer time periods 
appeared to be inactive, and enzyme activity, remained at 
basal levels upon incubation with these extracts, as is 
shown in Figure 50.
Incubation with undiluted extract prepared as above 
for varying exposure times to insulin exhibited the same 
pattern of enzyme stimulation as was observed above (Table 
30B). Again enzyme activity was stimulated non-specifically 
with mediator prepared after 5 minute exposure to insulin, 
as is shown in Figure 51, and relatively unchanged with 
other extracts. 5a-reductase and 17-oxosteroid 
oxidoreductase activities (Figures 51B and 51E respectively) 
did however remain elevated upon incubation with extracts 
prepared with 10 and 15 minute exposure to insulin.
Thus mediator prepared by incubation with insulin for 5
FIGURE 50 : Time course of generation of the INSULIN
MEDIATOR extract (1:2 dilution) upon treatment of 
hepatocytes with 10"9M INSULIN for 0.5 to 15 minutes on 
A) 7a-hydroxylase, B) 5a-reductase, C) 6p-hydroxylase, D) 
16a-hydroxylase and E) 17-oxosteroid oxidoreductase 
activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in
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FIGURE 51 Time course of generation of the INSULIN
MEDIATOR extract (1:1) —  _______
10-9M INSULIN for 0.5 to 15 minutes on 
A) 7a-hydroxylase, B) 5a-reductase, C) 
16a-hydroxylase and 
activities.
Results are expressed as 
values, where *=P<0.05
Table30B -
upon treatment of hepatocytes with
E)
6^-hydroxylase, D) 
17-oxosteroid oxidoreductase
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and N=3. Absolute data is given in
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TABLE 30 : Time course of the production of the INSULIN 
MEDIATOR A) 1:2 dilution and B) 1:1 dilution upon treatment 
of hepatocytes with 10-9M INSULIN for 0.5 to 15 minutes on 
7a-, 60-, and 16a-hydroxylases (OHases), 17-oxosteroid 
oxidoreductase (17-OHSD) and 5a-reductase activities.
A) Enzyme activities (pmoles/minute/million cells)
TIME(min) 7a-OHase 6p-OHase 16a-OHase 17-OHSD 5a-red
0. 5C 21±1 24±1 37±2 67±3 86±7
0.5IM 23±3 26±1* 41±4 67±4 74±4*
1.0C 2 0±1 22±2 50±4 67±3 72±8
1.0IM 21±4 22±1 37±6* 58±7* 69±8
2.0C 19±1 22±1 46±3 62±6 86±7
2.0IM 20±1 24±2 36±4* 52±9 76±8
5 .00 20±1 23±1 • 40±3 56±4 80±6
5.0IM 24±4 30±4* 49±7* 76±6* 118±11*
10. OC 23±1 28±2 64±6 78±4 96±11
10.0IM 23±1 27±1 52±8* 70±6 94±12
15. 0C 24±2 32±4 52±2 76±3 96±2
15.0IM 24±1 30±1 59±4* 80±9 102+10
Mi Enzyme activities (pmoles/minute/million cells)
TIME(min) 7a-OHase 6p-OHase 16a-OHase 17-OHSD 5a-red
0.5C 23±1 30±5 42±5 86±8 90±9
0.5IM 22±1 26±2 44±6 89±11 83±10
1.0C 22±1 27±3 49±3 75±9 116±14
1.0IM 21±1 28±3 49±6 74±8 92±5*
2.0C 29±3 32±3 54±2 96±4 114±17
2.0IM 26±1 28±3 41±4* 80±2* 94±2*
5.0C 19±1 22±1 42±5 72±8 104±11
5.0IM 24±2* 29±3* 51±1* 80±6 108±5
10. OC 20±3 28±4 52±6 76±8 102±8
10.0IM 23±3 34±1* 53±1 85±4 115±8*
15. 0C 28±4 32±1 60±8 68±8 101±14
15.0IM 27±3 29±1* 53±8 65±1 106±14
Results are expressed as MEAN :± S.D. (N=3); *=P<0.05 as
compared to control values.
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minutes appeared to optimally stimulate steroid metabolism. 
Subsequent insulin mediator extracts were therefore prepared 
by incubation with insulin for 5 minutes.
3.6.5 TIME COURSE OF INSULIN MEDIATOR ACTION
Insulin mediator was prepared as detailed in section 
2.8.2 and incubated with hepatocytes for 0 to 60 minutes in 
order to determine the time course of action (Table 31).
Figure 52A shows that 7a-hydroxylase activity is 
maximal after 30 minutes of incubation, and remains 
unchanged at other time periods. 5a-reductase,
6p-hydroxylase, 16a-hydroxylase and 17-oxosteroid 
oxidoreductase activities (Figures 52B, 52C, 52D and 52E 
respectively) are gradually increased over the incubation 
period, reaching maxima at either 15 or 30 minutes of 
incubation.
Future incubations with the insulin mediator extract 
were therefore carried out at 30 minutes, since not all 
effects were apparent early in the time course.
3.6.6 DOSE-DEPENDENT EFFECTS OF 30 MINUTE INCUBATION OF
HEPATOCYTES WITH VARIOUS DILUTIONS OF INSULIN MEDIATOR
Hepatocytes were preincubated for 30 minutes with 
various dilutions of the insulin mediator extract (Table 
32). As is illustrated in Figure 53, enzyme activity was 
significantly stimulated upon incubation with both 1:2 and 
1:1 dilutions of the insulin mediator extract. This
FIGURE 52 : Time course of the effects of preincubation of 
hepatocytes with 1:1 INSULIN MEDIATOR extract on A)
7a-hydroxylase, B) 5a-reductase, C) 60-hydroxylase, D) 
16a-hydroxylase and E) 17-oxosteroid oxidoreductase 
activities.
Results are expressed as percentages of relevant control
values, where *=P<0.05 and N=3. Absolute data is given in
Table 31
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TABLE 31 : Time course of the effects of preincubation of 
hepatocytes with 1:1 INSULIN MEDIATOR extract on la-, 6£-, 
16a-hydroxylases (OHases), 17-oxosteroid oxidoreductase 
(17-OHSD) and 5a-reductase activities.
Enzyme activities (pmoles/minute/million cells) 
TIME (min) 7a-0Hase 6j3-OHase 16a-0Hase 17-OHSD 5a-red
control 20+1 22±1 36±1 78±1 80±2
0 21±1 23±1 37±2 80±4 84±3
5 20+1 26±1 39±2 103±4* 88±4
15 21±1 28±2* 38±2 105±6* 88±5
30 29±2* 29±1* 41±2* 98±7* 90±14
60 22±1 28±2* 43±1* 90±6 86±5
Results are expressed as MEAN ± S.D. (N=3); *=P<0.05 as 
compared to control.
TABLE 53 : Dose-dependent effects of 30 minute preincubation 
of hepatocytes with 1:5, 1:2 and 1:1 dilutions of the
INSULIN MEDIATOR extract on A) 7a-hydroxylase, B) 
5a-reductase, c) 6p-hydroxylase, D) 16a-hydroxylase and E) 
17-oxosteroid oxidoreductase activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 3 2
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TABLE 32 : Dose-dependent effects of 30 minute preincubation 
of hepatocytes with 1:5, 1:2 and 1:1 dilutions of INSULIN 
MEDIATOR extract on 7 a-, 6p-, 16a-hydroxylases (OHases), 
17-oxosteroid oxidoreductase (17-OHSD) and 5a-reductase 
activities.
Enzyme activities (pmoles/minute/million cells)
TREATMENT
Control 
1:5 (B)
1:2 (C)
1 :1 (D)
7a-OHase 6{3-OHase 16a-OHase 17-OHSD 5a-red
36±3
37±3
4413*
6013*
44±1
47±8
5811*
7311*
96±1
104119
104±1*
13213*
11419
118111
114111
12815*
127111
13518
141115
14612*
Results are expressed as MEAN 1 S.D. (N=3); *=P<0.05 as 
compared to control.
Duncan's Multiple Range Test : 
7a-0Hase A B C D
6p-OHase A B C D
16a-OHase A B C D
17-OHSD A C B D
5a-red A B C D
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dose-dependent increase in enzyme activity was better 
illustrated with the P-450-dependent enzymes, 7a-, 60-and 
16a-hydroxylases, whereas the P-450-independent enzymes, 
17-oxosteroid oxidoreductase and 5a-reductase, appeared 
relatively unresponsive to increasing doses of the insulin 
mediator extract.
3.6.7 EFFECT OF 30 MINUTE INCUBATION OF HEPATOCYTES
WITH INSULIN MEDIATOR AND ITS INTERACTION WITH 10"9M
GROWTH HORMONE
As is illustrated in Figure 54, incubation of 
hepatocytes with both insulin mediator and 10"9M growth 
hormone resulted in a significant decrease in enzyme 
activity (Table 33). A significant interaction was not, 
however, observed with 5a-reductase activity^ upon incubation 
with growth hormone and insulin mediator, possibly since 
5a-reductase was not stimulated by the insulin mediator 
itself.
Thus the insulin mediator appears to interact with 
growth hormone in a similar manner to that observed with 
insulin and growth hormone before (section 3.2).
FIGURE 54 : Effects of 30 minute preincubation of
hepatocytes with 1:1 INSULIN MEDIATOR extract in the absence 
and presence of 10-9M GROWTH HORMONE on 7a-hydroxylase, 
5a-reductase, 6£-hydroxylase, 16a-hydroxylase and
17-oxosteroid oxidoreductase activities.
Results are expressed as percentages of relevant control
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 3 3
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TABLE 33 : Effects of 30 minute preincubation of
hepatocytes with 1:1 INSULIN MEDIATOR extract in the absence 
and presence of 10“9M GROWTH HORMONE on 7a-, 60-, 
16a-hydroxylases (OHases), 17-oxosteroid oxidoreductase 
(17-OHSD) and 5a-reductase activities.
Enzyme activities (pmoles/minute/million cells) 
TREATMENT 7a-QHase 60-OHase 16a-OHase 17-OHSD 5a-red
Control 36±3 44±1 96±1 114±9 121±11
IM 60±3* 73±1* 132±3* 128±5* 146±2*
Control 49±4 69±4 99±8 126±4 130±1
IM+GH 41±2* 53±7* 75±5* 98±11* 141±13
Results are expressed as MEAN ± S.D. (N=3); *=P<0.05 as 
compared to relevant control values.
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3.6.8 DOSE-DEPENDENT EFFECTS OF 30 MINUTE INCUBATION OF 
LIVER MICROSOMES WITH VARIOUS DILUTIONS OF INSULIN 
MEDIATOR
Incubation of liver microsomes with various doses of 
the insulin mediator extract exhibited dose-dependent 
effects on enzyme activity (Table 34). In all cases, enzyme 
activity was maximal at the lower concentrations of insulin 
mediator tested (Figure 55), and a reduction in enzyme 
activity was observed upon incubation with the undiluted 
insulin mediator extract.
7a-hydroxylase and 5a-reductase activities (Figures 55A 
and 55B respectively) showed maximal stimulation with the 
1:5 dilution of the original insulin mediator extract, and 
enzyme activity was restored to basal levels using the 
undiluted extract.
The male-specific enzyme activities all showed maximal 
stimulation with the 1:20 dilution of the insulin mediator 
extract (Figures 55C, 55D and 55E), again returning to basal 
levels with the undiluted extract. The P-450-independent 
17-oxosteroid oxidoreductase activity (Figure 55E) appeared 
to be relatively unaffected in this case, as was seen in 
3.6.7 above.
It therefore appears that the cell-free microsomal 
system is more responsive to the insulin mediator since 
maximum effects were exhibited at relatively low doses as 
compared to the situation with intact hepatocytes (see 3.6.7 
above), and that the male-specific enzymes 6p-hydroxylase 
and 16a-hydroxylase are more sensitive to the insulin
FIGURE 55 : Dose-dependent effects of 30 minute
preincubation of rat liver microsomes with 1:20, 1:10, 1:5, 
1:2 and 1:1 dilutions of the INSULIN MEDIATOR extract on A) 
7a-hydroxylase, B) 5a-reductase, C) 6p-hydroxylase, D) 
16a-hydroxylase and E) 17-oxosteroid oxidoreductase 
activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 3 4
180 I
160 H
o
c
oo
120
100 0.80.6 
IM dose
0.40.20.0
150 n
40 1
o
c.
o
o
100 0.6 
IM dose
0.40.20.0
% 
co
nt
ro
l 
% 
co
nt
ro
l 
 ^
co
nt
ro
l
180 I
160 -
120 "
100
o.o 0.2 0 .4 0.6 0.8 1.0 1.2
IM dose
160 i
140 -
120 "
100 -
80
0.8 1.00.6 1.20 .40.20.0
IM dose
17-QHSD
100 -
90 "
80 0.80.6 
IM dose
0.40.20.0
TABLE 34 : Dose-dependent effects of 30 minute preincubation 
of rat liver microsomes with 1:20, .1:10, 1:5, 1:2 and 1:1 
dilutions of INSULIN MEDIATOR extract on la-, 60-, 
16a-hydroxylases (OHases), 17-oxosteroid oxidoreductase 
(17-OHSD) and 5a-reductase activities.
Enzyme activities (pmoles/minute/mg protein)
TREATMENT
Control
20
10
5
2
1
(A)
(B)
(C)
(D)
(E)
(F)
7a-0Hase 60-OHase 16a-OHase 17-OHSD 5a-red
38±2 58±4 87±5 134±5 150112
7412* 9212* 126112* 195110* 16118
4814* 9012* 90±2 160±12* 15111
6611* 62±2 104±4 14116 20616*
5015* 61±5 9412* 14316* 15814
39±4 4212* 90±3 15012* 15811
expressed 
control.
as MEAN ± S.D. (N=3) ; *=P<0. 05 as
Duncan's Multiple Range Test : 
7a-0Hase A F C E D B
60-OHase F A E D C B
16a-0Hase A C F E D B
17-OHSD A D E -F C B
5a-red A C E F B D
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mediator than the female-specific enzymes 7a-hydroxylase and 
5a-reductase, since a lower dose was required to obtain the 
same effect.
3.6.9 ELUTION PROFILE OF THE INSULIN MEDIATOR EXTRACT 
ON AGlx8 ION-EXCHANGE CHROMATOGRAPHY
Insulin mediator was applied undiluted to an AGlx8 
ion-exchange resin and sequentially eluted with increasing 
concentrations of ammonium formate, as detailed in section 
2.8.1. The eluted fractions were then incubated with 
hepatocytes for 30 minutes in order to determine which 
fraction contained the insulin mediator. As is shown in 
Table 35 and in Figure 56, enzyme activity was significantly 
increased upon incubation with the 1.0M ammonium formate 
fraction 1, and to a greater extent with the fraction 2 
eluate. Some residual activity also appeared to be present 
in the 1.0M formic acid eluate. Some significant increases 
in enzyme activity were observed with the ImM and 0.2M 
eluates which may be attributed to the elution of 
nucleotides. Thus the insulin mediator activity appeared to 
be eluted mainly in the 1.0M ammonium formate fraction 2, 
and to a lesser extent in fraction 1. Remaining bound 
mediator activity was eluted in the 1.0M formic acid eluate. 
Fraction 2 was therefore used for further assay.
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FIGURE 56 : Effects of 30 minute preincubation of
hepatocytes with ImM formic acid, 0.025M, 0.1M, 0.2M, 0.5M,
1.0M ammonium formate and IM formic acid AGlx8 eluates and 
of the unpurified INSULIN MEDIATOR extract on 
7a-hydroxylase, 5a-reductase, 60-hydroxylase,
16a-hydroxylase and 17-oxosteroid oxidoreductase
activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 3 5
200 n
00 -
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TABLE 35 : Effects of 30 minute preincubation of hepatocytes 
with lmM formic acid (FOR) ; 0.025M, 0.1M# 0.2M, 0.5M, 1.0M 
(fraction 1), 1.0M (fraction 2) ammonium formate (AF) and IM 
formic acid (FOR) AGlx8 eluates and of the unpurified 
INSULIN MEDIATOR extract on 7a-, 60-, 16a-hydroxylases 
(OHases), 17-oxosteroid oxidoreductase (17-OHSD) and 
5a-reductase activities.
Enzyme activities (pmoles/minute/million cells)
TREATMENT 7a-OHase 60-OHase 16a-0Hase 17-OHSD 5a-red
control 24±2 34±3 78±6 90±9 57±9
1:1 IM 28±3 48±2* 81±11 120±1* 112±4*
control 24±1 36±3 50±2 44±4 68±6
lmM FOR 24±4 36±4 48±2 60±7* 76±9
control 25±1 27±3 72±1 82±3 98±1
0.025M AF 28±1* 34±7 72±1 84±1 107±1*
control 26±2 24±3 52±2 84±1 94±10
0.1M AF 27±7 26±1 52±1 94±10 102±1
control 28±3 36±2 . 60±2 97±2 94±6
0.2M AF 31±4 42±1* 75±4* 99±6 115±2*
control 26±2 26±1 46±1 70±1 86±10
0.5M AF 25±1 30±1* 48±1* 79±1* 96±1
control 27+2 26±1 48±2 86±5 118±7
1.0M AF,f1 36±5* 31±1* 60±1* 67±8* 105±1
control 24±5 20±1 48±1 62±1 96±2
1.0M AF,f2 28±3 34±4* 72±8* 100±4* 178±18*
control 23±2 22±3 45±2 62±7 100±6
1.0M FOR 32±4* 33±1* 64±1* 90±11* 130113*
Results are expressed as MEAN ± S.D. (N=3); *=p ,o .05 as
compared to relevant control values.
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3.6.10 DOSE-DEPENDENT EFFECTS OF 30 MINUTE 
PREINCUBATION OF HEPATOCYTES WITH VARIOUS DILUTIONS OF 
AGlx8-PURIFIED INSULIN MEDIATOR EXTRACT.
Table 36 shows the effects of incubation of hepatocytes 
with AGlx8-purified insulin mediator extract. As is 
illustrated in Figure 57, all activities remained unchanged 
upon incubation with a 1:10 dilution of the extract, and a 
dose-dependent increase in enzyme activity was exhibited 
thereafter with more concentrated extract. Enzyme activity 
reached a maximum with the highest dose of insulin mediator 
assayed (3:2), although this was not the case with 
60-hydroxylase activity (Figure 57C).
3.6.11 DOSE-DEPENDENT EFFECTS OF 30 MINUTE 
PREINCUBATION OF LIVER MICROSOMES WITH AGlx8-PURIFIED 
INSULIN MEDIATOR
Table 37 shows the effects of incubation of liver 
microsomes with varying doses of AGlx8-purified insulin 
mediator. As is illustrated in Figure 58, enzyme activity 
exhibited maxima using the undiluted fraction. Further,
P-450-dependent enzyme activities 7a-hydroxylase, 
60-hydroxylase and 16a-hydroxylase (Figures 58A, 58C and 58D 
respectively) were increased markedly with 1:5 and 1.2 
dilutions of the purified extract, although a peak in enzyme 
activity was demonstrated with the undiluted extract. The 
P-450-independent activities 5a-reductase and 17-oxosteroid 
oxidoreductase (Figures 58B and 58E respectively) however
EiGURE 57 : Dose-dependent effects of 30 minute
preincubation of hepatocytes with 1:10, 1:2, 1:1 and 3:2
dilutions of the AGlx8-purified INSULIN MEDIATOR extract on 
A) 7a-hydroxylase, B) 5a-reductase, C) 6p-hydroxylase, D) 
16a-hydroxylase and E) 17-oxosteroid oxidoreductase 
activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 3 6
' fa-hydroxylase130 i
20 I
o
■+-'c
oo
100 -
90
IM dose (ml)
150 n
140 1
130 H
oL.
120 Hc
oo
00 -
90
IM dose (m l )
160
150
140
£ 130
S 120
1 1 0
100
90
o 2
IM dose (ml)
16Q?-hydroxylase130
120
o
c  1 1 0  
o  
o
100
90
20
IM dose (ml)
17-OHSD140
130
120
o
c 1 10 
o  
o
*  100
90
80
IM dose (m l )
TABLE 36 : Dose-dependent effects of 30 minute preincubation 
of hepatocytes with 1:10, 1:2, 1:1 and 3:2 dilutions of the 
AGlx8-purified INSULIN MEDIATOR extract on 7a-, 60- and 
16a-hydroxylases (OHases), 17-oxosteroid oxidoreductase 
(17-OHSD) and 5a-reductase.
Enzyme activities (pmoles/minute/million cells)
IM dilution 7a-OHase 6p-0Hase 16a-OHase 17-OHSD 5a-red
control 22±3 28±2 46±1 44±1 100±1
1:10 21±1 28±6 50±2* 36±1* 92±2*
control 26±1 18±1 28±1 64±6 86±9
1:2 32±3* 23±4* 29±1 68±3 94±8
control 22±2 20±1 32±2 36±3 94±5
1:1 28±5 30±1* 36±4 38±1 106±11
control 19±2 25±3 29±2 50±7 92±4
3:2 24±3* 33±2* 36±3* 68±5* • 131±12*
Results are expressed as MEAN ± S.D. (N=3); *=P<0. 05 as
compared to relevant control values.
FIGURE 58 : Dose-dependent effects of 30 minute
preincubation of rat liver microsomes with 1:20, 1:10, 1:5, 
1:2 and 1:1 dilutions of the AGlx8-purified INSULIN MEDIATOR 
extract on A) 7a-hydroxylase, B) 5a-reductase, C) 
6p-hydroxylase, D) 16a-hydroxylase and E) 17-oxosteroid 
oxidoreductase activities.
Results are expressed as percentages of relevant control 
values, where *=P<0.05 and N=3. Absolute data is given in 
Table 37
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TABLE 37 : Dose-dependent effects of 30 minute preincubation 
of rat liver microsomes with 1:20, 1:10, 1:5, 1:2 and 1:1 
dilutions of AGlx8-purified INSULIN MEDIATOR on 7a-, 60-, 
16a-hydroxylases (OHases), 17-oxosteroid oxidoreductase 
(17-OHSD) and 5a-reductase activities.
Enzyme activities (pmoles/minute/mg protein)
TREATMENT 7a-QHase 60-OHase
Control 39±3 77±7
1:20 (B) 41±2 80±3
1:10 (C) 41±4 83±4
1:5 (D) 73±3* 72±3
iii (E)
(F)
72±2* 90±5*
66±3* 88±4*
Results are 
compared to
expressed 
control.
as MEAN
Duncan's Multiple Range Test
7a-OHase A B C F E D
60-OHase D A B C F E
16a-0Hase D A C E B F
17-OHSD A B E C D F
5a-red C A B D E F
16a-0Hase 17-OHSD 5a-red
93±4 99±7 101±9
102±2 103±6 102±2
94±9 111±3 100110
91±4 114±4 107±2
98±1* 104±7 126±4*
114±6* 136±14* 162±15
S.D. (N=3); *=P<0.05 as
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showed no marked stimulation of enzyme activity other than 
with the undiluted extract.
Thus the P-450-dependent enzymes appear to be more 
responsive to the insulin mediator extract. Enzyme activity 
was markedly increased with the more diluted original 
extract (see 3.6.8) as compared to the relatively higher 
doses of the purified extract required here. This may be due 
to the fact that all of the insulin mediator activity is not 
eluted in the fraction used here, but rather appears to be 
eluted in three separate fractions, as was shown in section 
3.6.10.
3.6.12 EFFECTS OF 30 MINUTE INCUBATION OF LIVER 
MICROSOMES WITH AGlx8-PURIFIED INSULIN MEDIATOR AND ITS 
INTERACTION WITH 10" 9 M GROWTH HORMONE
Rat liver microsomes were incubated with undiluted, 
AGlx8-purified insulin mediator and 10“9M growth hormone for 
30 minutes (Table 38). Growth hormone appeared to antagonise 
the stimulatory effects of the purified-mediator fraction 
(Figure 59).
3.6.13 CHROMATOGRAPHY OF THE INSULIN MEDIATOR EXTRACT
Insulin mediator extract, prepared as described in 
section 2.8.2, was subjected to acid-hydrolysis (section 
2.11) and samples were spotted onto 20x20cm squares of 
Whatman No. 1 filter paper. 5% standard solutions of 
galactose, mannose, galactosamine, glucosamine and inositol,
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FIGURE 59 : Effects of 30 minute preincubation of rat liver
microsomes with 1:1 AGlx8-purified INSULIN MEDIATOR extract
and presence of 10-9M GROWTH HORMONE on
5a-reductase, 6p-hydroxylase,
and 17-oxosteroid oxidoreductase
in the absence 
7a-hydroxylase, 
16a-hydroxylase 
activities.
Results are expressed as 
values, where *=P<0.05 
Table 3 8
percentages of relevant control 
and N=3. Absolute data is given in
xeOHase 
6(3-OHase 
16C£0Hase 
17-OHSD 
scared
Y////A
M dose
TABLE 38 : Effects of 30 minute preincubation of rat liver 
microsomes with 1:1 AGlx8-purified INSULIN MEDIATOR extract 
in the presence and absence of 10-9M GROWTH HORMONE on 7a-, 
6p-, 16a-hydroxylases (OHases), 17-oxosteroid oxidoreductase 
(17-OHSD) and 5a-reductase activities.
Enzyme activities (pmoles/minute/mg protein) 
TREATMENT 7a-QHase 6p-OHase 16a-0Hase 17-OHSD 5a-red
Control 39±3 77±7 93±4 99±7 10119
IM 6613* 8814* 11416* 136114* 162115*
Control 3613 67±3 89±4 10318 10919
IM+GH 34±4 5112* 84±2 10315 11117
Results are expressed as MEAN ± S.D. (N=3); *=P<0.05 as 
compared to relevant controls.
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which are thought to be the constituents of the insulin 
mediator (Larner 1987) were also applied in order to attempt 
to identify the components of the hydrolysed insulin 
mediator sample.
As is shown in Figure 60, several components were 
released upon hydrolysis of the insulin mediator extract. 
Although these components could be correlated with the 
standards used, exact identification was difficult since 
this technique did not distinguish significantly between the 
standard sugars applied. It can therefore be said that 
although carbohydrate components such as galactose, mannose, 
galactosamine, glucosamine and inositol do appear to be 
present in this insulin mediator extract, the exact nature 
requires a more sensitive technique.
FIGURE 60:CHR0M ATQGR APHY OF THE AG 1 X 8 -P U R IF I  ED. 
ACID-HVDRDLVSED INSULIN MEDIATOR EXTRACT.
1 :lnsulin mediator extract
2 mannose
3 galactose
4 glucosamine
5 galactosamine
6 inositol
DISCUSSION
DISCUSSION
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4.1 EXPERIMENTAL MODEL FOR THE STUDY OF HEPATIC STEROID
METABOLISM
Many of the studies carried out on hepatic drug and 
steroid metabolism have employed in vivo animal models. 
Further, the endocrine influence on this system, studied 
either by administration of exogenous hormones, or by 
removal of a particular gland(s) has also been extensively 
documented. An obvious conclusion from these in vivo studies 
has been that no single hormone is involved in the 
regulation of this system, and hormonal interactions are 
known to exist (reviewed by Skett 1987). For instance, 
androgens and oestrogens effect their regulatory influence 
on hepatic metabolism by modulating the secretory pattern of 
GH secretion (section 1.3. .2). It therefore became apparent 
at this stage that in vivo studies were not sufficiently 
adequate to evaluate the role of single hormones in this 
system.
In vitro microsomal preparations or reconstituted 
enzyme systems were subsequently used (Berg and Gustafsson 
1973, Gustafsson and Stenberg 1974). Although the effects of 
single hormones can be determined using liver microsomes, 
whether or not the results are applicable to the 
physiological situation is questionable.
In the present study, we have used intact isolated 
hepatocytes. The advantages of this preparation are twofold. 
Firstly, the hepatocyte preparation is a relatively
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physiological approach as compared to the situation with 
microsomal preparations in that the hepatocyte itself is not 
disrupted so that the components and enzymes of the cell are 
not interfered with (although cell-cell contact is 
obliterated). Secondly, the effects of single hormones on 
hepatic drug and steroid metabolism can be studied without 
the ambiguity of the hormonal interactions that may be 
encountered in vivo. In addition, precise combinations of 
hormones may be administered to attempt to mimic the 
situation in vivo under clearly defined culture conditions, 
thereby indicating which interactions may be taking place in 
the intact animal model.
Many studies have shown that isolated hepatocytes in 
culture do not maintain monooxygenase activity to levels 
found in vivo. However, numerous studies have subsequently 
reported that cytochrome P-450 content can be maintained in 
culture provided that the correct culture medium environment 
exists (Kremers et al 1981, Sinclair et al 1979, Doostdar et 
al 1988). Thus whereas cytochrome P-450 content and 
monooxygenase activity decreased during the first 48h in 
primary culture, activities were maintained at higher levels 
in hormone-supplemented media (Dickins and Paterson 1980). 
Cytochrome P-450 content was reported to be maintained at 
65% of control levels for up to 2-3 weeks in culture in the 
presence of high doses of dexamethasone (Dich et al 1988) . 
Similarily, cytochrome P-450 content in cultured female rat 
hepatocytes were maintained by low doses and induced by high 
doses of dexamethasone in the culture medium, although no 
effects were seen using male rat hepatocytes (Vind et al
-153-
1988). Further, the normal development of NADPH cytochrome 
P-450 reductase activity in cultured foetal hepatocytes was 
reported to be dependent on the presence of thyroid hormones 
in the culture medium (Kriz et al 1982).
Two additional culture systems were also shown to 
prevent the loss of cytochrome P-450 content in culture: 
Inclusion of a substituted pyridine such as nicotinamide 
(Villa et al 1988) and metyrapone or 6-aminolevulinic acid 
together with the exclusion of cystine and cysteine from the 
culture medium (Paine et al 1982, Lake and Paine 1982).
More recently, the long term culture of cytochrome 
P-450 activities in culture has been shown to be maintained 
by co-culturing hepatocytes with an epithelial cell line 
(Begue et al 1984) or on a basement membrane (Schuetz et al 
1988). Dimethylsulphoxide was also reported to maintain 
certain hepatocyte functions such as albumin secretion (Isom 
et al 1985) .
Hussin and Skett (1986) recently characterised a method 
for maintaining hepatocytes in a hormone-free culture system 
comprising Ham's F-10 culture medium supplemented with 0.1% 
bovine serum albumin and reported that cytochrome P-450 
content was maintained at levels close to those expected in 
freshly isolated hepatocytes after removal of hormonal 
influences. We have therefore employed this technique in the 
present study, and although certain limitations do exist, it 
appears to be an essential method to study the effects of 
single hormones and the hormonal interactions involved in 
the regulation of hepatic steroid metabolism.
Hepatocytes from untreated male rats have been used
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throughout this study. Firstly, since male rat hepatocytes 
contain exclusively somatogenic receptors (Ranke et al 
1976), this is important in the dissociation of the 
somatogenic and lactogenic properties of hGH (Barash et al 
1988). Secondly, the effects of diabetes, adrenalectomy and 
thyroidectomy appear only to be seen on male-specific 
enzymes and in male animals. Thus the effects of 
glucocorticoids, thyroxine and insulin should logically be 
studied in the male.
4.2 CHOICE OF SUBSTRATE
Androst-4-ene-3,17-dione was used as the substrate to 
monitor the effects of different hormones on the hepatic 
steroid-metabolising system. A number of advantages of using 
this substrate have been noted. Firstly, androstenedione is 
readily available in both a radio-labelled and unlabelled 
form. Secondly, androstenedione is metabolised by a number 
of enzymes (Sheets and Estabrook 1985) (Table 3). The 7a-, 
60-, and 16a-hydroxylases are all cytochrome P-450-dependent 
enzymes, whereas the 17-oxosteroid oxidoreductase and 
5a-reductase are flavin dependent. Since androstenedione is 
metabolised by all five enzymes, which are readily 
detectable in male rat hepatocytes, the hormonal regulation 
of both cytochrome P-450-dependent and independent steroid 
metabolism can be studied. In addition, hepatic steroid 
metabolism is sexually differentiated in rats due to the 
presence of sex-specific enzymes (Waxman 1988). The 
7a-hydroxylase and 5a-reductase are female-specific whilst
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the 6p- and 16a-hydroxylase s and 17-oxosteroid 
oxidoreductase are male-specific (Table 1). Thus the 
feminisation (ie decrease in 6p- and 16a-hydroxylases and 
increase in 5a-reductase activities) or masculinisation of 
steroid metabolism by treatment with hormones can be 
recognised depending on the metabolite profile of 
androstenedione. In addition, the metabolites of 
androstenedione have been previously characterised by gas 
chromatography-mass spectrometry and thin layer 
chromatography (Gustafsson and Stenberg 1974). Further, the 
regulation of androstenedione-metabolising enzymes has been 
widely documented by other groups (Waxman et al 1985, Waxman 
et al 1987, Waxman et al 1989a, Mode et al 1989).
4.3 EFFECTS OF INCUBATION OF HEPATOCYTES WITH GROWTH
HORMONE
The regulatory role of GH in the maintenance of the sex 
differences observed in hepatic steroid metabolism in rats 
have been extensively documented (Waxman 1984). The 
secretory pattern of GH (Eden 1979) is now known to impose 
the sex differences observed in steroid metabolism such that 
the pulsatile male GH secretory pattern results in higher 
oxidative metabolism and the continuous pattern in females 
in higher reductase activity (Mode et al 1981). Thus 
continuous GH infusion to hypophysectomised rats resulted in 
the feminisation of steroid metabolism and intermittent GH 
administration led to an increased expression of 
male-specific activities together with a reduction in
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female-specific enzymes (Mode et al 1982). These sex 
differences have also been determined at the biochemical 
level in that cytochrome P-450-male was increased upon 
intermittent GH administration and cytochrome P-450-female 
after continuous GH infusion (Kato et al 1986).
The results presented in this study, however, indicate 
that incubation of isolated hepatocytes with GH, that is, 
continuous GH exposure, exhibited no marked feminisation 
effects even at high GH concentrations (Figures 6 & 9). Time 
course studies with 10"9M GH (Figure 7) showed a reduction 
in male-specific activities at the earlier time periods, but 
no increase in female-specific activities, which would be 
indicative of a feminisation effect, was observed. Exposure 
to GH over 24, 48 and 7 2h also exhibited no significant 
effects (Figure 8), except for slight decreases at 72h which 
may be attributable to inadequate culture conditions rather 
than an effect of GH.
In contrast to these findings, several groups have 
previously reported that continuous GH infusion in vivo 
resulted in the feminisation of microsomal steroid 
metabolism (Mode et al 1981, Kato et al 1986).
More recently, cytochrome P-450i levels (gene IIC12) 
were reported to increased upon treatment of male rat 
hepatocytes with GH, together with an increase in P-450i 
mRNA formation (Guzelian et al 1988). However, the 
corresponding 15(3-hydroxylase activity was not measured by 
these authors. The failure to "masculinise" steroid 
metabolism upon intermittent GH administration to female 
rats may reflect the requirement for other hormones in this
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system. Thus it may be possible that the lack of effects of 
GH in isolated hepatocytes is as a direct result of the 
removal of other hormonal influences that may have been 
present in the intact animal.
The effects of growth hormone on hepatic drug 
metabolism were also reported to follow changes in NADPH 
cytochrome P-450 reductase activity rather than in 
cytochrome P-450 content (Wilson 1973).
Incubation of hepatocytes with GH exhibited no 
significant alterations in intracellular cyclic AMP content 
(Figures 10 & 11). Thus any effects of GH on this system 
are not mediated by the cAMP second messenger system. In 
contrast, previous attempts to elucidate the effects of GH 
on cAMP content in numerous systems have shown alterations 
in cAMP levels. Whereas GH appeared to act by reducing 
cyclic AMP levels in some reports (Thompson et al 1973,
Payne and Kostyo 1970, Rillema et al 1973), elevations in 
intracellular cAMP were thought to mediate the effects of GH 
in other cases (Fain et al 1971, Sengupta et al 1981,
Solomon et al 1987). In addition, other components of this 
system such as adenylate cyclase (Albertsson-Wikland and 
Rosberg 1982, Hughes and Friesen 1985) and cAMP 
phosphodiesterase (Payne and Kostyo 1970, Rillema et al 
1973) were also reported to be altered by GH. More recently, 
the insulin-like activity of GH to stimulate glucose output 
in hepatocytes isolated from hypophysectomised rats was 
reported to be inconsistent with previous reports where a 
glucagon-like (adenylate cyclase) or insulin-like (tyrosine
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kinase) mechanism was proposed for the GH action (Blake and 
Clarke 1988).
The lack of effects of GH on cAMP levels in this study 
could be due to a number of factors. Firstly, since GH 
itself exhibited no feminising effects under the present 
culture conditions, it may be that GH is inactive here, 
perhaps due to a lack of GH receptors, and thus no effects 
on cAMP content are observed. Van Neste et al (1988), 
however showed that GH receptors were present exclusively in 
liver parenchymal cell fractions. Ideally, intracellular 
cAMP content should be determined under conditions where GH 
exhibits an effect. If changes in cAMP content are involved 
in the reported actions of GH on steroid metabolism, the 
absence of these feminising effects of GH in this study 
correlates well with no changes in intracellular cAMP 
levels. In addition, elevations in intracellular cAMP were 
reported to non-specifically inhibit steroid metabolism in 
isolated hepatocytes, indicating that cAMP may not be 
involved in mediating the feminising effects of GH in this 
system (Weiner et al 1972, Berry and Skett 1988). Ros et al 
(1973) have, however, reported a sex-dependent inhibitory 
influence of cAMP on drug metabolism and cytochrome P-450 
content. In agreement with the present study, cAMP levels 
were unchanged upon hypophysectomy or replacement GH therapy 
of male animals, indicating that the cAMP system may not be 
important in GH action (Isaksson et al 1974, Klingensmith et 
al 1980) .
GH is known to stimulate the production of the low 
molecular weight somatomedin insulin-like growth factor-I
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(IGF-I) from hepatocytes in culture (Scott et al 1985) and 
IGF-I mRNA levels (Norstedt and Moller 1987). In addition, 
hypophysectomy resulted in a reduction in IGF-I levels and 
in the expression of IGF-I mRNA (Scott et al 1985), that was 
restored upon continuous GH infusion (Isgaard et al 1988, 
Jansson et al 1982, Clark et al 1985).
If IGF-I is responsible for mediating the effects of GH 
on steroid metabolism, the lack of feminising effects of GH 
may be due to an inability of GH to stimulate IGF-I 
production from the liver cells. Cultured hepatocytes have 
been shown to be responsive to IGF-I production stimulated 
by GH (Spencer 1979). Direct administration of IGF-I to 
isolated hepatocytes, however, resulted in a general 
stimulation of steroid metabolism in a dose-dependent manner 
(Figure 12), which is characteristic of an insulin-like 
effect (Hussin and Skett 1987) rather than the sex-specific 
effect expected of GH. In agreement with this result, the 
somatomedins are reported to mimic many of the effects of 
insulin (Froesch et al 1985). Thus the effects of GH on 
steroid metabolism do not appear to be mediated by IGF-I. In 
accordance with this finding, Guzelian et al (1988) have 
recently reported that the induction of cytochrome P-450i 
content (gene IIC12) by GH was not mediated by IGF-I since 
IGF-I administration did not mimic the effects of GH on 
P-450i expression.
In conclusion, the feminising effects of GH observed in 
vivo were not exhibited upon incubation of isolated 
hepatocytes with GH alone. The absence of any effects of GH 
under these conditions on intracellular cAMP shows that the
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cAMP system may not be the second messenger system involved 
in GH action on steroid metabolism. However, this result may 
be as a direct consequence of the apparent inactivity of GH 
in isolated hepatocytes. IGF-I does not appear to be 
involved in mediating the effects of GH on steroid 
metabolism, but rather exhibits an insulin-like effect.
4.4 EFFECTS OF INSULIN ON STEROID METABOLISM AND ITS
INTERACTION WITH GROWTH HORMONE
A number of reports have indirectly demonstrated that 
insulin plays an important role in the regulation of drug 
metabolism since diabetic rats exhibited marked changes in 
drug metabolism by hepatic enzymes (Kato and Gillette 1965). 
In addition, the diabetic state was reported to cause a 
feminisation of steroid metabolism, which implied that 
insulin may be acting as a "masculinising" factor (Skett
1986). Incubation of hepatocytes with insulin resulted in 
the marked stimulation of all enzyme activities in a 
sex-independent manner (Hussin and Skett 1987), although the 
diabetic state appears only to affect male-specific 
activities (Kato and Gillette 1965, Skett and Joels 1985).
In the present study, insulin stimulated steroid 
metabolism in a dose-dependent manner with maxima at 
physiological concentrations (Figure 13/, as has been shown 
previously by Hussin and Skett (1987). Incubation of 
hepatocytes with insulin in combination with GH (Figures 
13-16) showed that GH antagonised the stimulatory effects of 
insulin in a non-specific manner. Further, no effects of GH
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were observed in the absence of an insulin response, 
indicating that GH was indeed opposing insulin action. Thus, 
although GH alone exhibited no significant effects on 
steroid-metabolising enzymes, GH modified the effects of 
insulin, indicating that the hepatocyte culture system was 
functional and could respond to GH.
Insulin and GH are known to interact in numerous 
systems and, insulin, like GH, is also known to stimulate 
IGF-I release from the liver (Maes et al 1983). Conversely, 
GH also exhibits insulin-like effects in many systems 
(Betley et al 1989). Serum IGF-1 levels were low in 
insulin-dependent diabetics and were not restored upon GH 
administration (Maes et al 1986). This GH-resistance 
was thought to be due to a post-receptor defect since 
GH-binding was not altered in diabetic animals.
The GH secretory pattern was markedly suppressed in the 
diabetic animal, and led to the abolition of the pulsatile 
GH secretion in normal males (Harrison and Robinson 1980, 
Tannenbaum 1981). Thus removal of the insulin influence 
resulted in the feminisation of the GH secretory profile, in 
agreement with the reported feminisation of stdroid 
metabolism (Skett 1986). Insulin administration should 
therefore have resulted in a "masculinisation" of the 
steroid metabolising enzymes. However insulin stimulated 
steroid metabolism in a non-specific manner (Figure 13), 
showing that additional factors may also be involved. 
Co-incubation with GH modified the effects of insulin in a 
non-sex-specific manner since both male- and female-specific 
activities were decreased. Thus although the effects of
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insulin are antagonised by GH, other interactions appear to 
be involved in achieving the feminisation of steroid 
metabolism typical of continuous GH administration to the 
intact animal (Mode et al 1981).
Both native and recombinant bGH, but not bPRL 
antagonised the insulin-stimulated lipogenesis in cultured 
adipose tissue, showing that this effect was specific to GH 
(Etherton et al 1987). In addition, the effects of GH were 
augmented in the presence of hydrocortisone, showing the 
involvement of other hormones. It has further been reported 
that streptozotocin (STZ)-diabetes enhanced the sensitivity 
to lipolytic agents such as GH (Solomon et al 1987). 
Conversely, insulin sensitivity was enhanced in rats treated 
with a GH antibody (Schwartz 1980, Gause et al 1983). Tatro 
and Schwartz (1987) showed that endogenous GH suppressed 
glucose utilisation in diabetic animals, which was reversed 
by prolonged treatment with a GH antibody. Similarly, the 
interaction between insulin and GH was documented by the 
observed increase in sensitivity to insulin in 
hypophysectomised rats (Schwartz 1980).
The stimulatory effects of insulin on steroid 
metabolism did not appear to be as a result of de novo 
cytochrome P-450 synthesis since total cytochrome P-450 
content remained unchanged in insulin-treated hepatocytes 
(Hussin and Skett 1987). However alterations in the levels 
of specific cytochrome P-450 isoenzymes cannot be excluded 
as a possible mechanism. The mechanism of the stimulatory 
action of insulin on steroid-metabolising enzymes was 
postulated to involve a phosphorylation reaction since
-163-
incubation with insulin of hepatocytes pretreated with 
protein kinase inhibitors resulted in the abolition of the 
insulin response (A.H. Hussin, personal communication).
The cytochrome P-450 enzymes have been shown to be 
substrates for phosphorylation. The catalytic subunit of 
cyclic AMP-dependent protein kinase (Pyerin et al 1983), 
both in a reconstituted system and in purified form, 
phosphorylated cytochrome P-450 LM2 (gene IIB4) and 
cytochrome P-450 reductase from rabbit liver microsomes, 
resulting in an associated decrease in monooxygenase 
activity and conversion of cytochrome P-450 to inactive 
cytochrome P-420 (Pyerin et al 1984). It was further shown 
that phosphorylation of cytochrome P-450 occurred 
exclusively on serine residues, namely ser 128 (Pyerin et al
1986). Subsequent studies have categorised the 
phosphorylation of cytochrome P-450 into three groups : 
cytochrome P-450 isoenzymes that are phosphorylated by both 
cAMP-dependent protein kinase (protein kinase A) and 
calmodulin/phospholipid-dependent protein kinase (protein 
kinase C), cytochrome P-450 isoenzymes that are 
phosphorylated by either protein kinase A or protein kinase 
C, and isoenzymes not phosphorylated by either protein 
kinase (Pyerin et al 1987).
In agreement with the studies carried out by Pyerin and 
coworkers, Koch and Waxman (1989) have recently reported the 
phosphorylation of cytochromes P-450 PB-4 (gene IIB1) and 
PB-5 (gene IIB2) by dibutyryl-cAMP (and therefore by cyclic 
AMP-dependent protein kinase activation) at ser 128. The 
failure to achieve the phosphorylation of other cytochrome
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P-450 isoenzymes was attributed to either the involvement of 
protein kinase C or the absence of a serine residue at 
position 128, which is contained within a recognition 
sequence (Arg-Arg-x-Ser) used by many cyclic AMP-dependent 
protein kinases (Krebs and Beavo 1979).
It has been suggested that the phosphorylation sites of 
cytochrome P-450 may be closely associated with the 
cytochrome b5 binding domain since the effects of protein 
kinases A and C activation on cytochrome P-450 
phosphorylation were inhibited by cytochrome b5 (Epstein et 
al 1989).
Phosphorylation-dephosphorylation control by insulin 
has been well documented in numerous systems. Thus altered 
phosphorylation of cytochrome P-450 caused by insulin could 
result in a stimulation of enzyme activity. Conversely, the 
actions of glucagon to inhibit steroid metabolism correlated 
well with a diacylglycerol-mediated activation of protein 
kinase C, which then presumably phosphorylates cytochrome 
P-450 (Hussin et al 1988). Incubation of rat liver 
microsomes with alkaline phosphatase, however, also resulted 
in a decrease in monooxygenase activity (Taniguchi and 
Pyerin 1987), which is similar to the effects of cytochrome 
P-450 phosphorylation (Pyerin et al 1987). This discrepancy 
was resolved by the finding that alkaline phosphatase was 
acting to inactivate NADPH cytochrome P-450 reductase, 
rather than at the level of cytochrome P-450 (Taniguchi and 
Pyerin 1987).
The effects of GH to antagonise the stimulatory effects 
of insulin could also involve control at the phosphorylation
-165-
level. Certainly, GH was shown to cause the phosphorylate a 
46kDa species in isolated rat hepatocytes (Yamada et al
1987). Thus GH could be acting to phosphorylate cytochrome 
P-450 isoenzymes, which would result in a decrease in 
monooxygenase activity. Which protein kinase could be 
activated by GH to mediate cytochrome P-450 phosphorylation 
(Pyerin et al 1987) is not clear, since GH has been shown to 
activate both cAMP and PKC systems (Thompson et al 1973, 
Albertsson-Wikland and Rosberg 1982, Smal et al 1989, Doglio 
et al 1989), although no effects on cyclic AMP were observed 
in this study (Figures 10 and 11).
Insulin is also known to phosphorylate at serine and 
threonine residues (Espinal 1987). Activation of 
cytochrome P-450 activity by insulin could be mediated by 
activation of specific serine phosphatases (Czech 1988), and 
antagonism of this effect of insulin by GH could be due to 
phosphorylation at the level of cytochrome P-450, as a 
consequence of activation of PKA and/or PKC by GH. In 
accordance with this, it has been shown previously that 
increases in intracellular cAMP or PKC activation are 
associated with decreases in hepatic steroid (Berry and 
Skett 1988, Allan and Skett 1988) and drug (Weiner et al 
1973, Banheygi et al 1988) metabolism.
Hypophysectomy has been reported to result in the 
increased expression of cytochrome P-450j (gene IIE1), an 
effect that was reversed upon continuous GH administration 
(Williams and Simonet 1988). Thus GH appeared to act as a 
repressive factor for constitutive cytochrome P-450j levels 
(Waxman et al 1989b). Cytochrome P-450., (gene IIE1)
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induction has also been reported in diabetic animals (Past 
and Cook 1982), and so the observed interaction between GH 
and insulin in this study may be as a result of modulations 
of cytochrome P-450., content. The mechanism of this 
repressive action of GH is, as yet, not fully understood.
In conclusion, insulin appears to be a general 
stimulatory factor of steroid metabolism, an effect that is 
strongly antagonised by GH. This interaction between insulin 
and GH was optimal at physiological concentrations of 
insulin, and GH modulated enzyme activity in a 
sex-independent manner. Although the mechanism of this 
interaction is not fully clear at this stage, direct effects 
at the level of cytochrome P-450 are a strong possibility.
4.5 EFFECTS OF DEXAMETHASONE ON STEROID METABOLISM AND
ITS INTERACTION WITH GROWTH HORMONE
The permissive role of glucocorticoids has been 
demonstrated in numerous systems. Further, adrenalectomy 
resulted in a reduction in male-specific enzyme activities 
(Gustafsson and Stenberg 1974d, Kato and Gillette 1965). 
Administration of glucocorticoids to normal animals has 
given rise to a number of conflicting reports. Whereas the 
long acting synthetic glucocorticoids markedly stimulated 
enzyme activity, corticosterone administration resulted in 
the opposite effect (Tredger et al 1976). As these studies 
were carried out in vivo, the final effect could have been 
as a result of interactions with other factors.
In the present study, a low concentration of
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dexamethasone was added to isolated hepatocytes over varying 
time periods and in both the absence or presence of GH. 
Dexamethasone alone stimulated steroid metabolism 
non-specifically (Figures 17 and 18) over short incubation 
periods, while inclusion of GH in the culture medium 
restored enzyme activity to control levels (Figure 17). In 
addition, a certain degree of dose-dependency of GH was 
exhibited in modulating the response to dexamethasone 
(Figure 18). Incubation of cultured hepatocytes with 
dexamethasone over longer time periods resulted in a marked 
stimulation of all enzyme activities with time (Figure 19), 
and were decreased to control levels upon further incubation 
with GH (Figures 20-25).
Thus the results obtained from the present study show 
that dexamethasone stimulates steroid metabolism 
non-specifically over both short and long incubation 
periods, and that the GH response is modified in the 
presence of dexamethasone. The mechanism of action of these 
hormones remains obscure at this stage. While the short 
incubation studies probably represent a glucocorticoid 
function of dexamethasone, the mechanism of action in the 
longer term cultures may represent induction. The presence 
of dexamethasone in the culture medium has previously been 
shown to be important in the maintenance of the components 
of the cytochrome P-450 system in vitro to levels comparable 
with those in the intact animal (Kriz et al 1982, van der 
Hoeven and Guzelian 1987, Dich et al 1988, Vind et al 1988). 
However the culture medium used in the present study was 
shown to be adequate for maintaining cytochrome P-450
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content in isolated hepatocytes (Hussin and Skett 1986), and 
so the observed effects of dexamethasone in cultured 
hepatocytes are thought to represent induction rather than 
maintenance alone.
Schuetz et al (1984) have also reported a similar 
response upon incubation with dexamethasone and was 
dependent on the age of the culture. Whereas dexamethasone 
added to fresh cultures (0 days) led to a 70% increase by 
120h, dexamethasone added to 48h cultures resulted in a 
20-25% induction of cytochrome P-450pcn (gene IIIA1) by 120h 
(Schuetz et al 1984). In the present study, hepatocytes were 
exposed to dexamethasone after 48h of incubation (see 
section 2.5.2). The response between the two studies shows a 
striking similarity and so the results obtained in this 
study may therefore also represent cytochrome P-450pcn 
induction.
Thus low concentrations of dexamethasone induced 
steroid-metabolising enzymes in this study, and it has been 
shown that this induction is a dose-dependent effect 
(Schuetz et al 1984). In addition, natural glucocorticoids 
also induced cytochrome P-450pcn (gene IIIA1), although this 
effect was not as potent as with dexamethasone and required 
higher concentrations in order to achieve a reasonable 
response (Schuetz et al 1984). This effect may be as a 
consequence of the shorter half-life of the natural 
glucocorticoids in comparison to the synthetic analogues, as 
has been suggested previously by Tredger et al (1976).
In contrast, Mathis et al (1986) have reported that 
although dexamethasone induced monooxygenase activity
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synergist ically with polycyclic aromatic hydrocarbons upon 
incubation of cultured human foetal hepatocytes for 5 days, 
whereas dexamethasone alone exhibited no stimulatory 
effects. Further, these authors showed that dexamethasone 
was acting by the classical glucocorticoid receptor pathway 
and not by cytochrome P-450pcn (gene IIIA1) induction.
Hepatocytes incubated in the presence of pregnenolone- 
16a-carbonitrile (PCN) resulted in marked increases in 
cytochrome P-450pcn (gene IIIA1) content, drug metabolism 
and mRNA levels (Elshourbagy et al 1981). It was 
subsequently shown that dexamethasone and other 
glucocorticoids also stimulated de novo synthesis of 
cytochrome P-450pcn (gene IIIA1) (Althaus and Meyer 1981).. 
Further, dexamethasone appeared to be the most potent 
inducer of cytochrome P-450pcn (gene IIIA1) (Schuetz et al
1984). It was therefore proposed that both endogenous and 
synthetic glucocorticoids and PCN, but not sex steroids or 
mineralocorticoids, constituted the third class of inducers 
(Schuetz et al 1984) responsible for the induction of the 
steroid-inducible cytochrome P-450s of the P-450III gene 
family (Gonzalez 1989). Multiple isoenzymes of 
steroid-inducible cytochrome P-450pcn (gene IIIA1) have 
subsequently been isolated (Graves et al 1987, Halpert
1988). Dexamethasone also induced specific cytochrome P-450 
isoenzymes mediating the metabolism of 2-acetylaminofluorene 
in cultured rat hepatocytes (McManus et al 1987). A 
glucocorticoid-inducible cytochrome P-450 in human foetal 
livers that is related to cytochrome P-450 HLp (gene IIIA3) 
in adult human livers has also been identified (Wrighton et
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al 1988).
The mechanism of action of glucocorticoids in the 
induction of cytochrome P-450pcn (gene IIIA1) was 
subsequently reported to involve a mechanism distinct from 
the classical glucocorticoid receptor pathway. Firstly, 
tyrosine aminotransferase activity, a glucocorticoid- 
responsive function, showed no similarities in its induction 
as compared to cytochrome P-450pcn (gene IIIA1) induction 
with regards to either the time-course of induction or the 
concentration of glucocorticoid required for this in^Uc^ion 
(Schuetz and Guzelian 1984). The most convincing piece of 
evidence to support these results has been that whereas 
tyrosine aminotransferase activation was abolished in the 
presence of glucocorticoid antagonists, no
effect was observed on the magnitude of cytochrome P-450pcn 
(gene IIIA1) induction (Schuetz and Guzelian 1984). Thus 
although de novo cytochrome P-450pcn (gene IIIA1) synthesis 
appears to be involved in response to both glucocorticoids 
and PCN (Schuetz et al 1984), the mechanism of action 
appears to be other than that of the classical 
glucocorticoid receptor pathway (section 1.6) However, a 
glucocorticoid-responsive element (GRE) which binds the 
glucocorticoid receptor has been identified within the first 
intron of the cytochrome P-450c gene (IA1), thus implying a 
direct regulation of the rat cytochrome P-450c gene 
expression by glucocorticoids (Mathis et al 1989). Deletion 
of these glucocorticoid receptor binding sites within intron 
I led to the abolition of glucocorticoid responsiveness. 
These authors proposed that glucocorticoids may therefore
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play an important role in the regulation of cytochrome 
P-450c (gene IA1) to other xenobiotics and inducers. A 
direct action of glucocorticoids on the liver has also been 
implicated by the finding that cortisone acetate
administration to hypophysectomised rats resulted in a
decrease in cytochrome P-450b (gene IIB1) and P-450e (gene
IIB2) content (Yamazoe et al 1989).
The administration of adrenocorticotropin (ACTH), which 
stimulates the release of glucocorticoids from the adrenal 
glands, in combination with GH to hypophysectomised animals 
resulted in a decrease in the reductive metabolism of 
corticosterone whereas either of the hormones alone 
exhibited no such effects (Colby et al 1974). This result 
implied that hormonal interactions may be important in 
hepatic drug and steroid metabolism.
Cytochrome P-450b (gene IIB1) induction by 
dexamethasone has been suggested to be due to the 
stabilisation of its mRNA (Whitlock 1986). Rats treated with 
dexamethasone showed that mRNA levels for IIB1, IIB2 and 
NADPH cytochrome P-450 reductase were specifically 
stabilised in the absence of transcription (Simmons et al
1987). In contrast, Watkins et al (1986) reported that the 
PCN-1 gene was induced at the transcriptional level and that 
mRNA levels correlated well with PCN-1 protein content. The 
rat PCN-1 and PCN-2 proteins were also stabilised by the 
macrolide antibiotic triacetyloleandomycin (TAO), although 
by a mechanism distinct from that of dexamethasone (Watkins
et al 1986, Halpert 1988).
In the present study, GH restored the dexamethasone-
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induced stimulation of enzyme activity to control levels. GH 
is known to act as a regulatory factor in the development of 
a number of cytochrome P-450 isoenzymes (section 1.4.3).
Thus expression of cytochrome P-450!6a (gene IIC11) at 
puberty is as a direct consequence of the pulsatile 
secretory pattern of GH in males, while cytochrome P-450!5p 
(gene IIC12) and 5a-reductase activities are expressed in 
adult females following the development of a continuous GH 
secretory pattern. Conversely, the expression of cytochrome 
P-450ep (gene IIIA2) is suppressed by continuous GH 
secretion in females at the onset of puberty, and remains at 
prepubertal levels in adult males. It has further been 
suggested that maintenance of cytochrome P-450ep expression 
in adult males may also be partially dependent on the 
presence of adrenal corticosteroids (Waxman 1988), which 
correlates with the relatively specific effects of 
adrenalectomy on male-specific activities (Gustafsson and 
Stenberg 1974d).
More recently, an additional regulatory role of GH 
other than that exerted by its pulsatile secretory pattern 
has become apparent. Both cytochromes P-450 RLM2 (gene IIB4) 
and 2a (gene IIIA2) were suppressed upon GH administration 
to male rats, which would explain their relative absence in 
adult females (Waxman et al 1988a). Both constitutive and 
inducible levels of cytochromes P-450b (gene IIB1) and 
P-450e (gene IIB2) are regulated repressively by GH (Yamazoe 
et al 1987), as well as cytochrome P-4506P (gene IIIA2) 
expression (Yamazoe et al 1986). In addition, it was 
reported that the repressive effect of GH on these two
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isoenzymes was distinct from the regulatory influence 
exerted by its pulsatile secretion in that hypophysectomy 
abolished the sex differences by increasing both cytochrome 
P-450b and P-450e expression in phenobarbital-treated female 
rats (Yamazoe et al 1987). Similarly, no sex-related 
difference was observed in animals given large doses of 
dexamethasone, which is known to reduce serum GH in rats 
(Kokka et al 1972).
It has been suggested that GH may regulate cytochrome 
P-450b (gene IIB1) and P-450e (gene IIB2) synthesis both at 
the transcriptional and translational level, as has been 
suggested for a2u-macroglobulin (Kulkarni et al 1985). 
Cytochrome P-450b (gene IIB1) and P-450e (gene IIB2) were 
present at higher levels in 20-day old rats as compared to 
mature rats, which is consistent with P-450b mRNA levels 
(Giachelli et al 1986), and correlates well with the lower 
serum GH levels in 20-day old rats (Wehrenberg 1986). 
Cytochrome P-450b (gene IIB1) was reported to be more 
responsive to GH than cytochrome P-450e (gene IIB2) (Yamazoe 
et al 1987), which may partly be explained by the regulation 
of these isoenzymes by different genetic loci (Rampersaud 
and Walz 1983). Dexamethasone was reported to inhibit the 
GH-induced stimulation of IGF-1 mRNA in hypophysectomised 
rats and controls (Luo and Murphy 1989). Hence inhibition of 
IGF-1 mRNA gene expression may be the mechanism by which 
glucocorticoids inhibit growth, since IGF-1 is known to 
mediate the effects of GH on somatic growth (Jansson et al
1985). This mechanism is not likely with steroid metabolism, 
however, as GH does not appear to act via IGF-1 here
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(section 4.3) (Guzelian et al 1988).
Thus the mechanism of action of the stimulatory action 
of dexamethasone could be either by the classical 
glucocorticoid receptor pathway (Mathis et al 1989) or by 
induction of cytochrome P-450pcn (gene IIIAl) (Schuetz et al 
1984). The interaction with GH could be due to the 
repressive effect of GH that has been reported on the 
expression of a number of cytochrome P-450 isoenzymes 
(Yamazoe et al 1987, Waxman et al 1988).
In conclusion, dexamethasone acts as a non-specific 
stimulatory agent of steroid metabolism, an effect that is 
restored to basal levels upon incubation with GH. The 
mechanism of action of this suppressive effect is not clear, 
although GH has been documented to be a repressive factor 
for many cytochrome P-450 isoenzymes. Thus it is unlikely 
that a combination of GH and glucocorticoid can account for 
the feminising effect of GH seen in vivo.
4.6 EFFECTS THYROXINE ON STEROID METABOLISM AND 
ITS INTERACTION WITH GROWTH HORMONE
The role of the thyroid hormones in the regulation of 
hepatic drug and steroid metabolism has been noted 
indirectly by the effects of thyroidectomy. Kato and 
Takahashi (1968) showed that thyroidectomy resulted in a 
reduction in drug metabolism and in the activities of other 
components of the cytochrome P-450 system in both male and 
female rats. Administration of thyroid hormones exhibited 
sex-and substrate-dependent effects on drug metabolism (Kato
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and Gillette 1965, Rumbaugh et al 1978, Skett and Weir 1983, 
Colby and Rumbaugh 1985), although a number of discrepancies 
have been documented regarding the administered dose of 
thyroid hormones.
In the present study, thyroxine exhibited a 
dose-related and sex-specific effect on steroid metabolism 
(Figure 26 and 27). Whereas short incubation with thyroxine 
alone exhibited isoenzyme-specific effects, incubation with 
GH resulted in marked decreases in enzyme activities (Figure 
29). Incubation over longer time periods with thyroxine 
alone caused no significant effects, except at 72h with 
10“6M thyroxine, and enzyme activities were in general 
restored to control levels upon further incubation with GH 
(Figures 30-43). The nature of the discrepancy observed in 
GH action between short and long incubation periods 
indicates that GH may be acting by a different mechanism in 
each case.
Thyroid hormones, similar to steroid hormones (King
1987), interact with nuclear receptors and then exert their 
effects by binding to thyroid hormone responsive elements 
(TRE) on target genes (section 1.7).
The mechanism of action of the thyroid hormones was 
suggested to be dependent on the presence of androgens (Kato 
and Takahashi 1968). Thus supraphysiological doses of 
thyroxine antagonised the stimulatory effects of androgens 
on hepatic microsomal metabolism, but in the absence of 
androgens, thyroxine increased monooxygenase activity. Such 
a mechanism would account for the sex-specific effects of 
thyroxine observed by these authors. In contrast,
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physiological doses of thyroxine stimulated drug metabolism 
in a sex-independent manner irrespective of pituitary 
(Rumbaugh and Colby 1978) or gonadal status (Colby and 
Rumbaugh 1985). However, Skett and Weir (1983) demonstrated 
sex- and substrate-dependent effects of physiological doses 
of thyroxine, and further suggested that an optimal 
concentration of thyroxine existed that was responsible for 
maximum activity, in which case the discrepancies amongst 
the above reports can be accounted for purely on the basis 
of the use of different concentrations of thyroid hormone. 
This is further suppported by a recent report where 
physiological concentrations of thyroid hormone induced 
6-aminolaevulinate synthase activity (therefore increased 
cytochrome P-450 synthesis) while thyrotoxic doses induced 
haem oxygenase activity (therefore increased cytochrome 
P-450 degradation) (Smith and Drummond 1988).
The mechanism by which thyroxine elicits these effects 
on drug metabolism may be as a direct result of alteration 
in other components of the cytochrome P-450 system. The 
thyroid hormones have recently been shown to be important 
regulatory agents for the constitutive levels of cytochrome 
P-450 isoenzymes in male rats (Arlotto and Parkinson 1989), 
since thyroidectomy elevated microsomal 7a-hydroxylase 
activity which was restored to control levels upon 
replacement triiodothyronine therapy. In addition, 
cytochrome P-450b (gene IIBl) and P-450e (gene IIB2) content 
was markedly suppressed upon administration of 
triiodothyronine to hypophysectomised rats, indicating a 
regulatory role of the thyroid hormones in the control of
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specific cytochrome P-450 forms (Yamazoe et al 1989). Liver 
microsomal cytochrome b5, NADPH cytochrome P-450 reductase 
and haem oxygenase have been shown to be partially regulated 
by triiodothyronine (Hoch et al 1980, Smith et al 1982, 
Phillips and Langdon 1962, Rumbaugh et al 1978). Further, 
the stimulatory effects of thyroxine on hepatic drug 
metabolism was reported to correlate with changes in NADPH 
cytochrome P-450 reductase activity rather than with 
cytochrome P-450 content (Colby and Rumbaugh 1985). A 
similar dependence on NADPH cytochrome P-450 reductase 
levels in cytochrome P-450-dependent metabolism has recently 
been documented (Waxman et al 1989a).
In contrast to the present studies, increases in 
5a-reductase activity by GH were not modified upon inclusion 
of triiodothyronine in the incubation medium. However, this 
study was carried out using female rat hepatocytes, so the 
effect with GH is not a feminisation response (Miller and 
Colas 1982). A permissive action of thyroid hormones on the 
actions of hormones that act via cyclic AMP has been 
documented by Malbon et al (1968). Many of the actions of GH 
have been associated with the cyclic AMP system and so the 
modulation of the GH response in the presence of thyroxine 
may be as a direct result of this permissive action. In 
accordance with this, a cAMP-responsive region in the rat GH 
gene was reported to be synergistically activated by thyroid 
hormones and cAMP (Copp and Samuels 1989).
Thyroxine may directly affect GH at the transcriptional 
level since TRE have been identified on the GH gene (Ye and 
Samuels 1987). Triiodothyronine stimulates the transcription
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of the GH gene in the pituitary (Flug et al 1987). Thus T3 
could possibly act through the hypothalamo-pituitary axis by 
modulation of the GH-dependent process. Thyroxine has been 
reported to increase the synthesis of GH by the pituitary 
gland (Mirell et al 1987, Santos et al 1987). However, T3 
appears to act as a repressive factor directly in the liver 
and not via the pituitary in this case since triodothyronine 
exhibited suppression in hypophysectomised rats (Yamazoe et 
al 1989). Regulation at the level of the pituitary is an 
unlikely explanation for the effects seen in this study, 
however, as isolated hepatocytes were used (and therefore no 
synthesis of GH is taking place).
In conclusion, short incubation of hepatocytes with 
thyroxine altered steroid metabolism in a dose-dependent and 
sex-related manner. Co-incubation with GH exhibited marked 
decreases in enzyme activity as compared with the results 
obtained with thyroxine alone. Longer term culture of 
hepatocytes with thyroxine and GH did not exhibit 
significant decreases in enzyme activity, except at 72h of 
incubation, and there was a tendency of GH to restore 
steroid metabolism to control levels. Thus, as with.the 
previous section, it is unlikely that a combination of GH 
and thyroid hormone can account for the feminising effect og 
GH in vivo.
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4.7 EFFECTS OF DEXAMETHASONE AND THYROXINE ON STEROID
METABOLISM AND THEIR INTERACTION WITH GROWTH HORMONE
Thyroid hormones and glucocorticoids have been 
documented to be permissive factors in mediating the effects 
of numerous other systems. In the present study, the effects 
of incubation with thyroxine or dexamethasone were altered 
in the presence of GH, indicating a certain degree of 
interaction between these hormones (see above).
Although the continuous infusion of GH to 
hypophysectomised male rats resulted in the feminisation of 
hepatic steroid metabolism (Mode et al 1981), this effect 
was only achieved in the presence of both ACTH and thyroxine 
in another study (Rumbaugh and Colby 1980). It was 
subsequently suggested by these authors that the lack of 
effects of GH in isolated hepatocytes may have been due to 
inappropriate culture conditions, that is, the apparent 
requirement for ACTH and thyroxine was not fulfilled in 
these in vitro experiments.
Duran-Garcia et al (1979) reported that the number, but 
not affinity of GH binding sites in liver was markedly 
reduced in thyroidectomised rats, and restored upon 
replacement with thyroid hormone, suggesting that thyroid 
hormones may be required for the maintenance of GH 
receptors. Similarly, the role of dexamethasone and insulin 
has also been documented in the maintenance of GH binding 
sites in vitro (Christoffersen et al 1984). Thus it may be 
that the role of dexamethasone and thyroxine is not in 
cytochrome P-450 maintenance, but rather with the
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maintenance of the GH receptor in isolated hepatocytes.
As was discussed in section 4.2, incubation of 
hepatocytes with GH gave no significant feminisation of 
steroid metabolism. In addition, hepatocytes incubated with 
either dexamethasone or thyroxine in combination with GH 
exhibited non-specific effects and feminisation of steroid 
metabolism was not achieved.
Incubation of hepatocytes with dexamethasone and 
thyroxine caused no significant effects on enzyme activities 
(Figures 44 and 46), which is consistent with the 
maintenance of cytochrome P-450 levels in hepatocytes 
cultured in hormone-supplemented media (Vind et al 1988,
Dich et al 1988). In addition,•hepatocyte NADPH cytochrome 
P-450 reductase activity was maintained at original levels 
in the presence of dexamethasone, triiodothyronine and 
insulin while either of the hormones alone exhibited no 
significant effects (van der Hoeven and Guzelian 1987).
Incubation with GH in the presence of dexamethasone and 
thyroxine in the culture medium resulted in an increase in 
female-specific and a decrease in male-specific enzyme 
activities (Figures 44 and 46), which is characteristic of 
the feminisation of steroid metabolism (Mode et al 1981). In 
addition, the higher dose of GH more potently decreased 
male-specific activities whereas 10-9M GH was more effective 
in the stimulation of female-specific enzymes (Figure 45). 
This differential effect of the dose of GH on male- and 
female-specific activities probably reflects the 
sexually-differentiated secretory pattern of GH in vivo.
Thus both dexamethasone and thyroxine appear to be important
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in manifesting the feminising effects characteristic of GH 
in cultured hepatocytes. Similarily, Mode et al (1989) have 
recently reported that the feminisation of cytochrome 
P-45015p (gene IIC12) levels (female-specific) upon 
continuous GH administration to hypophysectomised rats was 
markedly potentiated in the presence of thyroxine and 
cortisol in a synergistic manner. In contrast, the 
masculinisation of cytochrome P-45016a (gene IIC11) by 
intermittent GH administration was unaffected by the 
presence of additional hormones. Thus thyroid hormones and 
glucocorticoids appear to be important in the maintenance of 
a "female-type” liver (Mode et al 1989). Contrary to this 
report, however, GH alone increased 5a-reductase activity in 
cultured female rat hepatocytes, an effect that was not 
potentiated in the presence of dexamethasone and/or 
triiodothyronine (Miller and Colas 1982).
A recent study carried out in adult female rat 
hepatocytes cultured on matrigel showed that administration 
of GH resulted in the increased expression of cytochrome 
P-4501 (gene IIC12) and its mRNA. IGF-I mRNA levels were 
also stimulated. In contrast, treatment of female rat 
hepatocytes with GH and other hormones did not induce 
cytochrome P-450h (gene IIC11) expression (Guzelian et al 
1988). Since continuous GH did not increase cytochrome 
P-45015p (gene IIC12) content to that found in control 
animals, together with the lack of masculinisation of 
cytochrome P-450h (gene IIC11) in females, this indicated 
that other factors may also be involved (Guzelian et al 
1988). These authors subsequently reported the need for
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glucocorticoids and thyroid hormones in order to achieve the 
same effect in hypophysectomised rats (Mode et al 1989). An 
additional discrepancy in these studies has been that 
insulin is present both in hypophysectomised rats and 
especially in the matrigel culture medium used by Guzelian 
et al (1988). The effects observed may therefore not reflect 
the true response to GH alone. Further, cytochrome P-450lsp 
(gene IIC12) expression was not induced by GH to levels 
found in normal control animals, suggesting that additional 
factors may also be involved (Zaphiropoulos et al 1988).
The mechanism of action by which GH elicits the 
feminisation of hepatic steroid metabolism in the rat is not 
known. Pretranslational control has been suggested in the 
induction of cytochrome P-45015p (gene IIC12) by GH (Mode et 
al 1989, Guzelian et al 1988) since associated mRNA levels 
were also increased in response to GH. GH was reported to 
have reduced the total amount of cytochrome P-450 in 
hypophysectomised male rats (Vockentanz and Virgo 1985). By 
labelling cytochrome P-450 with 3H-haem, it was shown that 
GH decreased the amount of cytochrome P-450-male (slow 
turnover) markedly as compared to cytochrome P-450-female 
(fast turnover) and increased the half-life of cytochrome 
P-450-female to a greater extent. The authors therefore 
proposed that the feminising effects of GH were as a result 
of a decrease in the synthesis of cytochrome P-450-male 
together with an increase in the half-life of cytochrome 
P-450-female (Vockentanz and Virgo 1985).
The feminisation of hepatic cytochrome P-450 expression 
by cisplatin was reported to be as a result of depletion of
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serum androgens which are required for the maintenance of 
male-specific activities (LeBlanc and Waxman 1988).
Although a number of actions of GH have been associated 
with changes in intracellular cyclic AMP content (Thompson 
et al 1973, Payne and Kostyo 1970, Rillema et al 1973, Fain 
et al 1971, Sengupta et al 1981, Solomon et al 1987) no 
conclusive second messenger of GH has been identified as 
yet. GH did not alter cAMP levels in the present study, and 
IGF-I administration exhibited an insulin-mimetic effect 
(section 4.3). However, IGF-I is now generally believed to 
mediate the actions of GH on skeletal growth (Jansson et al 
1985). Further, intermittent rather than continuous GH 
administration stimulated bone growth more effectively in 
hypophysectomised rats (Isgaard et al 1989). Recent studies 
on intracellular cyclic AMP led to the conclusion that 
agents elevating intracellular cyclic AMP (such as 
adrenaline, phosphodiesterase inhibitors, cyclic AMP 
analogues) resulted in marked inhibitions of steroid 
metabolism (Berry and Skett .1988). Since this effect was 
non-specific in nature, that is, both female- and 
male-specific enzymes were inhibited, elevations in cyclic 
AMP do not appear to be involved in mediating the feminising 
effects of GH, which is characterised by increased activity 
of the female-specific 5a-reductase. A similar approach has 
precluded the role of protein kinase C in mediating the 
feminising effects of GH since phorbol esters, which mimic 
the action of endogenous diacylglycerol to activate protein 
kinase C, non-specifically inhibited androstenedione 
metabolism in isolated rat hepatocytes (Allan and Skett
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(1988). However the role of PKC in GH action has been 
documented (Smal and De Meyts 1987).
It is, therefore, conceivable that the action of GH to 
decrease male-specific, cytochrome P-450-dependent 
60-hydroxylase and 16a-hydroxylase activities is a cyclic 
AMP- (PKA) or PKC-mediated event. Either PKA or PKC 
activation, which is capable of phosphorylation of 
cytochrome P-450 (Pyerin et al 1987) would result in reduced 
steroid-metabolising activity. In addition, GH was reported 
to suppress cytochrome P-450ep (gene IIIA1) activity 
(Yamazoe et al 1986) as well as other cytochrome P-450 
isoenzymes (Waxman et al 1989b).
In conclusion, GH exhibited a significant feminisation 
of steroid metabolism in isolated male rat hepatocytes in 
the presence of both thyroxine and dexamethasone. Although 
the role of the pemissive hormones, thyroxine and 
dexamethasone, in the manifestation of the feminising 
effects of GH is unclear, their involvement in this system 
has been widely documented (Colby 1980, Mode et al 1989, 
Guzelian et al 1988, Zaphiropoulos et al 1988, van der 
Hoeven and Guzelian 1987, Kriz et al 1982). The apparent 
requirement of these hormones in the culture medium in order 
to achieve feminisation of steroid metabolism strongly 
suggests that GH may be interacting with these hormones in 
vivo in order to produce its feminising effects. Thus 
treatment of isolated hepatocytes (and therefore removal of 
additional hormonal influences) with GH alone did not 
exhibit feminisation of steroid metabolism, whilst inclusion 
of dexamethasone and thyroxine in the culture medium, which
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may serve to mimic the situation thought to exist in vivo, 
resulted in the feminisation of steroid metabolism. The 
mechanism of action by which GH feminises steroid metabolism 
is, as yet, unclear, although the phosphorylation of 
cytochrome P-450 may be involved in the inhibition of 
male-specific activities. However the method of inhibition 
or stimulation of the flavin-dependent enzymes is yet to be 
elucidated.
4.8 STUDIES WITH THE PUTATIVE INSULIN MEDIATOR
SUBSTANCE
Although the precise mechanism by which insulin elicits the 
vast array of its effects is not yet fully known, a unifying 
pathway of insulin action has been proposed recently 
(Brautigan and Kuplic 1988). Insulin, upon binding to its 
receptor ci-subunit, activates the intrinsic tyrosine kinase 
residing in the transmembrane p-subunit. This activated 
kinase is thought to phosphorylate a G-protein, possibly 
Gins (Earner 1988), which in turn activates a membrane 
Pi-specific phospholipase C that is responsible for the 
generation of the putative mediators of insulin action from 
membrane-bound phosphatidylinositol-glycan precursors 
(Saltiel 1987). This is analagous to the insulin-induced 
release of heparan sulphate and alkaline phosphatase, both 
of which are also anchored to the plasma membrane by 
glycosyl-phosphatidylinositol glycan structures (Low anc* 
Saltiel 1988).
Numerous reports have accumulated over the past decade
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following the initial proposition of the existence of low 
molecular weight mediators of insulin action by Larner et al 
in 1979. The insulin mediators (polar head group, IP-glycan) 
are linked by a phosphodiester linkage to the parent 
phospholipid that is susceptible to hydrolysis by an 
insulin-sensitive Pi-specific phospholipase C. The 
observation that the substance generated by treatment of 
purified membranes with either bacterial phospholipase C 
(Fox et al 1986, Kelly et al 1986) or phospholipase C 
purified from liver plasma membranes (Fox et al 1987) 
mimicked the effects of insulin reinforced the idea of a 
mediator of insulin action.
In the present study, insulin was reported to act as a 
general stimulatory agent of steroid metabolism (section 
4.4), as has also been demonstrated by Hussin and Skett
(1987), although the mechanism by which insulin acts has not 
yet been fully characterised. A number of reports have 
demonstrated that the isolated insulin mediator mimics the 
effects of insulin in most cases (Table 4). We therefore 
isolated this insulin mediator substance from rat 
hepatocytes treated with insulin, and determined the effects 
of this extract on hepatic steroid metabolism.
In order to test whether or not the insulin mediator 
generated in this study was active in a system used 
previously, we assayed the effects of incubation with the 
extract on mitochondrial pyruvate dehydrogenase activity 
(PDH) (Suzuki et al 1987). As is shown in Figure 47, insulin; 
stimulated PDH activity in a dose-dependent manner,
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exhibiting an optimum at physiological concentrations. 
Incubation of mitoplasts with various dilutions of the 
insulin mediator extract prepared in response to 10_9M 
insulin (Figure 48) showed a concentration-dependent effect 
on PDH activity, and again an optimum concentration was 
apparent. Since the undiluted extract was less potent than 
the 1:100 dilution in stimulating PDH activity, a certain 
degree of amplification of the insulin signal was observed, 
in agreement with the findings of Newman et al (1985). This 
is consistent with the idea of hormone-stimulated activation 
of a second messenger system, where one molecule of insulin 
presumably causes the release of many molecules of the 
insulin mediator by a cascade mechanism. Thus the response 
observed with the undiluted extract may represent 
desensitisation due to the presence of excessive mediator. 
Alternatively, it has been reported that a stimulatory 
mediator is generated by low insulin concentrations, and an 
inhibitory mediator by high insulin concentrations (Saltiel 
et al 1982). However, the ethanol extraction step in the 
present study is likely to have removed the ethanol-soluble 
inhibitory insulin mediator from the extract used (Suzuki et 
al 1987). The effects of incubation with the insulin 
mediator on PDH activity are in agreement with recent 
reports (Jarett and Seals 1979, Saltiel et al 1981,Newman et 
al 1985), thus showing that the insulin mediator extract 
generated in our system is similar in action to that 
documented in the literature.
Incubation of hepatocytes with insulin mediator 
extracts prepared in response to various doses of insulin
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showed that the insulin mediator stimulated steroid 
metabolism in a dose-dependent manner and exhibited maximum 
stimulation of enzyme activity at physiological 
concentrations (Figure 49). This is consistent with the 
dose-dependent effects observed with insulin previously 
(Figure 13), therefore showing that the insulin mediator is 
active and appears to mimic the stimulatory effects of 
insulin on steroid metabolism. Thus the insulin mediator 
substance may be mediating the effects of insulin in this 
system. A similar dose-response relationship has been 
obtained with the insulin mediator induced increase of 
cyclic GMP-activated cAMP phosphodiesterase (Pyne and 
Houslay 1988) and of PDH activity (Suzuki et al 1987).
The time course of generation of the insulin mediator 
was optimal after 5 minute exposure to insulin (Figures 50 &
51), which is consistent with previous reports (Pyne and 
Houslay 1988, Newman et al 1985, Suzuki et al 1987). In 
addition, optimal mediator generation at such an early time 
point is consistent with this insulin mediator substance 
being the second messenger of insulin action and agrees with 
the time course of insulin action observed earlier (Figure 
15). Time course studies of incubation with the insulin 
mediator extract showed that steroid metabolism was 
stimulated in a similar manner to that with insulin (Figure
52) and enzyme activity was not significantly stimulated 
early in the time course, in accordance with the time course 
of generation of the insulin mediator substance (Figures 50 
& 51) .
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Incubation of hepatocytes with various dilutions of the 
insulin mediator extract exhibited a concentration-dependent 
stimulation of enzyme activity (Figure 53), in agreement 
with the results obtained with PDH and glucose-6-phosphatase 
activities (Suzuki et al 1984) and lipid synthesis (Caro et 
al 1983). In addition, a dissociation of the effects of 
insulin on cytochrome P-45O-dependent and independent 
enzymes was observed in that the latter were relatively 
unresponsive to increases in enzyme activity upon treatment 
with the insulin mediator extract (Figure 50). In contrast, 
no such differences have been reported upon incubation with 
insulin (Hussin and Skett 1987), and so this result may 
reflect different mechanisms of action for the stimulation 
of cytochrome P-450-dependent and independent enzymes by 
insulin.
The precursor phosphatidylinositol-glycan (Pl-glycan) 
was reported to be located in the plasma membrane of rat 
liver, and relatively absent from subcellular organelles. 
Further, the Pl-glycan appears to be localised specifically 
at the outer extracytoplasmic surface of the cell in both 
hepatocytes (Alvarez et al 1988) and adipocytes, where 
treatment of intact cells with Pi-specific phospholipase C 
mimicked insulin action (Saltiel and Sorbara-Cazan 1987). 
This is in accordance with the general idea that proteins 
anchored to the cell membrane in the form of Pl-glycans are 
located on the outer surface of the plasma membrane (Low and 
Saltiel 1988). If such a Pl-glycan is the precusor of the 
insulin mediator, as has been proposed (Saltiel 1987), then
-190-
the insulin mediator must be generated outside the cell.
This is supported by numerous reports that the insulin 
mediator is active when added to intact hepatocytes (Caro et 
al 1983) and adipocytes (Kelly et al 1988). Further, uptake 
of the insulin mediator into the cell rather than 
interaction with the insulin receptor appears to be involved 
(Caro et al 1983) since the insulin mediator mimics the 
effects of insulin in cell-free systems (Saltiel 1987).
Since the insulin mediator affects intracellular target 
enzymes, a carrier system is required to transport the 
insulin mediator from the extracellular to the cytosolic 
face of the cell. In addition, passive diffusion of the 
polar head group is not likely due to the charged nature of 
the molecule. Although a recognition protein (receptor) for 
the IPG has not yet been identified, a mediator transport 
mechanism has been proposed by Romero et al (1988). In 
addition, the uptake, and therefore action, of the insulin 
mediator was blocked by inositol phosphate (Saltiel and 
Sorbara-Cazan 1987). Since the insulin mediator is also 
thought to contain an inositol phosphate moiety, the 
attenuation of the effects of the insulin mediator in the 
presence of inositol phosphate strongly suggests the 
blockade of its transport mechanism. In the present report, 
the observation that higher concentrations of the insulin 
mediator are required to mediate stimulation of steroid 
metabolism in intact hepatocytes as compared to the 
concentrations required for PDH activation, may represent 
the dependence of sufficient insulin mediator molecules 
being transported to the cell cytosol by this carrier
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system.
Having established that the effects of insulin on 
hepatic steroid metabolism were mimicked by incubation with 
the insulin mediator extract, although to a lesser extent in 
the case of cytochrome P-450-independent enzymes (Figure
53), the striking interaction observed between insulin and 
GH (Figure 13) was further studied. As is illustrated in 
Figure 54, GH antagonised the stimulatory effects of the 
insulin mediator on steroid metabolism, which is reminiscent 
of the effects seen with insulin and GH (Figure 13). Thus 
the interaction observed between insulin and GH appears to 
take place distal to the step of insulin mediator generation 
from the plasma membrane since the same interaction was 
exhibited with the insulin mediator substance itself and GH 
(Figure 54).
A possible mechanism of action to account for this 
interaction could be the reported repression of certain 
cytochrome P-450 forms by GH (Yamazoe et al 1989), and so 
control may be exerted directly at the level of cytochrome 
P-450 either by phosphorylation-dephosphorylation (insulin), 
or by repression (GH). Alternatively, phosphorylation of 
cytochrome P-450 by either GH-activated PKA or PKC would 
also result in the inhibition of enzyme activity (Pyerin et 
al 1987).
The effects of the insulin mediator have been reported 
to mimic the actions of insulin in both intact cell systems 
and in membrane preparations (Cheng and Larner 1985). 
Incubation of liver microsomes with various dilutions of the 
insulin mediator extract showed that diluted extracts were
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more potent in stimulating steroid metabolism than the 
undiluted extract (Figure 55). This is similar to the 
concentration effects observed with mitochondrial PDH 
activation previously (Figure 48), and with other studies 
(Caro et al 1983, Suzuki et al 1987, Pyne and Houslay 1988), 
but does not correlate with identical studies carried out in 
intact hepatocytes (Figure 53). As was mentioned earlier, 
this discrepancy in insulin mediator potency between 
hepatocytes and microsomal preparations may reflect the 
requirement for a carrier process to transport insulin 
mediator molecules into the cell cytoplasm. Such a process 
would not be required with subcellular preparations (such as 
mitoplasts or microsomes), and so lower concentrations of 
the insulin mediator are effective as compared to the 
situation with hepatocytes.
A number of studies have described the purification of 
the insulin mediator extract (Saltiel 1987, Cheng and Larner 
1985, Romero et al 1988). In the present study, insulin 
mediator extracts were applied undiluted to AGlx8 
ion-exchange columns and sequentially eluted with increasing 
concentrations of ammonium formate. Each of the fractions 
were then assayed in order to detect where the insulin 
mediator was eluted. As is shown in Figure 56, some 
stimulation of enzyme activity was observed with the 0.2M 
and 0.5M ammonium formate fractions, but it has been 
reported that nucleotides are primarily eluted at these 
concentrations (Suzuki et al 1987). Cytochrome 
P-45O-dependent activities were markedly stimulated by the
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contents of 1.0M ammonium formate fraction (fraction 1), 
whereas the cytochrome P-45O-independent activities remained 
unresponsive until the next fraction. Significant increases 
in enzyme activity were also observed upon incubation with 
the 1.0M formic acid fraction, and it is thought this may 
represent insulin mediator not eluted by 1.0M ammonium 
formate. Merida et al (1988) have reported multiple 
phosphorylation states of the insulin mediator, and so the 
residual insulin mediator activity eluted by 1.OM formic 
acid in the present study may represent a different 
phosphorylated form to that eluted by 1.0M ammonium formate. 
In contrast to the elution profile of the insulin mediator 
reported in this study and by Suzuki et al (1987), Merida et 
al (1988) showed that insulin mediator generated upon 
treatment of purified rat hepatocyte glycophospholipid with 
B. cereus Pi-specific phospholipase C, was eluted in three 
distinct peaks with lOOmM, 200mM and 500mM ammonium formate 
upon Dowex AGlx8 chromatography. The 500mM fraction was the 
most potent in the inhibition of cyclic AMP-dependent 
protein kinase and represented a highly phosphorylated form 
of the insulin mediator. The authors therefore proposed that 
three forms of the insulin mediator with different 
phosphorylation states (2, 3, 4 phosphate groups) were 
present and that the extent of phosphorylation determined 
biological activity (Merida et al 1988). Incubation with 
various dilutions of fraction 2 of the AGlx8-purified 
insulin mediator exhibited dose-dependent stimulations of 
steroid metabolism in both microsomes (Figure 58) and 
hepatocytes (Figure 57). However this stimulation of enzyme
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activity was more marked in the case of the microsomal 
preparation, again implying that transport of the insulin 
mediator into hepatocytes may be the hindering factor 
responsible for lower potency of the insulin mediator in 
this preparation. Co-incubation of microsomes with purified 
insulin mediator and GH resulted in decreases in enzyme 
activity (Figure 59), thus showing that the fraction 2 does 
indeed contain the insulin mediator since its effects were 
antagonised by GH.
Preliminary experiments to attempt to elucidate the 
nature of the components of this insulin mediator by paper 
chromatography and thin layer chromatography (Figure 60) 
showed that although carbohydrates such as galactose, 
mannose, glucosamine, and galactosamine, and inositol are 
present, more sensitive techniques are required to 
distinguish these compounds. The presence of these sugar 
components in the purified, acid-hydrolysed insulin mediator 
though, even at this level, shows homology to compounds 
reported by other authors. The constituents of the insulin 
mediator are thought to be inositol, glucosamine, galactose 
and phosphate (Saltiel 1987, Mato et al 1987b), although an 
insulin mediator containing mannose and galactosamine 
residues has recently been identified (Larner et al 1988).
In fact, a whole family of different insulin mediators has 
been reported (reviewed by Cheng and Larner 1985, Gottschalk 
and Jarett 1985, Romero et al 1988). It has been postulated 
that the differences in the components of the insulin 
mediator may reflect either tissue differences or species
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differences (Larner et al 1988). Conclusive proof of the 
involvement of the insulin mediator in insulin action will, 
however, be provided if structural analogues or 
synthetically prepared insulin mediators also mimic the 
actions of insulin.
A possible mechanism of action of the insulin mediator 
on the stimulation of steroid metabolism would undoubtedly 
involve a phosphorylation-dephosphorylation control 
mechanism (Avruch et al 1982, Larner et al 1979). Insulin is 
known to stimulate protein dephosphorylation by activating 
protein phosphatases as well as by promoting phosphorylation 
of other proteins by protein kinases (Espinal 1987). In 
addition, it has recently been suggested that 
insulin-induced phosphorylation reactions may be mediated by 
serine kinases (Espinal 1987), which may be activated by 
tyrosine kinases or directly by the insulin mediator itself 
(Czech et al 1988). Certainly, in the case of activation of 
PDH, it has been shown that activation of the PDH 
phosphatase, intrinsic to the PDH complex, and therefore 
a-subunit dephosphorylation, is responsible for the 
stimulation of PDH activity by the insulin mediator (Jarett 
et al 1980, Kiechle et al 1980, Suzuki et al 1984, Macaulay 
and Jarett 1985). In addition, the effect of insulin to 
increase glycogen synthase activity was also mimicked by the 
insulin mediator (Armstrong and Newman 1987). Protein 
phosphatase I, which is responsible for the 
dephosphorylation of glycogen synthase, glycogen 
phosphorylase, glycogen phosphorylase kinase, acetyl CoA
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carboxylase and hormone sensitive lipase is activated by 
insulin (reviewed by Brautigan and Kuplic 1988) and this may 
constitute the mechanism by which the insulin mediator 
affects these enzymes.
The insulin mediator mimicked the phosphorylation 
-dephosphorylation effects of insulin on a number of target 
proteins in intact adipocytes (Alemany et al 1987). For 
instance, the phosphorylation of ATP citrate lyase was 
mimicked by the insulin mediator in a time- and 
dose-dependent manner, as was the dephosphorylation of 
hormone-sensitive lipase. In addition, both insulin and the 
insulin mediator blocked the isoprenaline-induced 
phosphorylation of glycogen phosphorylase and hormone 
sensitive lipase. Both insulin and the insulin mediator, 
inhibited the phosphorylation of phospholipid 
methyltransferase in intact adipocytes (Kelly et al 1987), 
an enzyme that is regulated by a phosphorylation 
-dephosphorylation mechanism. The reduction in 
glucagon-stimulated glycogen phosphorylase a and pyruvate 
kinase activities by the insulin mediator was thought to 
occur by reducing the phosphorylation of these enzymes since 
cAMP-dependent protein kinase activity was also inhibited by 
the insulin mediator (Villalba et al 1988).
Both stimulation of PKA and PKC have been reported to 
result in significant decreases in steroid-metabolising 
activity (Berry and Skett 1988, Allan and Skett 1988), which 
correlates well with the inactivation of cytochrome P-450 
upon phosphorylation by PKA or PKC (Pyerin et al 1987). In 
addition, a phosphorylation-dependent mechanism has been
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proposed in the action of insulin on steroid metaboliism (AH 
Hussin : personal communication). Thus if either insulin or 
the insulin mediator act by inhibition of protein kinase, 
this would result in reduced cytochrome P-450 
phosphorylation and therefore increased steroid-metabolising 
activity. However, neither cAMP nor PI turnover appeared to 
be functional in insulin-stimulated steroid metabolism (AH 
Hussin : PhD thesis), and so this phosphorylation 
-dephosphorylation control may be exerted by 
serine/threonine phosphatases. Certainly, the insulin 
mediator has been reported to phosphorylate serine/threonine 
kinases (Czech 1988, Larner 1988), and this may constitute 
the mechanism of insulin action rather than PKA or PKC 
activation. Contrary to these results, however, both insulin 
and the insulin mediator have been reported to alter the 
activities of various components of the cyclic AMP system. 
Insulin is known to antagonise hormone-stimulated cyclic AMP 
levels. In agreement with this, the insulin mediator did not 
alter basal cyclic AMP levels in hepatocytes, but reduced 
glucagon-stimulated cyclic AMP content (Alvarez et al 1987), 
possibly by its action to elevate low Km phosphodiesterase 
activity (Kiechle and Jarett 1981, Saltiel et al 1986) or to 
decrease adenylate cyclase activity (Pyne and Houslay 
1988). Insulin mediator generated from insulin-treated 
diabetic rats also inhibited the catalytic subunit of 
adenylate cyclase and cAMP-dependent protein kinase 
(Malchoff et al 1987) at a site distinct from the 
ATP-binding site (Villalba et al 1988). The effect of the 
insulin mediator on cAMP phosphodiesterase activity was
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reported to be due to an increased phosphorylation of the 
enzyme (Marchmont and Houslay 1980). However insulin action 
to inhibit cAMP accumulation was demonstrated in the 
presence of phosphodiesterase inhibitors (Davidson and 
Berliner 1974), suggesting that adenylate cyclase inhibition 
was mediating the effects of insulin. The cAMP-lowering 
effect of insulin is, however, thought to be linked to 
phosphodiesterase inhibition in hepatocytes (Zhang et al 
1983). Since both cAMP-dependent and cAMP-independent 
effects of insulin are mimicked by the insulin mediator, its 
generation is likely to be an early event following insulin 
binding to its receptor. The mechanism of action involved in 
the activation of the cytochrome P-450-independent enzymes 
remains obscure at this stage.
Diacylglycerol production upon hydrolysis of the 
Pl-glycan (Saltiel et al 1987) may directly be involved in 
PKC activation. PKC has been reported to be involved in the 
action of insulin in BC3H-1 myocytes (del C. Vila et al 
1989, Farese et al 1988), although this has been disputed 
(Spach et al 1986, Blackshear et al 1987, Chu et al 1987, 
Klip et al 1987).
A number of criteria for the involvement of insulin 
mediators in the action of insulin have been proposed 
(Armstrong and Newman 1987) :
1) The insulin mediator is generated by physiological
concentrations of insulin.
-This criterion has been satisfied in the present study 
and in other reports (Suzuki et al 1987, Pyne and Houslay
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1988). In addition, physiological concentrations of insulin 
appeared to generate optimal amounts of the insulin 
mediator.
2) The time course of the generation of the insulin 
mediator should be consistent with the onset of insulin 
action.
-The time course of insulin mediator generation 
correlated well with the stimulation of steroid metabolism 
both by insulin and the insulin mediator in this study. A 
similar result was obtained regarding cAMP phosphodiesterase 
activity (Pyne and Houslay 1988).
3) The insulin mediator substance must be generated by 
all insulin-responsive cell types.
-The insulin mediator has been generated from a number 
of systems upon exposure to insulin (Table 4). However, 
streptozotocin-diabetic rats failed to generate the insulin 
mediator upon treatment with insulin (Amatruda and Chang 
1983). Similarly PDH activation was not achieved in response 
to insulin in adipocytes from NZO mice (Macaulay and Jarett 
1988). Gi was reported to be abolished in diabetes (Gawler 
et al 1987) and this may result in impaired activation of 
the G-protein-activated phospholipase C, and thus the loss 
of insulin sensitivity in diabetic animals.
4) The insulin mediator should mimic the effects of 
insulin.
-The insulin-mimetic actions of the insulin mediator 
have been widely documented (Table 4), and insulin mediator 
mimicked the stimulatory effects of insulin on hepatic 
steroid metabolism in the present study.
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5) The insulin mediator should be degraded by tissues 
at a rate consistent with insulin action.
-The duration of action of the insulin mediator to 
stimulate steroid metabolism, that is, loss of activity 
after 30 minutes of incubation, may reflect degradation of 
this substance at that time.
6) Chemically synthesised analogues of the insulin 
mediator should possess insulin-like activity.
-This approach will conclusively confirm the 
involvement of insulin mediators in insulin action.
This study therefore provides considerable evidence to 
support the role of the insulin mediator in insulin action.
In conclusion, the insulin mediator extract prepared 
upon treatment of hepatocytes with insulin mimics the 
stimulatory effects of insulin on steroid metabolism in a 
dose-dependent manner. The time course of both insulin 
mediator generation and action is consistent with the role 
of the insulin mediator as a second messenger of insulin 
action. Microsomal preparations appeared to be more 
responsive to the insulin mediator than intact hepatocytes 
in the stimulation of steroid metabolism, implying that 
transport of the insulin mediator into the cell is involved. 
In addition to mimicking the stimulatory effects of insulin, 
the effects of the insulin mediator were also antagonised by 
GH, thus indicating that interaction between the two 
hormones occurs distal to the step of insulin mediator 
generation. The insulin mediator extract purified by AGlx8 
ion-exchange chromatography and eluted by 1.0M ammonium
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formate also exhibited dose-dependent effects, although once 
again the microsomal system appeared to be more responsive 
than the intact hepatocytes. This effect was also 
antagonised by GH, showing that this fraction contained 
insulin mediator activity.
Paper chromatography of the purified, acid-hydrolysed 
insulin mediator substance showed the presence of 
carbohydrate components in the molecule, although exact 
identification of these requires a more sensitive technique.
The mechanism by which the insulin mediator acts 
probably involves a phosphorylation-dephosphorylation 
control at the level of cytochrome P-450, as does the 
interaction with GH. However, the mechanism of activation 
of the cytochrome P-45O-independent activities remains 
unexplained.
4.9 GENERAL DISCUSSION
1) GH alone exhibited no significant effects upon 
administration to isolated rat hepatocytes. In contrast, GH 
is known to cause the feminisation of steroid metabolism in 
vivo (Mode et al 1981).
2) GH did not alter intracellular cyclic AMP content, 
and the effects of GH on steroid metabolism do not appear to 
be mediated by insulin-like growth factors, which exhibited 
an insulin-mimetic action in this system.
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3) Insulin stimulated steroid metabolism in a 
non-specific manner, as has been reported previously (Hussin 
and Skett 1987), an effect that was strongly antagonised by 
GH, although in a sex-independent manner.
4) Dexamethasone stimulated steroid metabolism in a 
non-specific manner, and enzyme activity was restored to 
control levels upon incubation with GH in a dose-dependent 
manner.
5) Thyroxine exhibited concentration- and sex-dependent 
effects in short incubation studies. Co-incubation with GH 
resulted in marked decreases in enzyme activity in a 
sex-independent manner. Prolonged exposure to thyroxine in 
cultured hepatocytes exhibited no significant effects until 
72h of incubation. Further treatment with GH restored enzyme 
activity to control, values.
Thus GH appeared to non-specifically modulate the 
effects of insulin, dexamethasone and thyroxine on steroid 
metabolism in isolated hepatocytes.
6) Incubation of hepatocytes with GH in the presence of 
a combination of dexamethasone and thyroxine resulted in the 
feminisation of steroid metabolism, that is, an increase in 
female-specific and a decrease in male-specific activities. 
Thus dexamethasone and thyroxine appeared to play a 
permissive role in the action of GH to feminise steroid 
metabolism in isolated male rat hepatocytes. An extension of
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this observation to the situation in vivo clearly indicates 
an interaction of GH with at least glucocorticoids and 
thyroid hormones in achieving its feminising effect.
7) The effects of insulin on hepatic steroid metabolism 
appear to take place by the generation of an insulin 
mediator substance. This insulin mediator was most active 
upon use of physiological concentrations of insulin, as 
measured by its ability to stimulate both PDH activity and 
hepatic steroid metabolism. The enhanced potency of the 
insulin mediator in microsomes and mitoplasts, as compared 
to the situation with hepatocytes was thought to be due to 
the involvement of a carrier mechanism present on the 
hepatocyte plasma membrane. In agreement with the results 
obtained with insulin, GH antagonised the stimulatory 
effects of the insulin mediator in a non-specific manner.
8) Insulin mediator activity was detected in the 1.0M 
ammonium formate and 1.0M formic acid eluates upon AGlx8 
ion-exchange chromatography. Acid hydrolysis followed by 
paper chromatography of this AGlx8-purified insulin mediator 
extract showed that carbohydrate components were present, 
although their exact nature could not be determined due to 
the limitations of the technique used.
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